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ABSTRACT 
 
Complications of type 2 diabetes mellitus are one of the major causes of 
morbidity and mortality around the world. Diabetic foot infections remain one 
of the major complications leading to a leg loss every 3 seconds due to 
amputations causing mental trauma and distress. In diabetic foot ulcers 
aerobes, anaerobes and fungus often interact with each other and form 
biofilms which is difficult to treat, enhancing antimicrobial resistance and 
lead to a non-healing ulcer. Co-existing peripheral vascular disease and 
neuropathy exacerbate the problems. In T2DM patients’ minor cuts and 
wounds, often lead to hard to treat and chronic ulcers which can worsen to 
gangrene formation which may lead to osteomyelitis compromising the 
mechanics of the foot.  It is necessary to identify the virulence factors of 
these clinically significant microbes and to identify the resistance patterns 
regularly to limit the antibiotic usage and target to the specific organisms.  
 
A Cohort studies were carried out in India and in the UK to identify the risk 
factors among the diabetic foot patients along with their microbial aetiology 
and antibiotic resistance patterns from the tissue and pus samples. This part 
of the research has shown the presence of mixed cultures mainly from the 
Indian diabetic foot ulcer specimens with higher percentages of anaerobes 
than aerobes. Multi-drug resistant organisms were one of the peculiar 
characteristics of the diabetic foot ulcer profiles of Indian patients. As 
compared to the Indian patients, UK patients had few resistant organisms 
and the patients admitted to hospitals in India were at the last stage of foot 
ulcers whereas in the UK, surveillance and preventative strategies allow 
early detection and intervention. 
 
Currently there is a lack of rapid, robust and an inexpensive diagnostic 
method for the rapid typing and identification of clinically significant 
anaerobes. Another part of the research focussed on utilising the glycan-
lectin interactions by developing a simple enzyme linked lectin sorbent 
assay by employing biotinylated lectins to develop to an enzyme linked 
lectin sorbent assay (ELLA) on whole cells, Proteinase K treated cells and 
glycolipids of clinically significant aerobes and anaerobes. This study is 
concluded by utilising the glycan-lectin interactions and to develop a rapid 
typing method for clinically significant Methicillin resistant and sensitive 
Staphylococcus aureus and epidermidis species. The rapid identification of 
anaerobes and typing of Peptostreptococcus species was also by facilitated 
by the developed ELLA method. 
 
Finegoldia magna is one of the most significant anaerobes from soft tissue 
infections and the Gas Chromatography – mass spectrometry (GC-MS) of 
the glycolipids of Finegoldia magna on composition analysis using show the 
presence of sialic acid which could be involved in pathogenesis. This sugar 
may be one of virulence factor employed by this organism in either 
attachment to the host or to other organisms. 
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CHAPTER – 1 
 
GENERAL INTRODUCTION 
 
1.1 History of Diabetes 
Diabetes has been known to be a potentially lethal disease for more than a 
thousand years (Dobson, 1968). In the past, different types of treatment 
were tried by Physicians from medications, concoctions to diets, which 
might prolong life. 
The history of diabetes has involved contributions from many people from all 
over the world. It has evolved by step wise discovery from the identification 
of symptoms, to the recognition of the formal name for the condition, 
understanding the various types of diabetes and finally to the elucidation of 
the biochemistry of diabetes. The identification of the pancreas as the organ 
involved in causing this condition led to the discovery of Islets of 
Langerhans and subsequently the isolation of insulin: one of the most 
significant milestones in diabetes research (Leibiger, Brismar and Berggren, 
2010). Most recently hopes have been raised that a cure is imminent with 
advances in the transplantation of beta cells, stem cell therapies and 
research into gene therapy (George, 2009; Robertson, Drexler and Vernillo, 
2003 and Johnson and Luciani, 2010). 
From the ancient times Physicians with different beliefs on the cause of 
diabetes tried a variety of treatments to take care of the condition. The first 
mentioned medical condition that was distinguishable as diabetes was found 
in an ancient papyrus, discovered in 1862 by German Egyptologist George 
Ebers (Papaspyros, 1982). From around 1500 B.C translations have 
revealed different concoctions that “could remove the urine which runs very 
often among the people with such condition”. A Roman writer, who lived 
during the times of Hippocrates, translated Greek writings on medicine and 
claimed that people with this medical condition urinated more than they 
drank. His view was accepted for hundreds of years, until Girolamo Cardano 
measured the amount of fluid consumed by such patients and then 
compared this to the amount of urine produced (Pyke, 1997). It was 
equivalent and hence the error was rectified. Aretaeus of Cappadocia in the 
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1st century AD were the first to describe the condition formally as diabetes 
and described the condition as the passing of copious amounts of urine and 
the loss of body flesh (Dobson, 1776). Another Greek Physician Galen said 
that this condition was “a weakness of the kidney which cannot hold back 
water” thus advising horse riding at the time as a good way to get rid of the 
excess urine. The Chinese physician Gang-ke suggested that the urine from 
diabetic people was sweet and that it attracted dogs.  
In the fifth and the sixth century a reputed Indian Physician, Dr. Susruta, for 
the first time recognised the two primary types of diabetes, one affecting 
very thin people and another form most often seen among the obese and 
more sedentary individuals (Raghunathan, 1976). He recommended a 
moderate diet with low fat, salt and sugar along with exercise for overweight 
patients; a treatment still offered to people with diabetes (O‟Gorman and 
Krook, 2008; Bluherm and Zimmer, 2010). Thomas Willis, a 17th century 
Oxford University Physician, believed that diabetes was the disease of blood 
and suggested that sugar found in the blood was found aberrantly in the 
urine. It was only in 1857 that Claude Bernard isolated a substance, 
glycogen, and illustrated the role it played in the metabolism of glucose 
(Young, 1957). Until this time however the organ involved was not known 
(Pyke, 1997). In 1869, German researcher Paul Langerhans highlighted a 
special cluster of cells within the pancreas. Although the cells were 
recognised, the role they played in diabetes was not established. In 1889, 
Oskar Minkowski performed experiments on removing the pancreases of 
dogs, thus inducing diabetes in the animals and definitively proving the 
significance of the pancreas (MacLeod, 1978; Leibowitz, 1972). This led to 
Miskowski and others to search unsuccessfully for the substance that 
differentiated diabetics from non-diabetics (MacLeod, 1978). In 1893, 
Edouard Laguesse noted the importance of the cells identified by 
Langerhans and in honour of Langerhans called them “Islands of 
Langerhans”. They are now known as islets of Langerhans (Leibowitz, 
1972). 
In the early 20th century Rennie and Fraser used the extracts of islets of 
Langerhans from a special fish purchased from the Aberdeen fish market to 
treat patients with diabetes. Doctors ran out of the fish and hence the 
compounds could no longer be used to treat the patients (Rennie et al., 
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1907). It was only in 1921 that Drs. Frederick Banting and Charles Best 
isolated insulin from the pancreas of an animal and used that to treat 
diabetes in humans. Throughout the years since the insulin from the animals 
were used the ingredients and forms of insulin have been changed and 
improved. Banting and Best‟s work on the discovery of insulin has overcome 
many potentially fatal symptoms of diabetes by controlling the blood sugar 
and acetone bodies (Allan, 1972 and Fulton, 1956). In the 21st century the 
treatment options for patients with diabetes include transplantations of beta 
cells, stem cell transplants as well as well transplants of organs such as 
pancreas or pancreas/kidney (Gunaselli and Doss, 2010 and Johnson and 
Luciani, 2010). Recombinant insulin identical to human insulin and modified 
human insulin with more rapid and much slower absorption are used thus 
replacing the traditionally used porcine insulin. Genetic engineering is now 
used to produce naturally occurring peptides that are able to stimulate the 
growth of insulin-producing cells in the pancreas (Garcia et al., 2001). 
Advances in diabetes research are significant and much needed because 
diabetes is on the rise worldwide and is considered by some experts already 
to be at an epidemic level (Zimmet et al., 2001 and Wild et al., 2004). 
1.2 Types of diabetes  
It is clear from history that diabetes is a chronic incurable disorder which can 
be managed but not cured apart from pancreas transplantation. There are 
two main types, diabetes mellitus and diabetes insipidus (Rybka, 2010). 
Both diseases have the same symptoms of thirst and urination except that 
diabetes insipidus is caused due to changes in the antidiuretic hormone 
produced by the pituitary glands which directly affects water retention hence 
diabetes insipidus is called the „water‟ diabetes. Diabetes mellitus on the 
other hand is often called the „sugar‟ diabetes and is caused by the 
pancreas malfunctioning leading to insulin deficiency or a defect in the 
secretion of insulin or insulin resistance discussed in details in section 1.The 
research presented in this thesis is focussed only on diabetes mellitus. 
Diabetes mellitus is a common disorder affecting individuals world wide and 
can be broadly classified into 3 main types. Type 1 diabetes mellitus (T1DM) 
formerly known as insulin dependent diabetes mellitus is an auto-immune 
disease where the body's immune system destroys the insulin-
producing beta cells in the pancreas. This type of diabetes is also 
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known as juvenile-onset diabetes and accounts for 10-15% of all 
people with the disease. It can appear at any age although most often 
below the age of 40. The second most significant type is the Type 2 
diabetes mellitus (T2DM) previously known as non-insulin dependent 
diabetes mellitus. This type of diabetes is also known as late-onset 
diabetes and is characterised by insulin resistance and relative insulin 
deficiency therefore insulin concentrations in the blood are high. The 
pathophysiology, symptoms, prevalence and the complications arising 
due to T2DM are detailed later in this chapter. The third type of diabetes 
includes the gestational diabetes (GDM) which is often seen among 
pregnant women. GDM, or carbohydrate intolerance, is first diagnosed 
during pregnancy through an oral glucose tolerance test. Risk factors 
for GDM include a family history of diabetes, increasing maternal age, 
obesity, ethnic group with a high risk of developing T2DM (Landon, 
2010 and Rybka, 2010). While the carbohydrate intolerance usually 
returns to normal after the birth, the mother has a significant risk of 
developing permanent diabetes while the baby is more likely to 
develop obesity and impaired glucose tolerance with diabetes later in 
life (Landon, 2010).  
1.3 Prevalence of T2DM in the world: Projections for 2030  
Type 2 diabetes mellitus (T2DM) has become a worldwide health problem 
that is almost certain to worsen. It remains an important cause of mortality 
and morbidity worldwide. Poor glucose control and presence of diabetes 
complications (detailed in this chapter in section 1.7) are commonly 
regarded as risk factors for mortality and morbidity.  It has been predicted by 
the World Health Organisation (WHO) that Type 2 diabetes mellitus will 
soon become a serious health problem worldwide with an estimated 300 
million diabetics in 2025 (Zimmet et al., 2001 and Wild et al., 2004). 
According to WHO the top 10 countries with high number of diabetics are 
India, China, USA, Indonesia, Japan, Pakistan, Russia, Brazil, Italy and 
Bangladesh.  The estimates for India include 31.7 million in the year 2000 to 
a drastic increase to 79.4 million diabetics by the year 2030. As per WHO 
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facts and figures in the UK the estimates include 1.7 million in the year 2000 
to 2.6 million of diabetics by 2030 (WHO website). 
1.4 Pathophysiology of Type 2 diabetes mellitus  
Type 2 diabetes results from the body's ineffective use of insulin or defects 
in the synthesis of insulin and affects 90% of people with diabetes around 
the world (worlddiabetesday.org). The endocrine cells namely α and β cells 
produced by the islets of Langerhans in the pancreas are responsible for the 
production of hormones glucagon and insulin respectively (Spellman, 2007). 
About 60% of the endocrine mass comprises of the β cells which produce 
both insulin and amylin of which insulin is released in response to the 
elevated plasma glucose (Spellman, 2010). Thus the homeostasis in the 
body to control blood sugar relies on the production of the hormones insulin 
and glucagon. Insulin in a healthy individual converts the extra glucose in to 
glycogen and this is stored in the muscles. Insulin is essential for the entry 
of glucose into tissues and cells to provide energy. Glucagon is normally 
produced by α cells when the sugar levels in the body are low and this 
stimulates the liver to convert glycogen to glucose. Therefore the regulation 
of glucose involves the production of both hormones insulin and glucagon 
by the endocrine cells. The metabolic response to ingested carbohydrate is 
different in individuals with normal glucose tolerance in comparison to those 
with T2DM. After ingestion, there is a predictable increase in the plasma 
glucose levels consequently an increase in the insulin levels to dispose of 
the ingested glucose load in contrast however the glucagon secretion is 
discontinued (Spellman, 2010 and Unger and Parkin, 2010). This response 
keeps the plasma glucose within a homeostatic range despite the variation 
in food intake in healthy individuals. With the development of impaired 
glucose tolerance, and as the condition progresses, pre-diabetes is 
recognised with impaired fasting glucose (Wheatcroft et al., 2003). The 
metabolic responses to ingested glucose changes dramatically. Since 
insulin levels are not routinely measured in the clinical laboratory as a part 
of the standard biochemical measurements, insulin resistance is not clearly 
evident in a normal day to day life. Insulin resistance leads to a decrease in 
the uptake of glucose which results in postprandial hyperglycaemia Weyer 
et al., 1999). Thus the pathophysiology of T2DM is mainly characterised by 
peripheral insulin resistance (an insensitivity of the tissues to the effects of 
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insulin), impaired regulation of glucose production and declining β-cell 
function, eventually leading to β-cell failure (Unger and Parkin, 2010).  
There are many other factors which can lead to insulin resistance one of 
which is obesity. Body fat content in obese people produces insulin 
resistance by depositing the excess intra-abdominal fat within the adipose 
tissues which in normal healthy individuals would have held into liver and 
skeletal muscle cells (Matsuzawa, 2010). Due to this there are increasing 
levels of triglycerides by the release of fatty acids and the excess fat cells 
release chemicals called inflammatory cytokines which block the insulin 
receptors hence the pancreas produces more and more insulin eventually 
damaging the beta cells (Gabriely et al., 2002). In contrast, in low-birth 
weight individuals there is less adipose tissue to hold the excess fat leading 
to a similar increase in triglycerides levels leading to insulin resistance 
(Gabriely et al., 2002). Other studies have suggested that there are certain 
hormones such as leptin and resistin which play a significant role in 
increasing insulin resistance. In the absence of leptin, triglycerides 
accumulate in non-adipose tissues leading to insulin resistance while 
resistin similar to leptin plays a major role in pathogenesis of insulin 
resistance by virtue of its ability to oppose certain actions of insulin. Other 
studies have suggested that low adinopectin (an adipose tissue-derived 
protein) concentrations also can produce insulin resistance by stimulating 
the fatty acid oxidation (Rea and Donnelly, 2004 and Beltowski, 2003).  
Fatty acids levels are elevated in obese individuals, and this has a direct 
effect on carbohydrate metabolism such that fatty acid decreases the 
glucose uptake, glycogen synthesis and glycolysis: the effects that are 
normally promoted by insulin. Additionally the fatty acids also inhibit 
suppression of hepatic glucose production thus leading to increased hepatic 
glucose production (Boden, 2003).Another study suggests that islet amyloid 
could be involved in beta - cell failure as a result of T2DM (Andersson et al., 
2008 and Udayashankar et al., 2009). Amyloid is a proteinaceous fibrillary 
deposit that is seen in certain pathologic processes. In T2DM, islet 
amyloidosis which is responsible for promoting beta cell damage 
consequently death is frequently observed (Hoppener et al., 2002). The 
regulation of glucose can also be altered by certain environmental factors 
such as sedentary lifestyle which can lead to obesity in turn leading to 
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insulin resistance. Genetic predisposition could be one of the factors which 
can cause beta cell damage and in turn ineffective production of insulin. The 
entry of glucose into the cells is necessary to provide energy and cell 
starvation can lead to an increased synthesis of ketone bodies which are a 
cause of a number of complications discussed below in section 1.6. Some of 
these complications however can be controlled by administration of insulin-
secretory drugs such as sulfonylureas (Baron, 2002). If the insulin-secretory 
drugs can regulate the insulin levels in the blood then exogenous insulin 
would not be required as an essential part of the treatment.  
1.5 Symptoms of Type 2 diabetes mellitus 
To summarise from the above literature, the characteristic symptoms of 
diabetes mellitus are the result from abnormal glucose metabolism. Due to 
insulin resistance glucose does not reach the cells and hence glucose 
accumulates in the blood causing hyperglycaemia which is subsequently 
excreted in the urine (glycosuria). Glucose in the blood causes osmotic 
imbalance and hence causes frequent urination (polyuria). Because of the 
protein breakdown during gluconeogenesis in an attempt to provide more 
glucose to the cells there is weight loss. These symptoms are more 
common when there is severe insulin deficiency. T2DM often leads to 
severe complications described in this chapter in section 1.6. 
 1.6 Complications of Type 2 diabetes 
Complication of diabetes affects almost all parts of the body. Patients with 
Type 2 diabetes mellitus (T2DM) are known to have an increased risk of 
microvascular coronary heart disease, myocardial infarction leading to 
cardiovascular disease, peripheral vascular disease, neuropathy, 
nephropathy, retinopathy, cerebrovascular disease and diabetic foot 
ulcerations. Progressive diabetes often leads to a depletion of vitamins and 
minerals excreted in the urine because of the kidneys attempting to remove 
the excess glucose. The loss of these nutrients prevents carbohydrate, 
protein and fat metabolism leading to electrolyte imbalance especially 
imbalance in salt and water that affect nerve protection, muscle relaxation 
and insulin regulation.  Due to visceral fat and insulin resistance discussed 
earlier there is an increase in the production of triglycerides due to the 
conversion of extra glucose which further increases the viscosity of the 
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blood and cholesterol levels. Due to hyperinsulinemia, there is an increase 
in the blood pressure with thicker blood and narrow arteries. The 
Inflammatory mediators such as C-reactive proteins, fibrinogen, and 
lipoproteins are released due to T2DM and cause the formation of plaques 
in the artery walls which can over time lead to formation of blood clots. 
These inflammatory mediators can cause severe cardiovascular diseases 
such as heart attacks as well as strokes due to ischaemia (lack of blood 
supply). These inflammatory mediators can also cause damage to the 
proteins in the cells due to the increased production of advanced glycated 
products. When the blood glucose rises too high and hyperglycaemia is 
uncontrolled the glucose can attach permanently to the cells and is 
eventually converted to the toxic chemical sorbitol which destroys the cells 
(Wheatcroft et al., 2003).This process along with other risk factors can lead 
to blurred vision, burning foot syndrome, tingling and loss of feeling in the 
limbs eventually to life-threatening conditions. The research presented in 
this thesis focuses on Type 2 diabetes mellitus and one of the 
complications, diabetic foot infections associated with it. 
1.7 Prevalence of diabetic foot (DF) infections 
Diabetic foot infections are one of the major long term complications of Type 
2 diabetes mellitus which can result in gangrene and lower extremity 
amputation. Every year 4 million people around the world develop foot 
ulcers. Patients with diabetes are 25 times more likely to lose a leg than 
those without the condition, and up to 70% of all leg amputations occur in 
people with diabetes. The result is that a leg is lost to diabetes every 30 
seconds somewhere in the world (Bakker, Houtum and Riley, 2005). The 
complications related to diabetic foot ulcers are so serious that a consensus 
document was produced in 1999 by the International Working Group on the 
guidelines on diagnosing and treating infected diabetic foot and most 
recently guidelines for the treatment of diabetic foot osteomyelitis in 2007.  
1.8 Pathophysiology of diabetic foot infections  
Foot infections in diabetic patients usually begin with the formation of the 
acute wound. A wound is defined as a break in the epithelial integrity of the 
skin; the disruption could be deeper, extending to the dermis, subcutaneous 
fat, muscle of even the bone. Healing in an acute wound involves a 
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sequential flow of overlapping processes which requires various cellular and 
inflammatory pathways including phagocytosis, chemotaxis, mitogenesis, 
collagen synthesis and the synthesis of other matrix components shown 
below in figure 1.1 (Clark, 1996).   
 
Figure 1.1 Cellular and Inflammatory responses to acute wound 
healing  
http://www.worldwidewounds.com/2004/august/Enoch/Pathophysiology-of-Healing.html - 
reprinted with permission from the author Prof. Patricia Price. 
 
A completely healed wound is one which restores its normal anatomical 
structure, function and appearance within a reasonable timeframe. In 
diabetic patients the cellular and the inflammatory pathways involved in 
wound healing are affected. In diabetes hyperglycaemia particularly through 
hyperosmotic effects influence neutrophils and fibroblasts breaking the 
healing cascade (Lazarus et al., 1994). The faulty healing response is 
additionally affected due to the wound hypoxia caused by the microvascular 
and macrovascular conditions within the diabetic patients (Yamasaki et al., 
2010 and Kashiwagi et al., 2010). The microvascular conditions lead to 
injury in small blood vessels often leading to vasoconstriction. As the 
condition progresses the vascular abnormalities affect the membranes of 
the blood vessels leading to macrovascular conditions mainly peripheral 
vascular disease affecting the leg artery. Neuropathy predisposes the foot to 
infection and angiopathy influences the outcome (Edmonds and Foster, 
2004 and Armstrong and Boulton, 2007). Autonomic neuropathy causes dry 
skin and predisposes the skin to cracking. A foot with sensory neuropathy 
tends to suffer repeated injury, thus disrupting the skin integrity and 
providing a route for microbial invasion leading to an unhealed wound which 
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further develops into a chronic ulcer (Bjarnsholt et al., 2008). Motor 
neuropathy causes atrophy of the intrinsic foot muscles, altering the foot 
architecture leading to osteomyelitis. Bacterial invasion results from the loss 
of integrity of the skin and causes trauma and results in infections (Tan and 
File, 1999). Due to the higher glucose levels and free fatty acid metabolism 
there is an oxidative stress in the wound often referred to as ischemic 
wound which renders a perfect environment for the anaerobes. Patients with 
these additional risk factors such as ischemia, neuropathy and peripheral 
vascular disease often have unsuccessful inflammatory responses and 
hence have weakened immune system. One of the peculiar characteristics 
often seen in the chronic wound within an immuno-compromised diabetic 
patient is replicating micro-organisms. Additionally the excess sugar lowers 
the resistance to infections which further leads to a gangrenous ulcer with 
lower limb amputations (Gadepalli et al., 2006). About 60% of the 
amputations are as a result of infection of the diabetic foot ulcer making 
infection the most important pathway of DF. Infection, however, is never the 
sole cause of DF and other risk factors include increasing age, sex, race, 
smoking habits, duration of diabetes and glycated haemoglobin (HBA1C) 
(Mavian et al., 2010). The history of previous hospitalisations for the same 
wound, duration of the wound, duration of hospital stay, osteomyelitis, 
previous antibiotic therapy and non-healing gangrenous foot ulcer can also 
affect the diabetic foot ulcer and its prognosis (Singh, Armstrong and Lipsky, 
2005). Thus multiple factors contribute to the aetiopathogenesis of diabetic 
foot infections (Neu et al., 2001). 
1.9 Rationale and objective of the research 
An Infection plays a significant role in the worsening of the ulcers and can 
lead to the formation of gangrenous wounds which often can lead to 
amputations (Zayed et al., 2009). The research presented in this thesis is an 
attempt to identify the aetiology of the varied microbial floras from two 
different diabetic foot patient‟s cohorts and understand if there are any 
antibiotic resistant strains present in the diabetic ulcers and understand the 
differences within the Indian and UK diabetic foot cohorts  discussed in 
chapter 2 of this thesis.  After understanding the microbial flora dominating 
in the DFI, the study was further extended to understand the pathogenic 
mechanisms utilised by these organisms to impart infections and worsen the 
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diabetic foot ulcer leading to amputations. There have been studies 
suggesting that glycan – lectin interactions can be utilised for cell – cell 
adherence or attachment of bacterial glycan and host lectin or glycans from 
one bacterium to the lectins of another bacterium facilitating their 
attachment and forming biofilms which often can be difficult to treat (Dowd 
et al., 2008). The glycan – lectin interactions were then identified by an in 
house developed method discussed in chapter 3 of this thesis. The 
identification of anaerobes has always been a tedious and expensive 
procedure therefore there is a need to explore different methods that are 
easy and cost-effective for identification of the clinically significant 
anaerobes (Menon et al., 2007 and Nagy, 2010). Since unique glycan – 
lectin binding patterns were obtained these were further explored for their 
potential in rapid diagnostics of microbial typing and identification. 
Finegoldia magna is one of the most dominant anaerobes cultured from DF 
ulcers (Wall et al., 2002 and Stephens et al., 2003). It remains significant to 
understand the ways by which this organism can be pathogenic. Glycolipids 
have shown to be involved in imparting pathogenic characteristics to 
organisms (Lis & Sharon, 1998; Lloyd et al., 2007 and Schauer, 2000). 
Glycolipids were therefore extracted and glycan profiles were analysed 
using the in house developed method along with GC-MS and HPAEC that 
robust were tools for the characterisation of Finegoldia magna glycolipids 
discussed in chapter 4 of this thesis. 
The aims of this research study were: 
 To identify and compare the microbial aetiology and antibiotic 
susceptibility testing on the clinical isolates obtained from the diabetic 
foot patients from India and the UK. 
 To investigate the use of glycan-lectin interactions as a robust tool in 
typing and identifying pathogens pre-dominantly present in diabetic 
foot infections. 
 To characterise the glycolipids of Finegoldia magna one of the most 
dominant anaerobe cultured from the diabetic foot infections using 
robust methods such as GC-MS and HPAEC.  
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Chapter 2 
Pilot study on the microbiology and antibiotic susceptibility 
testing of clinical isolates from the diabetic foot patients 
from India and the UK  
Rationale for the study:  
In the UK the National Health Service provides a network of diabetic foot 
clinics resulting in early diagnosis of the diabetic foot infections (Home et al., 
1999). National diagnostic and treatment guidelines are set out by the 
Department of Health and the National Institute of Clinical Excellence 
(NICE). In India however due to the lack of guidelines, patient non – 
compliance to treatment, poverty and lack of health education, the diabetic 
foot patients often only reach the hospital at a very late stage of their 
infections (Jayasinghe et al., 2007 and Pradeepa et al., 2002). In India alone 
there are 40,000 amputations a year and there are only 100 diabetic foot 
clinics all over India (Pendsey, 2010). Infections often play a significant role 
in causing amputations (Zayed et al., 2009). It is important to have an 
effective knowledge of the principal bacteria, their local antibiotic 
sensitivities and the prevalence of resistant organisms. If clinicians could 
gain a better understanding of the wound‟s microbiota, and ecology, this 
would allow them to better manage healing of the wound improving the 
prognosis for patients. 
2.1 Clinical aetiology of diabetic foot infections 
 
A diabetic foot ulcer involves repeated infections due to aerobes, anaerobes 
or fungi individually or in combination (Zayed et al., 2009). The infection 
often starts locally with an ulcer affecting immediate surrounding skin with a 
purulent discharge and erythema. These signs can be missed due to the 
presence of neuropathy and ischaemia which are the two of the commonest 
risk factors to DFI (Boulton, 2007 and Pendsey, 2010). The infection can 
become subsequently a spreading infection as the sepsis progresses to 
cellulitis. This spreading infection can become severe causing extensive 
deep soft tissue damage. The deep tissue fills with pus and can cause 
abscess formation subsequently leading to tissue necrosis and severe 
bacteraemia. DF wound classifications is used to classify the stage of 
infection (Lavery, Armstrong and Harkless, 1996). 
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2.1.1 Different diabetic wound classification systems 
Classification of ulcerations can facilitate a logical approach to treatment 
and can aid in the prediction of outcome (Frykberg et al., 2002 and 
Armstrong and Lavery, 1998). Many wound classification systems which 
have been created based on the parameters such as extent of infection, 
neuropathy, ischaemia, depth of tissue loss, and location are discussed 
below. 
2.1.1.1 Wagner’s ulcer classification system 
Wagner‟s ulcer classification system is based on the depth of penetration, 
the presence of gangrene and the extent of tissue necrosis shown below in 
table 2.1 (Wagner, 1987). 
Table 2.1 Wagner’s DFU classification 
Wound grades Description of grades 
0 No lesion 
1 Superficial ulcer 
2 Deep ulcer 
3 Abscess Osteitis 
4 Gangrenous forefoot 
5 Whole foot 
  
The Wagner‟s grade classification is one of the most widely used 
classification system however the Wagner classification system does not 
consider two critically important parameters, ischaemia and infection 
(Frykberg, 2002).   
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2.1.1.2 University of Texas: diabetic wound classification 
The University of Texas diabetic wound classification system assesses the 
depth of ulcer penetration, the presence of wound infection, and the 
presence of clinical signs of lower-extremity ischaemia (Oyibo et al., 2001).  
The stages and grades of ulcers depth and ischaemia are discussed below 
1) Stages 
 stage A - No infection or ischaemia 
 stage B - Infection present 
 stage C - Ischaemia present 
 stage D -  Infection and Ischaemia present 
2) Grading 
 Grade 0 - epithelialized wound 
 Grade 1 - superficial wound 
 Grade 2 - wound penetrates to tendon or capsule 
 Grade 3 - wound penetrates to bone or joint  
This system uses the four grades of ulcer depth (0 to 3) and four stages (A 
to D), based on ischaemia or infection, or both thus covering both the 
significant co-morbidities of a DFU. 
2.1.1.3 Curative health services (CHS) database 
The CHS wound database classifies the wound on the basis of the rate at 
which the anatomy of the wound was affected to the progression of infection 
as seen in table 2.2 (Margolis et al., 2002).  
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Table 2.2: CHS wound grade scale 
 
 
Although the diabetic wound classification systems aid in the prediction of 
outcome and can help to initiate appropriate management, treatment is 
influenced by the nature of the aerobes, anaerobes and fungi affecting the 
DFU.  
2.1.2 Predominant aerobes in diabetic foot infections 
The microbiology of diabetic foot wound is complex. The Human body has a 
vast number of bacteria living as normal flora with skin harbouring many 
commensal. In a diabetic patient with poor immune responses even a 
normal skin commensal can cause significant infection. Common skin 
commensal such as Staphylococcus aureus (S. aureus) and 
Staphylococcus epidermidis (S. epidermidis) are seen as pathogens in 
diabetic wounds (Citron et al., 2007). Other nasal commensal such as 
Streptococcus species have also been cultured from the diabetic wound 
clinical specimens. Streptococcus species rarely cause infection but can, in 
rare cases cause severe blistering cellulitis and tissue destruction (Loan et 
al., 2005). Gram – negative aerobes such as the Citrobacter sp., 
Escherichia coli (E. coli), Pseudomonas aeruginosa (P. aeruginosa), 
Acinetobacter and Serratia sp. are examples of normal flora often cultured 
from a diabetic wound. There have been a number of studies showing the 
pathogenic nature of the Gram – negative bacteria in DFI (Bansal, 2008, 
Viswanthan, 2005, Citron et al., 2007, Abdulrazak et al., 2005, Gadepalli et 
al., 2006). Although these are normal flora of the gut and intestinal tract they 
 16 
are isolated from the diabetic foot ulcer as the patient may lack good 
hygiene due to their age or obesity (Cowen and Steels, 2004). These 
organisms often act in synergy with  other bacteria and can cause severe 
infections (Ambrosch, Lehnert and Lobmann, 2003). In the Microbiological 
laboratory the processing of the clinical specimens involves the identification 
of these clinically significant bacteria and often involves the use of 
biochemical tests which facilitate in their differentiation.  
The tables below describe some of the distinguishing characteristics used 
for identification.  
 17 
 
Table 2.3:  Characteristics of Gram – positive aerobes from DFI 
 
Table  2.3 presents the various characteristics of Gram – positive aerobes that are some of 
the clinically significant species isolated from the DFI. Staphylococcus species S. aureus 
and S. epidermidis can be further distinguished such that S. aureus is normally coagulase 
(+ve) and catalase (+ve) while S. epidermidis is coagulase (-ve) and catalase (+ve). 
Similarly bile esculin test aid in distinguishing Streptococcus and Enterococcus species with 
the former being bile esculin (+ve) and later being bile   esculin          (-ve). Other      colony  
characteristics can also help in initial identification.
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Table 2.4: Characteristics of Gram – negative aerobes from DFI 
 
The table 2.4 shows all the characteristics which are often used in microbiological 
laboratories to help distinguishing the clinically significant Gram – negative aerobes using 
traditional biochemical identification. Gram – negative aerobes from the DFI are mainly from 
the Enterobacteriaceae family and are mainly grouped as lactose fermentors and non 
fermentors using Mac Conkey‟s agar. Proteus species most significantly shows 
Phenylalanine test (+ve) while Pseudomonas species shows oxidase and catalase (+ve). 
Serratia species often show red pigmented colonies on the Mac Conkey‟s agar.  
 19 
2.1.3 Predominant anaerobes in diabetic foot infections 
Anaerobes are often present as normal flora of the skin and mucous 
membranes. In states of distorted host defence or where the skin‟s integrity 
is disrupted they can colonise and invade up to the vassal channels 
Finegold, 1993). Some of the anaerobes are rich in enzymes and toxins 
which help them in crossing the natural or anatomical barriers of the body 
causing toxaemic or septic syndromes (Gubina, 1997). In diabetic foot 
patients, due to ischaemia and neuropathy with vascular inefficiency, tissue 
anoxia occurs which lowers the redox potential and favours the growth of 
anaerobic bacteria (Armstrong et al., 2002 and Stefanopoulos and 
Kolokotronis, 2004). Within a wound environment, and particularly in the 
presence of dead tissue, obligate anaerobes are amongst the dominant 
groups of micro-organisms, despite the frequent exposure of the wound to 
air (Bowler, Duerden and Armstrong 2001). Anaerobes are able to cope with 
the toxic effects of oxygen by interacting with aerobes. As the aerobic 
bacteria grow they consume oxygen and create a more favourable 
environment for anaerobic bacteria. This has been demonstrated in 
laboratory studies involving communities of oral bacteria (Bradshaw et al., 
1996; and Bradshaw et al., 1998). Many bacteria have a relatively narrow 
pH range for growth; but when present within a wound, they are able to 
survive within a broader pH range (Bradshaw et al., 1996). Therefore 
microbial communities overcome the constraints of the external macro-
environment by creating, through their metabolism, microenvironments that 
enable the survival and growth of the component species. Similarly the 
breakdown of various nutrients within a polymicrobial community leads to 
the formation of a food chain where the product of one organism will 
become the substrate of another. This process leads to the development of 
microbial homeostasis within the community with one species relying on 
another to provide substrates for growth and development.  
Most of the infections that harbour anaerobes have a foul odour, gas in the 
specimen and the location of infection is in proximity to a mucosal surface. 
There are specific major populations of bacteria evident in the diabetic 
wound. Gram - positive anaerobes include the Gram - positive cocci 
(Peptostreptococcus spp.) which form part of the normal flora of humans yet 
are the most frequently isolated from the clinical specimens others include 
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the Gram - positive spore forming cocci (Clostridium spp.) along with other 
Gram - positive non spore forming cocci (Propionibacterium spp) (Esposito 
et al., 2008, Citron et al., 2007 and Baines et al, 2008). Most common Gram 
– negative anaerobes cultured from the DFI are Bacteroides fragilis, 
Prevotella species, Fusobacterium species and Veillonella species (Fille et 
al., 2006, Ge et al., 2002). 
Anaerobes have recently undergone extensive taxonomic changes with the 
advances in molecular techniques. The genus of one clinically significant 
anaerobe Peptostreptococcus was shown, by 16S rRNA sequencing to be 
very heterogeneous and phylogenetically incoherent (Song, et al., 2007a 
and 2007b). The table 2.5 below shows the classification of 
Peptostreptococcus spp. from past and present.  
 
Table 2.5 Re - classification of gram positive anaerobes 
 
Previous approved name Current classification 
P. asaccharolyticus Pst. asaccharolyticus, 
Peptoniphilus asacharolyticus 
P. glycinophilus Pst. micros, Micromonas 
micra, Parvimonas micra 
P. indolicus Pst. Indolicus 
P. magnus Pst. magnus, Finegoldia 
magna 
P. niger P. niger 
P. prevottii Anaerococcus prevottii 
P. anaerobius Pst. Anaerobius 
P. parvulus Pst. Parvulus 
P. productus Pst. Productus 
 
Newly proposed strains 
 
Peptoniphilus gorbachii 
Peptoniphilus olsenii 
Anaerococcus murdochii 
P = Peptocococcus, Pst = Peptostreptococccus 
The changes in the nomenclature were made on the basis of one of the 
following: differing G+C ratios, differing atmospheric requirements, 
nucleic acid studies and saccharolytic activities. As a routine in a 
Microbiological laboratory identification of the anaerobes is not carried 
out or restricted to the genus level. Identification of species often 
requires tedious and expensive use of procedures which are not 
economical routinely in laboratories. The tables discussed below collate 
all the most commonly isolated anaerobes from DFI and the different 
characteristics that can be used to distinguish them. 
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Table 2.6: Characteristics of clinically significant Peptostreptococcus 
species from DFI 
 
 
SPS – sodium polyanethol sulfonate, clinical strains of P. prevottii are urease (-ve) 
(Jousimies - Somer et al., 2002). Presumptive identification on the basis of the colony 
morphology can help in speciation of the Peptostreptococcus species as shown in this 
table. Traditional manual methods using the biochemical tests shown helped in speciation 
of the Peptostreptococcus species.  
 
Clostridium species have been most commonly cultured from a DFI (Baines 
et al., 2008). These anaerobes are more often seen in severe infection often 
causing tissue gangrene and necrosis. The characteristics of some of the 
most commonly cultured Clostridium species are described below in table  
2.7
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Table 2.7: Characteristics of clinically significant Clostridium species 
from DFI  
 
The Clostridium species of clinical importance have been subdivided based on proteolytic 
activity (gelatin hydrolysis), saccharolytic (glucose fermentation) or both. Egg yolk agar was 
the selective medium which allowed the detection of lecithinase and lipase activity 
(Jousimies - Somer et al., 2002). 
 
Eubacterium, Propionibacterium spp. and Actinomyces spp. are very 
occasionally isolated from DF clinical specimens (Goldstein et al., 2003 and 
Citron et al., 2007). They generally occur in association with other 
organisms and can be pathogenic. Some of the characteristics of the Gram 
– positive anaerobes are described below in table 2.8
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Table 2.8: Characteristics of other Gram – positive anaerobes from DFI 
 
Catalase and nitrate test were useful in the grouping of the non spore formers (Jousimies - 
Somer et al., 2002). 
 
Some of the most significant Gram – negative anaerobes from DFI, their 
colony and biochemical characteristics are shown in table 2.9 and  are often 
used in Microbiological laboratories for identification of Gram – negative 
anaerobes.
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Table 2.9:  Characteristics of Gram – negative anaerobes from DFI 
 
All Gram-negative bacilli are curved with pitting colonies (Jousimies - Somer et al., 2002).
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2.1.4 Predominant fungi in diabetic foot infections  
Fungi are present as normal flora in the mucosal organs, skin, mouth and 
the digestive system. In certain situations, such as during illness, use of too 
many antibiotics, use of steroids, obesity and in immuno compromised hosts 
fungi are capable of multiplying. Moist skin or any damage to the skin can 
encourage fungal infections. These characteristics are often seen among 
the diabetic foot patients due to neuropathy and repeated trauma to the 
skin, fungi gain entry and multiply. One of the clinically significant fungi 
cultured from DF ulcers is Candida spp. Candida belongs to the family 
Saccharomycetaceae. In the laboratory Candida appears as large, round, 
white or cream dry colonies which under microscope show budding yeast 
cells. Candida is a clinically significant fungus and has been shown to cause 
bloodstream infections, oropharyngeal, superficial infections such as thrush 
and vaginal Candidiasis. Candida has also been shown to cause other deep 
seated yeast infections in immuno compromised diabetic foot patients 
(Bansal et al., 2008). 
 In one study carried out by Heald and his colleagues, (001) Candida was 
grown from the bone and deep fissures of an affected DF rather than 
superficial ulcers. Osteomyelitis was also seen due to Candida in one of the 
studies based on the clinical characteristics and radiographs. Some of the 
Candida species particularly C. albicans exist in more than one 
morphological form and have long been regarded as significant in 
pathogenesis, particularly in relation to the penetration of host tissues. One 
study has shown that morphogenesis helped in the formation and 
persistence of adherent cell populations. C. albicans strains are capable of 
dimorphism and form biofilms on catheter disks consisting of a basal yeast 
layer, which serves as an anchor to the substratum, and an outer hyphal 
layer, which has a more open architecture likely to facilitate the transport of 
nutrients (Baillie and Douglas, 1999). These dimorphic structures thus prove 
to an advantage to Candida albicans giving firm attachment and hence 
rendering an infection untreatable. 
Tthe most significant species of Candida isolated from diabetic foot ulcers 
include C. tropicalis, C. albicans, C. guilliermondii and C. pseudotropicalis 
there are other species which in association with other organisms become 
opportunistic (Mlinaric et al., 2005). There are many host factors in patients 
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suffering from diabetic foot ulcers which contribute to the pathogenicity of 
Candida.  Hyperglycaemia is known to induce defects in the host 
granulocyte function, thereby leading to enhanced growth and tissue 
invasiveness, thus diabetic patients are at substantially higher risk of 
systemic Candida infections (Heald et al., 2001).   
2.1.5 Mixed infections in diabetic foot infections 
Diabetic foot infections are often complex and polymicrobial in nature 
(Bowler and Davies, 1999; Lipsky, Pecoraro and Wheat, 1990; Ge et al., 
2002; Vishwanathan et al., 2002 and Hunt, 1992). One of the largest 
surveys carried out, on a total of 825 patients, investigated the 
microbiological profiles of patients with mild and moderately infected 
diabetic foot ulcers. They revealed an average of 2.4 organisms recovered 
per wound. Of the infected diabetic foot ulcers, 75% had multiple micro-
organisms (Ge et al., 2002). One of the most intriguing observations made 
in all microbiological studies of diabetic foot ulcers is that the obligate 
anaerobes were never found alone, they were always isolated with aerobes 
signifying a relationship with each other and the polymicrobial nature of the 
infection (Finegold and Wexler, 1988 and Hartemann et al., 2004). 
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2.2 Antibiotic treatment of diabetic foot infections  
 
The Infectious Diseases Society of America termed the 6 most feared  
pathogens as “ESKAPE” these included the Enterococcus faecalis, 
Staphylococcus aureus, Clostridium difficile, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter species, often referred to in the 
press as the „Superbugs‟ due to their resistance to almost all antibiotics 
(Rice, 2008). Choosing an antibiotic would depend on clinical diagnosis, 
Gram nature of the organisms , the aetiology of the organism and patient 
allergies to antibiotics, renal and hepatic insufficiency, local antibiotic 
susceptibility data, gastro intestinal absorption impairment and most 
importantly  the severity of the infection.  
Since DF ulcers often start with localised infection topical agents such as 
antiseptic lotions with antimicrobial properties can be initially used to irrigate 
or cleanse the wounds. These can only be helpful for a brief contact time 
with the wound surface. Antiseptic lotions in the form of hypochlorite or  
potassium permanganate are used for localised infections. Some 
preparations can stay in contact with the wound surface for a longer period 
of time in the form of dressings these mainly include creams, ointments or 
impregnations. Silver based products have recently shown to have broad – 
spectrum effect against both the Gram – positive and Gram – negative 
organisms along with the yeasts and fungi (O‟Meara et al., 2000). Oral 
antibiotics have most commonly been used as treatment on an outpatient 
basis (Lipsky et al., 2004). Clinicians normally use systemic antibiotics as 
the last resort when topical interventions fail to initiate healing of the DF 
ulcer. Systemic antibiotics mainly including the penicillins, cephalosporins, 
aminoglycosides and quinolones can be used against a wide variety of 
Gram – positive and Gram – negative organisms (Vuorisalo, Venermo and 
Lepantalo, 2009).  The penicillins interfere with the development of bacterial 
cell walls and cross linkages. Some of the broad - spectrum antibiotics such 
as ampicillin and amoxicillin are active against both the Gram – positive and 
Gram – negative organisms. These are often inactivated by penicillinases 
and  cephalosporinases produced by organisms such as S. aureus and E. 
coli (Bush, 1989). To overcome resistance, combination antibiotics such as 
amoxicillin/clavulanic acid and piperacillin/tazobactam can be used as β – 
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lactamase inhibitors. Aminoglycosides and tetracylines inhibit protein 
synthesis and bind to the conserved sequences within the 16s rRNA of the 
30s rRNA subunit while macrolides and chloromphenicol act on the 23s 
rRNA on the 50s rRNA subunit (Livermore, 2003). Bacterial growth depends 
on the DNA and RNA synthesis. The aminoglycosides are active against 
many Gram – negative organisms. There are some antibiotics such as 
fluoroquinolones which can disrupt the nucleic acid synthesis directly, 
whereas sulfonamides and trimethoprim act indirectly on folic acid 
metabolism (Mascaretti, 2003). The quinolones are active against both the 
Gram – positive and Gram – negative organisms. When the number of the 
possible pathogens causing infections is small the antibiotic susceptibility is 
predictable and empirical treatment could be justified. It covers the most 
common pathogens with some modifications according to the severity of the 
infection is being considered (Frykberg, 2002). For spreading and severe 
infections the patients admitted to the hospital can be given antibiotics with 
wide spectrum intravenously.  Recent clinical trials have shown that patients 
treated with ertapenem gave clinical outcomes equivalent to those for 
patients treated with piperacillin/tazobactam in a randomised trial in adults 
(n = 586) with diabetes and a foot infection classified as moderate to severe 
and requiring intravenous antibiotics (Lipsky et al., 2005).  
The primary goal in the treatment of diabetic foot ulcers is to obtain wound 
closure. Along with antibiotic treatment the management of the foot ulcer is 
largely determined by the severity of grades and vascularity, along with the 
infections present. A multidisciplinary approach needs to be used because 
of the multi factorial nature of foot ulcers and the numerous co morbidities 
that can occur in the DF patients. Treatment of peripheral neuropathy and 
ischaemia is critical as these impair the delivery of oxygen, leucocytes and 
other host defence factors along with the antibiotics (Singh, Armstrong and 
Lipsky, 2005 and Steed et al., 2008). This can lead to deformities due to 
abnormal pressure and therefore it becomes imperative to tackle vascular 
supply. Many vaso-dilator drugs have been proved to be beneficial in 
promoting the healing of lesions (Caputo et al., 1994b). Since surgical 
methods would not restore the normal host factors, adjunctive therapy using 
hyperbaric oxygen therapy (Cimsit, Uzun and Yildiz, 2009) and the use of 
maggots (fly larva) for bio surgical debridement of calluses (Frykberg, 2002) 
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can prove advantageous in the healing of diabetic ulcers (Steed et al., 
1996). These calluses further increase the pressure and cause a non 
healing ulceration. Debridement promotes re-epithelialisation from the edge 
of the ulcer with a cast applied on the wound enabling the patient to walk 
freely but still keeping the pressure off the lesion (Frykberg, 2002). A 
continuous monitoring for the degree of neuropathy using a widely accepted 
instrument known as nylon Semmes-Weinstein monofilament is essential for 
closed progression of the foot (Steed et al., 2008).  
2.2.1 Trends in antibiotic resistance among the aerobic bacteria 
Organisms belonging to the Enterobacteriaceae family and the species from 
the Staphylococcus genus are the 2 most common organisms isolated from 
the diabetic foot ulcers. Antimicrobial resistance first emerged due to the 
production of β-lactamases; these are plasmid or chromosomally encoded 
bacterial enzymes that catalyse the hydrolysis of the β-lactam C-N bond of 
the β-lactam antibiotic to give the corresponding β-amino acid devoid of 
antibacterial activity (Nikaido, 1998). Resistance to β-lactam antibiotics was 
known even before penicillin was clinically used. In 1940 Abraham and 
Chain first described a bacterial enzyme in E. coli that destroyed penicillin 
and termed it as penicillinase as the structure of β-lactams were unknown 
(Mascaretti, 2003). There are 5 classes of the β-lactamases from the Gram - 
negative bacteria mainly named after their substrate profiles. β-lactamases 
are often the penicillinases, cephalosporinases and carbapenemases (Bush, 
1989). Many species of the Enterobacteriaceae family are ESBL (extended 
spectrum β-lactamase) producers and are a global problem. One study has 
highlighted the number of ESBL producing organisms from DFI. Of the total 
134 isolates of E. coli and K. pneumoniae 31 isolates showed ESBL 
production: 15 E. coli and 16 K. pneumoniae (Varaiya et al., 2008).  These 
are a group of enzymes that have the common property of providing 
resistance to extended-spectrum β-lactamases antibiotics such as 
cefotaxime, ceftazidime, ceftriaxone, cefpime and cefpirome (Rossi et al., 
2006). AmpC genes acquired by the Pseudomonas aeruginosa are 
responsible for imparting ESBL resistance. Pseudomonas aeruginosa 
exhibits high intrinsic resistance to penem antibiotics such as faropenem, 
ritipenem, sulopenem, and sulphonamides due to the permeability barrier to 
the compound (Okamoto, Gotoh and Nishino, 2001). K. pneumoniae 
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carbapenemase (KPC) and metallo- β-lactamases (MBL) are some of the 
other ESBL seen among the Enterobacteriaceae family imparting high 
antibacterial resistance (Jacoby, 2009).  
Penicillin resistance emerged in Staphylococcus aureus in the early 1940s, 
shortly after its introduction (Thornsberry, 1988). Resistant Staphylococci 
have been a clinical problem since 1944 when sulphonamide-resistant 
strains appeared among the wounded during the 2nd world war (Massad et 
al., 1993). By the 1948 it was reported that in over half of the hospital 
Staphylococcus strains were penicillin resistant. Streptomycin and 
erythromycin, tetracycline and chloromphenicol resistance had also 
developed by the 1950s. Within 10 years of the introduction of methicillin in 
the 1960 resistance to methicillin was discovered.  Staphylococcus species 
have been shown to possess the penicillin binding protein PBP2a which is 
encoded by the mec A gene. The PB2a protein has a low affinity binding for 
the beta lactam antibiotics (Grubb, 1998). This mecA gene thus has 
rendered many of the Staphylococcus species resistant to methicillin. By the 
1980s epidemic strains of MRSA emerged (Enright, 2002). In 2002, there 
were various studies reporting some strains of Staphylococcus showing 
resistance to Vancomycin. The Vanco gene Van A was co- transferred from 
the resistant organism Enterococcus faecalis NCTC 12201 to 
Staphylococcus (Chang et al., 2004). Most predominantly favoured 
organisms in DFI are the methicillin resistant Staphylococcus aureus 
(MRSA) followed by methicillin resistant Staphylococcus epidermidis 
(MRSE) (Citron et al., 2007).  
2.2.2 Trends in antibiotic resistance among the anaerobic bacteria 
Susceptibility testing of anaerobes originated after the methods had been 
used for the aerobic bacteria. Early in the 1950s  antimicrobial testing 
included the tube dilution, plate dilution and disk method, all revealing the 
minimum inhibitory concentration (MIC) but without any standardisation for 
the inoculum, period of incubation, choice of complete or partial inhibition as 
an endpoint. The testing varied in different locations; different media and 
even different methods were used (Hecht, 2002). In 1985, a standardised 
method was published for carrying out antimicrobial susceptibility testing. 
However, until today it is undergoing continuous refinement. A survey 
carried out by Smith and his colleagues (2010) as a part of the UK Clinical 
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Pathology Accreditation (CPA) scheme based in the NHS suggested that 
the methodology and reproducibility of the susceptibility testing of 
anaerobes in routine diagnostic laboratories had been diverse in different 
laboratories. Literature on the antimicrobial susceptibility of anaerobes is 
very limited as compared to the aerobes, and most often the antimicrobial 
agents are tested against very few isolates as anaerobes are difficult to 
isolate and identify; thus the frequency of testing at the hospitals is 
extremely low. This is evidenced by one study carried out in New Zealand 
by Roberts and her colleagues (2006), where she reported that over 15 
years only 3 surveys had been carried out looking at the susceptibility 
patterns of the clinical isolates (Roberts et al., 2006).  In Belgium a 3rd multi-
centre antimicrobial susceptibility survey was carried out on 443 anaerobes 
collected over a period of 2 years and their antimicrobial susceptibility 
patterns remained stable except for reduced susceptibility to clindamycin 
(Wybo et al., 2007).   
Since the early 1970s antibiotic resistance among the anaerobes has 
become evident. Bacteroides fragilis was one of the most frequently isolated 
resistant anaerobes. Bacteroides fragilis groups have shown complete 
resistance to penicillin G and clindamycin due to the presence of the ermF, 
ermG and ermS determinants (Aldridge et al., 2001). Many of the 
Clostridium species have also shown resistance to clindamycin due to 
ermQ, ermP determinants. All these determinants were shown to be 
encoded by genes on the chromosome, plasmid or transposons and are 
transferable by conjugation (Brazier et al., 2008). Piperacillin had been 
effective in the treatment of infections against anaerobes until the 1990s. No 
more than 25% of the Gram - negative anaerobes showed resistance to 
piperacillin alone (Behra-Miellet et al., 2003a). Most of the anaerobes have 
been shown to produce zinc metallo- β-lactamases encoded by the ccrA, 
cfiA genes that hydrolysed the carbapenems imipenem, meropenem and 
ertapenem (Yang et al., 1992). β-lactamases are inhibited by the classical β-
lactamase inhibitors such as clavulanic acid, sulbactam and tazobactam and 
hence these are used in combination with other antibiotics (Maiti et al., 
1998). Metronidazole resistance has been more common among the Gram -
positive anaerobes and is caused due to the presence of the nim genes 
(Mory et al., 1998). Resistance to quinolones, mainly the fluoroquinolones, 
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is seen due to the presence of the gyrA and gyrB genes (Brazier et al., 
2008). These antibiotics are generally given in combination with 
aminoglycosides or cephalosporins. Very few anaerobic strains have shown 
resistance to carbapenems such as imipenems. Most of the anaerobes are 
susceptible to piperacillin/tazobactam, ampicillin/sulbactam, meropenem 
and vancomycin (Brazier et al., 2008; Behra-Miellet et al., 2003b and Citron 
et al., 2007). One of the studies highlights the use of tetracycline showing 
there is less resistance seen among the anaerobes in the UK because 
tetracycline had not been routinely prescribed in the past (Hecht, 2004). 
Similarly fusidic acid is not frequently used in Asia hence very few resistant 
strains are seen. Although Gram – negative organisms except Bacteroides 
species are intrinsically resistant to fusidic acid but can be effective against 
the Gram – positive organisms mainly the Staphylococcus and 
Streptococcus species (Chinedum, 2005). Both these studies highlight the 
need to limit the use of antibiotics and use other mechanisms to combat 
infections (Brazier et al., 2008 and Behra-Miellet, et al., 2003b). There have 
been a  number of new antimicrobial agents used for the treatment of 
infections due to Clostridium difficile these include the lipoglycopeptides, 
macrocyclic esters, nitrothiazoles and diarytdiamines (Koeth et al., 2004; 
Brook, 2007 and Caputo, 1994a).There have been very few new 
antimicrobials developed for the treatment of Gram - negative anaerobes 
which could be a problem in the future.  
2.2.3 Biofilms in DFI and their resistance to antibiotics 
Biofilms are found to be present in two-thirds of chronic wounds and they 
are often been resistant to antibiotics (Dowd et al., 2008). In many animal 
models combinations of anaerobic and aerobic bacteria have been shown to 
produce levels of sepsis or disease that could not be induced by individual 
species (Bradshaw et al., 1996). Such synergy has been demonstrated 
between wound pathogens such as: Prevotella melaninogenicus, 
Porphyromonas asaccharolytica and Parvimonas micra (Devine et al., 1999 
and Sundqvist et al., 1979) Porphyromonas asaccharolytica and Klebsiella 
pneumoniae; Escherichia coli and Bacteriodes fragilis and Staphylococcus 
aureus (Mayrand et al., 1980). 
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There are number of familiar mechanisms of antibiotic resistance, such as 
efflux pumps (Nikaido, 1996), modifying enzymes (Livermore, 2003) and 
target mutations (Hall and Partridge, 2001). However, in biofilms even the 
most sensitive bacteria with no genetic basis for resistance can have greatly 
reduced susceptibility to antibiotics. Biofilms are defined as communities of 
microbial cells growing on a surface and embedded in a self-synthesized 
matrix composed of extracellular polymeric substances (Laue et al., 2006). 
The major components of these are the exopolysaccharides with DNA, 
protein and lipids making up a significant proportion of the matrix. These 
exopolysaccharides have been reported to play a very important role in the 
attachment of bacterial cells to the surface and/or in building and 
maintaining the three–dimensional, complex structure of the biofilms. 
Exopolysaccharides have been utilised, for example, for the initial 
attachment to a surface of the Vibrio cholerae and for the development of 
Pseudomonas, Staphylococcus epidermidis and many other pathogenic 
biofilms (Laue et al., 2006). These biofilms protect organisms from 
phagocytosis and facilitate antibiotic resistance, acting as a barrier, 
decreasing the diffusion of antibiotics, antimicrobial proteins, lysozymes and 
small molecular antimicrobials such as defensins. Biofilms concentrate 
bacterial enzymes that degrade antibiotics for example β-lactamases 
(Wilson and Devine, 2003). Antimicrobial agents kill rapidly growing 
bacterial cells more effectively than those of the slower growing ones. Some 
antibiotics, in order to be active, require certain rates of bacterial growth, for 
example penicillin and ampicillin fail to kill non-growing bacterial cells. Other 
new antibiotics such as aminoglycosides and fluoroquinolones can kill non-
growing bacterial cells, but they are more effective at killing fast growing 
cells (Wilson and Devine, 2003).  In biofilms, the bacterial cells experience 
limited diffusion of nutrients and oxygen and also accumulation of metabolic 
waste. These conditions favour anaerobic metabolism producing acidic 
compounds that act on the deeper regions of the biofilms further reducing 
the activity of certain antibiotics such as aminoglycosides and quinolones 
(Stewart and Costerton, 2001). 
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2. Materials and Method 
2.1 Research design for Indian diabetic foot Cohort study 
Ethics approval for this study was obtained for the patients from the UK and 
India (appendix I). Patient‟s consent was obtained (appendix II) and a 
questionnaire (appendix III) was designed. In collaboration with  the „All 
India Institute of Diabetes‟ at Raheja hospital in Mumbai a pilot study was 
carried out over a period of 3 months on 89 patients with diabetic foot ulcers 
admitted at Raheja hospital. This was funded by the Society for General 
Microbiology – President Fund (appendix IV). Diabetic patients were 
interviewed by their doctors about diabetes mellitus type, duration along with 
their treatment profile, level of glucose control and presence or absence of 
chronic DM complications including previous ulcer/amputation of the lower 
limbs (appendix III). Both feet were also examined for signs of peripheral 
vascular disease and neuropathic symptoms of tingling, numbness, and 
burning sensation including skin status (colour, thickness, dryness, 
cracking), nail status (colour, thickness) and the presence of deformities 
(such as claws and hammer toes), oedema, infection, ulceration, callus and 
blistering. Gangrene and amputation were also noted and if a wound existed 
it was classified on the Wagner‟s based classification system (appendix V). 
Additionally, the research nurse took measurement of patients' blood 
pressure, using a standard mercury sphygmomanometer. The WHO 
definition of hypertension was used in this study: systolic blood pressure 
160 mmHg or more and/or a diastolic blood pressure 95 mmHg or more and 
any on going treatment with anti-hypertensive drugs was recorded. Height, 
weight measurements, electrocardiogram, insulin usage and duration of 
insulin use were recorded for all patients. Other clinical parameters such as 
fasting blood sugar, lipid profile, serum electrolytes, haemoglobin, cell count 
and packed cell volume (PCV) were measured in the Biochemistry 
department of the hospital. Any other complications or diseases were also 
recorded. Clinical specimens such as tissue biopsies and pus samples were 
obtained and were processed for microbiological study. Antibiotic 
susceptibility testing was carried out on the clinical isolates obtained from 
tissues and pus specimens.  
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2.1.1 Identification of clinical isolates 
Following superficial pre-cleansing of wounds with iodine, tissue biopsies in 
case of a necrotic wound or amputated toe(s) were placed in sterile saline 
and send immediately to the Microbiology laboratory located on the same 
site as the collection ward by the duty doctor. Pus samples were aspirated 
after pre – cleansing of the wounds with iodine or in some cases swabs 
were taken by targeting the moist and necrotic areas of the ulcer which are 
likely to contain aerobic and anaerobic microbial populations.  
2.1.1.1 Clinical processing of tissue specimens 
A total of 73 tissue biopsies were cultured to record their microflora. On 
obtaining the tissue biopsies or an amputed toe, the necrotic or gangrenous 
part was teased and sectioned using forceps and scalpel and then placed 
on the slide and gram stained. Small gangrenous tissue sections were 
placed on one corner of the series of selective and non - selective media 
agar plates shown in figure 2.1, and incubated under aerobic and anaerobic 
conditions. To obtain anaerobic conditions an anaerobic gas jar with 
anaerobic gas pack – Anaerogen sachet (Oxoid, Basingstoke, UK) and an 
anaerobic indicator (Oxoid, Basingstoke, UK) were used (Ng et al., 2008). A 
sterile loop was used to spread the bacteria from the tissue by touching the 
loop on the tissue and using the streak plate technique to obtain an even 
distribution of colonies. All the microbiological processing was carried out 
immediately on receipt of the tissue specimens to sustain the viability of 
fastidious anaerobic as well as aerobic organisms.
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Figure 2.1 Selection of media agar plates for the microbiological 
processing of tissue and pus specimens 
Plates 1 to 5 was used for the processing of clinical specimens obtained from the Indian 
and the UK diabetic foot patients and incubated at different temperatures, time and 
incubation conditions.  
2.1.1.2 Clinical processing of pus specimens 
For aspirated pus, a total of 27 pus samples were cultured to record their 
microbial aetiology. A sterile loop was used and a loop full of the pus was 
streaked on the selection of different media plates shown in figure 2.1 
incubated under aerobic and anaerobic conditions. To obtain anaerobic 
conditions an anaerobic gas jar with anaerobic gas pack – Anaerogen 
sachet (Oxoid, Basingstoke, UK) and an anaerobic indicator (Oxoid, 
Basingstoke, UK) were used. All the microbiological processing was carried 
out immediately on receipt of the pus specimens to sustain the viability of 
fastidious anaerobic as well as aerobic organisms. 
2.1.1.3 Identification of organisms to genus or species 
After the respective incubation periods, shown in figure 2.1, the aerobes, 
anaerobes and fungi present  were distinguished from each other on the 
basis of their morphological characteristics such as size, colour of colonies, 
texture, consistency and most importantly Gram staining . In the case of all 
the colony types obtained from the media plates that were incubated 
anaerobically an aero-tolerance test was performed such that examples of 
each colony type were sub cultured on aerobic and anaerobic blood agar 
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plates and left for overnight incubation. To rule out the presence of Gram – 
negative aerobes on the anaerobic plates the catalase, nitrate and spot 
indole tests were carried out on the different colony types. Traditional 
biochemical testing was carried out for aerobes. Techniques usually 
followed at the Microbiology laboratory at Raheja Hospital and the schemes 
of identification shown in the figure 2.2 were followed to identify the aerobes 
to genus level. Due to lack of expertise and lack of funding at Raheja 
Hospital‟s Microbiology department, anaerobic culturing was not a regular 
practice. For this pilot study a Rapid id 32A system (Biomerieux, France) 
was used for the identification of anaerobes, Hi Staph kit (Hi - media, 
Mumbai, India), Hi Strep kit (Hi – media, Mumbai, India) and Hi Candid (Hi – 
media, Mumbai, India) were used for identification of Staphylococcus, 
Streptococcus and Candida to species level. Although, due to import, 
logistical and financial constraints, the materials were sourced from different 
suppliers than those used in the UK study, they had undergone QA and QC 
and were good substitutes, though ideally the same kits should have been 
used in both studies.  
Additionally Oxacillin discs (6 µg/ml) were used for the identification of 
methicillin resistant and methicillin sensitive Staphylococcus spp on Muller 
Hinton agar plates with a concentration of 4% of NaCl. 
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Figure 2.2 Scheme for the identification of aerobes to genus level 
using traditional biochemical tests (adapted using Bailey and Scotts, 
2002).  
The workflow shown in figure 2.2 was used in the identification of aerobes from the Indian 
DF patient‟s tissue and pus samples. The biochemical tests included for lactose fermentors 
included Indole, citrate, methyl red (MR), Voges-Proskauer (VP) and Triple sugar iron test 
(TSI) such that E. coli showed Indole (+ve), citrate (-ve), MR (+ve) and VP (-ve). Klebsiella 
spp. showed Indole (-ve), MR (-ve), VP (+ve) and citrate (+ve). Enterobacteria spp. showed 
Indole (-ve), MR (-ve), VP (+ve), citrate (+ve), TSI slant blackening. The biochemical tests 
for the identification of lactose non fermentors included Phenyl pyruvic acid test (PPA), 
urease, oxidase, nitrate, gelatin liquefaction such that Proteus spp. showed PPA (+ve), 
urease (+ve) and oxidase (-ve) while Pseudomonas spp. showed oxidase (+ve), urease (-
ve), nitrate (+ve) and gelatin liquefaction.  The biochemical tests were predicted on the 
organism‟s ability for substrate utilisation or their metabolic activities.  
Streptococcus and Enterococcus spp. were distinguished using bile esculin test being (+ve) 
for Enterococcus spp. All the bio chemicals were prepared in the hospital and the materials 
were purchased from HiMedia, Mumbai – India. 
 39 
2.1.2 Antimicrobial susceptibility testing 
2.1.2.1 Antibiotics used in the Indian study  
At Raheja hospital‟s Microbiology department the antibiotic susceptibility 
testing on aerobes was routinely carried out for the following antibiotics: 
Amikacin (Ak-30 µg), amoxicillin/clavulanic acid (Ac 20 by 10), ampicillin (A-
10 µg), ampicillin/sulbactam (As-10 by 10), azithromycin (Az-15 µg), 
carbenicillin (Cb-100 µg), cefazolin (Cz 30 µg), cefepime (Cpm 30 µg), 
cefoperazome (Cs-75 µg), ceftazidime (Ca-30 µg), ceftizoxime (Ck-30 µg), 
cefuroxime (Cu-30 µg), chloromphenicol (C-30 µg), co-trimaxazole (Co-25 
µg), gentamycin (G-10 µg), gatifloxacin (Gf-05 µg), imipenem (I-10 µg), 
lomefloxacin (Lo-10 µg), levofloxacin (Le-05 µg), meropenem (Mr-10 µg), 
nitrofurantoin (Nf-300 µg), penicillin (P-10 µg), piperacillin/tazobactam (Pt-
100 by 10) and ticarcillin/clavulanic acid (Tc-75 by 10). All of the antibiotic 
discs used were obtained from Hi-Media (Mumbai, India). For the 
anaerobes isolated from the pus and tissue specimens however, MIC 
(minimal inhibitory concentrations) was obtained. This was an important 
aspect of this study as anaerobic culturing was not carried out on regular 
basis and this was the first time in many years that antibiotic sensitivity of 
anaerobes had been assessed. The antibiotics tested against the 
anaerobes included amikacin, ciprofloxacin, clindamycin, linezolid, 
levofloxacin, piperacillin/tazobactam and metronidazole. The MIC ranges 
for all the antibiotics were 0.01 – 256 µg/ml and all of these were obtained 
as E-comb (Hi – media, Mumbai, India). Briefly the E – comb is similar to 
the E- test (used in the UK) such that the different concentrations of 
antibiotics are impregnated on Hicomb filter paper discs of strips. The comb 
is directly placed on the respective media agar plate using a sterile forceps. 
On incubation, the resulting zone of inhibition appears as an eclipse that 
intersects the concentration marking. The results are expressed in terms of 
MIC of that particular antibiotic (Hi – media Manual). The E-comb test is 
validated as by the NCCLS (National community for clinical laboratory 
standards) standards and is very commonly used in Indian hospitals as a 
quick and convenient method for determining MIC.  
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2.1.2.2 Method used for antimicrobial susceptibility testing of aerobes 
and anaerobes 
The Kirby Bauer‟s disc diffusion method was used routinely for the antibiotic 
susceptibility testing of aerobes at the Microbiological laboratory at Raheja 
hospital. NCCLS guidelines were followed for the selection of media, 
inoculum turbidity, and preparations of media plates along with the 
application of discs and the interpretations of zone of inhibition. For 
determining the MIC of anaerobes using the E-comb test, the agar diffusion 
method was used. 
2.1.2.3 Selection of media and direct colony suspension for inoculum 
preparation 
As recommended by the NCCLS, Muller Hinton agar plates with a 
concentration of 4% of NaCl were used for the susceptibility testing of 
aerobes and Brucella agar supplemented with 5% defibrinated horse blood, 
5 mg/L haemin and 1 mg/L vitamin K1 was used for the antibiotic 
susceptibility testing of anaerobes. The plates were prepared in- house in 
150 mm diameter plates containing 60ml of agar media in case of anaerobic 
testing and 30 ml of agar media for aerobic testing. The different colony 
types were suspended in sterile saline in the case of aerobes and Brucella 
broth for anaerobes and prepared to a turbidity of 0.5 McFarland turbidity 
standards (using 0.5 ml of 0.048 mol/L of barium chloride to 99.5 ml of 0.18 
mol/L of 0.36 N sulphuric acid with constant stirring to maintain a 
suspension). In total 4 antibiotic discs per media plate and 2 E-comb per 
media plate were placed using sterile forceps. 
2.1.2.4 Control organisms used in the study 
All the antibiotics were also tested on the control organisms such as E. coli 
ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 as suggested by 
the NCCLS during the susceptibility testing against aerobes. All the 
antibiotics were also tested on the control organisms such as Bacteroides 
fragilis ATCC 25285, Bacteroides thetaiotaomicron ATCC 29741 and 
Eubacterium lentum ATCC 43055 recommended by the NCCLS.  
2.1.2.5 Interpretation of antibiotic susceptibility testing 
The zone of inhibition around the tested antibiotics was measured in case of 
aerobes and interpretations were made using the breakpoints detailed in the 
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HiMedia manual validated according the NCCLS standards shown in 
Section 2.3.4 table 2.15. The breakpoints recommended by NCCLS in the 
Manual for the Methods for Antimicrobial Susceptibility Testing of Anaerobic 
Bacteria (M11-A7) were used for the MIC determination of anaerobes 
shown in Section 2.3.4.3 Table 2.17. An organism would be considered 
sensitive for a concentration of antibiotic and that implies that an infection 
due to the isolate may be appropriately treated with the dosage of an 
antimicrobial agent recommended for that type of infections unless other 
wise indicated. Intermediate levels of antibiotic susceptibility imply that the 
infection may be appropriately treated in body sites where the drugs are 
physiologically concentrated or when a high dosage of drug can be used.  
Resistant isolates are not inhibited by the usually achievable concentrations 
of the agent with normal dosage schedules and/or fail in the range where 
specific microbial resistance mechanisms are likely and clinical efficacy has 
not been reliable in treatment studies (NCCLS, M11 – A7). 
2.2 Research design for the UK diabetic foot Cohort study 
Unlike the pilot study carried out in India where the risk factors were noted 
the study carried out on the UK diabetic foot patients concentrated on 
determining the microbial aetiology of the diabetic foot ulcers and 
performing antibiotic susceptibility testing. This study was also carried out 
after obtaining ethics approval from the UK. To maintain patient‟s 
confidentiality there was no access to the patient‟s profile. Unlike the Indian 
study where tissue and pus samples were both used for microbiological 
studies , only 25 pus swabs were collected by the UCLH (University College 
London Hospitals) Clinical Microbiology laboratory and processed.   
2.2.1 Identification of clinical isolates 
2.2.1.1 Clinical processing of pus samples 
For the clinical processing of the pus samples obtained from the UK, similar 
method were used as discussed in section 2.1.1.2.  
2.2.1.3 Identification of organisms up to their genus or species 
For the identification of aerobes, kits such as API 20E (bioMerieux, France) 
were used to identify the organisms belonging to the Enterobacteriaceae 
family. Pro -Staph (Pro – lab, Ontario,Canada) was used to identify the 
Staphylococcus aureus and Staphylococcus epidermidis . Pro – Strep (Pro 
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– lab, Ontario,Canada) was used for grouping of the Streptococcus species. 
For the identification of anaerobes up to species level Rapid id 32A system 
(bioMerieux, France) was used.  
2.2.2 Antimicrobial susceptibility testing 
2.2.1 Antibiotics used in the UK study 
In the UK, since all the antibiotics were readily available, the MIC 
determination was carried out on the antibiotics generally prescribed for 
aerobic and anaerobic infections. E-test (bioMerieux, France) was used for 
determining the MIC of clinical isolates obtained in the UK study. The 
antibiotics used in this study were amoxicillin/clavulanic acid, clindamycin, 
daptomycin, erythromycin, imipenem, levofloxacin, linezolid, 
piperacillin/tazobactam and metronidazole both for aerobes and anaerobes.  
These MIC ranges for all the antibiotics were 0.01 – 256 µg/ml. 
2.2.2 Method used for antibiotic susceptibility testing of aerobes and 
anaerobes 
Similar to the Indian study discussed in section 2.1.2.2 – 2.1.2.6 the method, 
selection of media, turbidity, agar and plates, applications of E-test and 
control organisms used for the E-comb test were used for the E-test for the 
clinical isolates from the UK. 
Although originally the aim had been to keep the usage of materials 
consistent, due to logistical reasons (importing and exporting rules) this was 
not facilitated, however similar antibiotic susceptibility testing was carried 
out on different isolates obtained from India and the UK. 
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2.3 Results and Discussion  
All of the 89 patients included in the Indian cohort study had been 
diagnosed with type 2 diabetes mellitus of which 24 (26.96%) were females 
and 65 (73%) were males. The average age of females was 61 years and 
males were 57 years; both the sexes had an average 13 years of diabetes 
history and an average 10 days of hospitalisation. Of the total 89 patients 
included in this study 60 patients had undergone amputations of toe/toes 
although none had a leg amputed. After evaluating the questionnaire it was 
evident that the likely risk factors that could have led to amputations 
included peripheral vascular diseases, hypertension, ischaemic heart 
diseases, ischaemia, trauma and most significantly infection. Patients 
suffering with foot ulcers had other type 2 diabetes related complications 
affecting their kidneys, heart and liver. Due to the small numbers of each 
risk factor identified among Indian patients statistical analysis was not 
undertaken. Gangrene and infections dominated in all the 89 patients and 
hence a microbiological study identifying the organisms was imperative for 
empirical treatment.   
2.3.1 Comparative analysis of clinical isolates from pus 
specimens from the Indian and the UK diabetic foot patients 
The microbiological study was carried out on 27 pus samples along with 73 
tissue biopsies from the Indian diabetic foot patients and 25 pus samples 
from the diabetic foot patients from the UK. This section (2.3.1) details the 
clinical isolates from pus specimens from India and the UK diabetic foot 
patients. 
The diversity of both aerobic and anaerobic isolates was extensive for both 
the cohorts. From the 27 pus specimens from Indian diabetic foot patient‟s 
30 aerobes and 20 anaerobes were cultured while from 25 pus specimens 
from the UK 35 were aerobes and only 5 anaerobes. Not surprisingly neither 
of the cohorts‟ pus samples showed  infections due to fungi.  
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2.3.1.1 Distribution of aerobes from the Indian and UK diabetic 
foot pus samples 
There were 12 and 13 Gram – positive aerobes and 18 and 7 Gram – 
negative aerobes isolated from the 27 and 25 pus samples from Indian and 
the UK diabetic foot patients respectively. The Gram – positive aerobes from 
the Indian diabetic foot pus samples mainly included the methicillin resistant 
Staphylococcus species, methicillin sensitive Staphylococcus species and 
Streptococcus species. With the use of Hi Staph kit the methicillin resistant 
species were identified and these included S. aureus, S. arlettae, S. 
intermedius, S. kloosii, S. capitis, S. schleiferi and S. epidermidis. 
Streptococcus species were mainly Streptoccocus pyogenes. The Gram – 
negative aerobes from the Indian diabetic foot pus samples mainly belonged 
to the Enterobacteriaceae family as shown in figure 2.3.  
The Gram – positive aerobes from the diabetic foot patients from the UK 
mainly included the methicillin resistant Staphylococcus species, methicillin 
sensitive Staphylococcus species and the Streptococcus species. Pro – 
Strep kit identified the Streptococcus species to be from Group B, F, D and 
G and Pro – Staph kit identified the Staphylococcus species to be methicillin 
resistant Staphylococcus aureus (n = 6), methicillin sensitive 
Staphylococcus aureus (n = 2), methicillin resistant Staphylococcus 
epidermidis (n = 2) and methicillin sensitive Staphylococcus epidermidis (n = 
1). The Gram – negative aerobes from the diabetic foot pus samples from 
the UK mainly belonged to the Enterobacteriaceae family as shown in figure 
2.3. 
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Figure 2.3 Distribution of aerobes from the diabetic foot pus samples 
from India and the UK 
The total number of Gram – positive aerobes and Gram – negative aerobes from the Indian 
and UK diabetic foot patients. MSS spp – methicillin sensitive Staphyloccocus species, 
MRS spp – methicillin resistant Staphylococcus species, E. coli – Escherichia coli, P. 
aeruginosa – Pseudomonas aeruginosa and K. pneumoniae – Klebsiella pneumoniae. The 
aerobes from India were identified using traditionally used biochemical identification while 
Rapid id 20E was used for identifying Gram – negative aerobes from the 
Enterobacteriaceae family while Hi – Staph and Hi Strep was used to identify the 
Staphylococcus and Streptococcus species in the UK.  
2.3.1.2 Distribution of anaerobes from the Indian and the UK 
diabetic foot pus samples  
The figures 2.4 and 2.5 clearly show that in comparison to the UK cohorts 
the Indian diabetic foot pus samples showed high number of anaerobes 
suggesting the severity of infections.  From the total 20 anaerobes from the 
27 Indian pus samples there were 13 Gram – positive anaerobes mainly the 
Clostridium species and among the 7 Gram – negative anaerobes mainly 
included the Bacteroides ureolyticus (n = 5) with Fusobacterium (n = 1) and 
Veillonella species (n = 1). While from the total 5 anaerobes from the UK 
diabetic foot pus samples 3 of them were Clostridium species and others 
belonged to Bacteroides ureolyticus and Veillonella species.
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Figure 2.4 Distribution of Clostridium species from the diabetic foot 
pus samples from India and the UK  
The number of Clostridium species recognised using Rapid id 32A for the Indian and the 
UK diabetic foot pus samples.  
 
 
Figure 2.5 Distribution of Gram – negative anaerobes from the diabetic 
foot pus samples from India and the UK  
The number of Gram - negative species recognised using Rapid id 32A for the Indian and 
the UK diabetic foot pus samples.  
 
The number of pus samples only infected due to aerobes in the UK diabetic 
cohorts exceeds four fold that from India. While the number of pus samples 
with mixed infections from India was higher than that of UK as seen in table 
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2.10 Although it should be taken into consideration the table 2.10 only 
discusses the number of pus samples with aerobes or anaerobes or fungi or 
mixed infections. The numbers are reflected in figures 2.3 - 2.5 discussed 
earlier.  
Table 2.10 Evaluation of aerobes, anaerobes and fungi from pus 
samples from the diabetic foot patients from India and UK 
 
 
Number of 
species grown 
Status India UK 
Number of pus with aerobes 
only 7 31 
Number of pus with 
anaerobes only 0 0 
Number of pus with fungi only 0 0 
Number of pus with mixed 
infection 16 6 
Number of pus with no growth 4 1 
 
The table 2.10 shows the evaluation of the microbial flora from the Indian and UK diabetic 
foot pus samples although statistically significant correlation cannot be made due to the 
small sample sizes. 
2.3.2 Distribution of aerobes, anaerobes and fungi obtained 
from the tissue specimens from the Indian diabetic foot 
patients 
Due to the severity of infections and amputations seen among the Indian 
diabetic foot patients, tissue biopsies were also sent to the Microbiological 
laboratory at Raheja Hospital – India for microbiological culturing. On 
microbiological processing of tissues samples, a wide variety of organisms 
were identified. Figure 2.6 shows the percentage of each aerobe cultured 
from tissue specimens with 34% belonging to methicillin sensitive 
Staphylococcus species and 13% methicillin resistant Staphylococcus 
species. Among the gram negative aerobes E. coli and P. aeruginosa were 
shown to comprise 10% of the total gram negative organisms. In total from 
73 tissue samples 77 aerobes were cultured of which 42 were Gram – 
positive aerobes and 35 were Gram – negative aerobes.  
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Figure 2.6 Distribution of aerobes from the tissue specimens from the 
Indian diabetic foot patients 
The total number of Gram – positive aerobes and Gram – negative aerobes from the Indian 
diabetic foot patient‟s tissues. MSS spp – methicillin sensitive Staphyloccocus species (n = 
26), MRS spp – methicillin resistant Staphylococcus species (n = 10), E. coli – Escherichia 
coli (n = 8), P. aeruginosa – Pseudomonas aeruginosa (n = 4) and K. pneumoniae – 
Klebsiella pneumoniae (n = 8). These were identified using traditionally used biochemical 
identification. 
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There were a total of 51 anaerobes cultured from the tissue specimens, 33 
Gram – positive and 18 Gram – negative. The Gram – positive anaerobes 
were mainly from the Clostridium species other Gram – positive anaerobes 
(n = 13) included those from Peptostreptococcus species and Eubacterium 
and Actinomycetes as seen in Figure 2.7 
 
Figure 2.7 Distribution of Gram – positive anaerobes from the tissue 
specimens from the Indian diabetic foot patients 
Clostridium species (n = 20) and other Gram – positive anaerobes (n = 13) cultured from 
the tissues specimens from the Indian diabetic foot patients. These were identified to their 
species level using Rapid ID 32A. 
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Among the 18 Gram – negative anaerobes 71% were identified as 
Bacteroides ureolyticus Veillonella, Fusobacterium and Capnocytophaga 
were also isolated as shown in figure 2.8. 
 
Figure 2.8 Distribution of Gram – negative anaerobes from the tissue 
specimens from the Indian diabetic foot patients 
The identification of Gram – negative anaerobes up to their species level was facilitated 
with the use of Rapid Id 32A.  
 
Fungi were only cultured from the tissue samples from the Indian diabetic 
foot patients and not from the pus samples from the diabetic foot patients 
from either India or the UK as shown in figure 2.9. The most common fungi 
were the Candida species with Candida tropicalis being the highest detected 
(n = 7) from the total 14 Candida species obtained from 73 tissues. 
 
Figure 2.9 Distribution of fungi from the tissue specimens from the 
Indian diabetic foot patients 
Candida species were identified using the Hi Candid kit available from Hi Media, Mumbai, 
India. 
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Of the total 73 tissues 22 tissues only had infection due to aerobes, while 5 
tissues only had infections caused due to anaerobes as seen in table 2.11. 
37 tissues showed mixed infections while none of the tissues showed 
infections caused solely due to Candida suggesting that fungi were from 
mixed cultures.  
Table 2.11 Evaluation of aerobes, anaerobes and fungi from tissue 
samples from the diabetic foot patients from India 
 
Status  
Number of 
species cultured 
Tissues with aerobes only 22 
Tissues with anaerobes only 5 
Tissues with fungi only 0 
Tissues with mixed infection 37 
Tissues with no growth 9 
 
2.3.3 Distribution of aerobes, anaerobes and fungi from the 
Indian pus and tissue specimens according to their 
Wagner’s grades  
The diabetic foot patient‟s ulcers from the Indian study all were categorised 
according to their Wagner‟s grades (Appendix V). The categories of 
organisms obtained from these ulcers are grouped and shown in the table 
2.12 . 
Table 2.12 Spectrum of aerobic organisms from pus and tissue 
specimens from the Indian diabetic foot patients correlated to their 
Wagner’s grades 
Aerobes from pus and 
tissues Wagner’s Grades 
 I II III IV 
MSS spp (n = 35) 4 10 12 9 
MRS spp (n = 12) 0 0 9 3 
Enterococcus (n = 7) 0 3 3 1 
E. coli (n = 12) 0 5 3 4 
P. aeruginosa (n = 8) 0 1 3 4 
S. pyogenes (n = 9) 2 3 2 2 
K. pneumoniae (n = 11) 2 3 4 2 
Proteus spp (n = 8) 0 0 4 4 
Actinomycetes (n = 5) 0 0 2 3 
The aerobes categorised in this table includes collections from both pus and tissue 
specimens from the Indian diabetic foot patients. 
 
From the table 2.12 it is clear that MRS spps mainly were obtained from 
grades III and IV suggesting that the infections must have been deep 
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seated. MSS spps were isolated from all grades with higher numbers seen 
in grades II and III. Amongst the Gram – negative aerobes P. aeruginosa, 
Actinomycetes and Proteus species were isolated from higher grade 
infections, mainly grades III and IV.  
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Among the anaerobes from the tissue specimens it is evident from the table 
2.13 shown below that they were more commonly obtained from grades III 
and IV again suggesting the severity of infections. This was expected as 
most of the tissues obtained were from an amputed toes or from patients 
who had high level of infection. 
Table 2.13 Spectrum of anaerobic organisms from pus and tissue 
specimens from the Indian diabetic foot patients as per their Wagner’s 
grades 
 
Anaerobes from pus and 
tissues Wagner’s Grades 
 I II III IV 
Actino.naeslundii 0 0 1 1 
Anaerococcus prevottii 0 0 0 1 
Bacteroides ureolyticus 2 3 5 8 
Capnocytophaga 0 1 0 0 
Clostridium acetobutylicum 0 2 2 1 
Clostridium buturicum 0 0 1 0 
Clostridium diificile 0 0 1 1 
Clostridium fallax 0 1 0 0 
Clostridium histolyticum 0 0 1 0 
Clostridium innocuum 0 0 2 1 
Clostridium paraputrificum 0 2 2 1 
Clostridium perfringens 0 2 1 2 
Clostridium tertium 0 0 1 3 
Clostridium tetani 0 0 2 3 
Clostridium tyrobutricum 0 1 1 0 
Eubacterium limosum 0 0 2 3 
Fusobacterium necrogenes 0 0 0 1 
Fusobacterium varium 0 0 0 1 
Parvimonas micra 0 0 1 0 
Peptoniphilus asaccharolyticus 0 0 2 1 
Peptostreptococcus anaerobius 0 0 0 1 
Propionibacterium acnes 0 0 1 0 
Veillonella sps 0 1 2 1 
The anaerobes categorised in the table 2.13 includes collections from both pus and tissue 
specimens from the Indian diabetic foot patients. 
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Similar to the anaerobes the Candida species were more commonly isolated 
from grades III and IV as shown in the table 2.14 below 
Table 2.14 Spectrum of Candida species from the tissue specimens 
from the Indian diabetic foot patients as per their Wagner’s grades 
 
Candida species from tissues Wagners Grades 
 I II III IV 
Candida guilliermondii 0 0 0 1 
Candida tropicalis 0 0 2 5 
Candida rugosa 0 0 1 0 
Candida glabrata 0 1 0 0 
Candida krusei 0 0 1 0 
Candida pseudotropicalis 0 1 0 0 
Candida kefyr 0 0 1 0 
Candida stellatoid 0 0 1 0 
The Candida species categorised in the table 2.14 include collections from only the tissue 
specimens from the Indian diabetic foot patients as there were no fungi cultured from the 
pus samples. 
 
Although there were high numbers of anaerobes and Candida species 
obtained from Grades III and IV as seen from tables, the figure below shows 
a steady increase in the number of anaerobes as the Wagner‟s grades 
increases from I - III. At grade IV the numbers of anaerobes and fungi were 
similar to those found at grade III. The number of aerobes also showed an 
increase up to grade III but at grade 4 there was a decrease in numbers.  
 
Figure 2.10 Average numbers of organisms per Wagner’s grades 
isolated from the pus and tissue specimens from Indian diabetic foot 
patients   
Total aerobes (n = 107), anaerobes (n = 71) and fungi (n= 14) combined from pus and 
tissues.
 55 
2.3.4 Antimicrobial susceptibility testing of aerobes and 
anaerobes from the diabetic foot patients from India and the 
UK 
From the 27 pus and 73 tissue specimens from the Indian diabetic foot 
patients there were in total 107 aerobes and 71 anaerobes cultured. 
Antimicrobial sensitivity however was only carried out on 79 aerobes and 51 
anaerobes. From the UK diabetic foot pus samples the total numbers of 
aerobes cultured were 35 and anaerobes 5, antimicrobial susceptibility 
testing however was only carried out on 23 aerobes and for all 5 cultured 
anaerobes. 
As a routine practice antimicrobial testing by Kirby Bauer‟s disk diffusion 
method on aerobes is regularly carried out at Raheja Hospital in India. 
Therefore for antimicrobial susceptibility testing of aerobes antibiotic discs 
were used with the recommended NCCLS antibiotic potency. The antibiotic 
disc were purchased from Hi media (Mumbai India) and their manual was 
used to categorise the organisms antibiotic profiles (sensitive, intermediate 
and resistant) and these are extracted from the Hi media manual and 
represented in table 2.15. 
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Table 2.15 Zone-size interpretive charts for antibiotics used for testing 
aerobes from the Indian diabetic foot patient’s pus and tissue 
specimens  
Hi-media 
interpretation for the 
following antibiotics 
Potency Sensitive 
(mm or 
more) 
Inter-
mediate 
Resistant 
(mm or less) 
Amikacin 30 mcg 17 15-16 14 
 
 
 
Amoxicillin/ Clavulanic 
acid 
30 mcg 
for 
Staphyloc
occus  
 
 
20 
 
 
_ 
 
 
19 
30 mcg 
for enteric 
organism 
 
 
18 
 
 
14-17 
 
 
13 
 
 
 
 
Ampicillin 
10 mcg 
for 
Staphyloc
occus 
 
29 
 
_ 
 
 
28 
10 mcg 
for  
Strepto - 
coccus  
 
26 
 
19-25 
 
18 
Ampicillin/Sulbactam 10 mcg 15 12-14 11 
Azithromycin 15 mcg 18 14-17 13 
 
 
 
 
 
Carbenicillin 
100 mcg 
for enteric 
organism 
 
 
 
23 
 
 
20-22 
 
 
19 
100 mcg 
for 
Pseudom
onas 
aerugi-
nosa 
 
 
17 
 
 
14-16 
 
 
13 
Cefazolin 30 mcg 18 15-17 14 
Cefepime 30 mcg 18 15-17 14 
Cefoperazone 75 mcg 21 16-20 15 
Ceftazidime 30 mcg 18 15-17 14 
Ceftizoxime 30 mcg 20 15-19 14 
Cefuroxime 30 mcg 18 14-17 13 
Chloramphenicol 30 mcg 21 18-20 17 
Co-trimaxazole 23.75 
mcg 
19 16-18 15 
Gentamicin 10 mcg 15 13-14 12 
 
 
Gatifloxacin 
5 mcg for  
Staphyloc
occus 
 
23 
 
20-23 
 
19 
5 mcg for 
Strepto-
coccus 
 
21 
 
18-20 
 
19 
Imipenem 10 mcg 16 14-15 13 
 
 
 
5 mcg 
Staphyloc
occus 
 
19 
 
16-18 
 
15 
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Levofloxacin  5 mcg for 
enteric 
and 
Strepto-
coccus 
 
 
 
17 
 
 
 
14-16 
 
 
 
13 
Lomefloxacin 10 mcg 22 19-21 18 
Meropenem 10 mcg 16 14-15 13 
Nitrofurantoin 300 mcg 17 15-16 14 
Penicillin 10 units 29 - 28 
Piperacillin/tazo-
bactum 
100/10 
mcg 
21 18-20 17 
 
 
 
 
 
 
 
Ticacillin/Clavulanic 
acid 
75/10 
mcg for 
enteric 
and 
Pseudom
onas spp  
 
 
20 
 
 
 
15-19 
 
 
14 
75/10 
mcg for 
Staphyloc
occus spp 
 
 
23 
 
 
_ 
 
 
22 
*based on results obtained using Muller Hinton agar by disc – diffusion method  
* Hi media chart used which is validated in accordance to the performance standards for 
antimicrobial disc tests by NCCLS. 
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2.3.4.1 Antimicrobial susceptibility testing of Gram – positive 
aerobes from the diabetic foot patients from India and the 
UK 
There are some antibiotics which were commonly tested in the UK and India 
and therefore the data is represented in this manner. It is very important to 
note that there is no significant comparison as the antibiotic methods used 
in India and UK was different due to logistical issues of importing/exporting 
of antibiotics. In India the method followed was Kirby Bauer‟s disk diffusion 
using antibiotic discs (normally carried out at Raheja Hospital – India) as per 
NCCLS standards. While in the UK due to the availability of E-test, MIC was 
carried out on aerobes using the agar diffusion method as per NCCLS 
standards but represented not as MIC value but as sensitive, intermediate 
and resistant. The antimicrobial susceptibility testing was carried out on 45 
Gram – positive aerobes cultured from the Indian DF patient‟s pus and 
tissue specimens while 14 Gram – positive aerobes cultured from the UK 
DF patient‟s pus specimens as shown in the figures below.  
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The antibiotics tested in India and the UK included amikacin, 
amoxicillin/clavulanic acid, imipenem, levofloxacin and 
piperacillin/tazobactam. The figure 2.11 below represents the MSS species 
susceptibility profiles and it is evident that few MSS spps showed resistance 
to the tested antibiotics in either the Indian and UK cohorts. Higher numbers 
in the range of 16-22 out of the 26 MSS spps from Indian DF patients 
showed susceptibility to all the tested antibiotics. Similar results were seen 
from the DF patients from the UK. 
  
 
Figure 2.11 In vitro activities of antimicrobial agents against methicillin 
sensitive Staphylococcus species obtained from the Indian diabetic 
foot pus and tissue specimens and pus specimens from the UK 
Antibiotics discs: Amikacin (30 µg), amoxicillin/clavulanic acid (20 by10), imipenem (10 µg), 
levofloxacin (05 µg) and piperacillin/tazobactam (100 by 10) used from MSS spps from 
Indian tissues and pus specimens. All the E-test strips ranged from 0.01 to 256 µg/ml used 
for the MSS species from the UK. 
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A different type of sensitivity to the tested antibiotics was seen in figure 2.12 
for the MRS spp from the two cohorts. All the MRS spp from the UK DF 
patients showed sensitivity to amikacin, 5 out of 6 showed sensitivity to 
imipenem, levofloxacin and piperacillin/tazobactam and a complete 
resistance to amoxicillin/clavulanic acid. While in the range of 3 – 8 out of 12 
of the MRS spp from the Indian DF patients showed sensitivity to the tested 
antibiotics worryingly there were a number of intermediate strains of MRS 
spp which could become resistant in the future.  
 
 
Figure 2.12 In vitro activities of antimicrobial agents against methicillin 
resistant Staphylococcus species obtained from the diabetic foot pus 
and tissue specimens from India and pus specimens from the UK  
Antibiotics discs: Amikacin (30 µg), amoxicillin/clavulanic acid (20 by10), imipenem (10 µg), 
levofloxacin (05 µg) and piperacillin/tazobactam (100 by 10) used from MRS spps from 
Indian tissues and pus specimens. All the E-test strips ranged from 0.01 to 256 µg/ml used 
for the MRS species from the UK 
 
 
 
 61 
As seen in the figure 2.13 all the Streptococcus strains from the Indian and 
the UK DF patient‟s specimens showed good sensitivity to the tested 
antibiotics with no intermediate levels seen. However, 5/7 tested from the 
Indian group and 2/3 of the UK group showed resistance to 
amoxicillin/clavulanic acid. In the Indian group 1/7 was resistant to amikacin 
and 1/7 to levofloxacin.    
Figure 2.13 In vitro activities of antimicrobial agents against 
Streptococcus species from the Indian diabetic foot pus and tissue 
specimens and pus specimens from the UK 
Antibiotics discs: Amikacin (30 µg), amoxicillin/clavulanic acid (20 by10), imipenem (10 µg), 
levofloxacin (05 µg) and piperacillin/tazobactam (100 by 10) used from Streptococcus spps 
from Indian tissues and pus specimens. All the E-test strips ranged from 0.01 to 256 µg/ml 
used for the Streptoccocus species from the UK. 
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2.3.4.2 Antimicrobial susceptibility testing of Gram – 
negative aerobes from the diabetic foot patients from India 
and the UK 
The antimicrobial susceptibility testing was carried out on 34 Gram – 
negative aerobes from the Indian DF patient‟s pus and tissue specimens 
and 10 Gram – negative aerobes from the UK DF patient‟s pus specimens. 
Good susceptibility was seen for the two P. aeruginosa strains from the UK 
DF patient‟s pus samples as seen in the Figure 2.14. Fifty percent of the 
isolates were resistant to amoxicillin/ clavulanic acid. Among the 8 tested P. 
aeruginosa strains from the Indian DF patient‟s pus samples 7 were 
sensitive to imipenem and piperacillin/tazobactam while 50% showed 
sensitivity and 50% resistance to levofloxacin. There were 5 strains (50%) 
showing resistance to amoxicillin/clavulanic acid.   
 
 
Figure 2.14 In vitro activities of antimicrobial agents against P. 
aeruginosa from the Indian diabetic foot pus and tissue specimens 
and pus samples from the UK 
Antibiotics discs: Amikacin (30 µg), amoxicillin/clavulanic acid (20 by10), imipenem (10 µg), 
levofloxacin (05 µg) and piperacillin/tazobactam (100 by 10) used from P. aeruginosa spps 
from Indian tissues and pus specimens. All the E-test strips ranged from 0.01 to 256 µg/ml 
used for the P. aeruginosa species from the UK.
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In the figure 2.15 below, eleven  K. pneumoniae strains from the Indian DF 
patients pus and tissue specimens showed good sensitivity to imipenem (10 
out of 11) amikacin (7 out of 11) and levofloxacin and 
piperacillin/tazobactam (6 out of 11) although 5 strains did show resistance 
to levofloxacin. Among the isolates from UK DF patients K. pneumoniae 
showed good susceptibility to all the tested antibiotics with one isolate 
intermediate and one isolate resistant to imipenem. 
 
 
Figure 2.15 In vitro activities of antimicrobial agents against K. 
pneumoniae from the Indian diabetic foot pus and tissue specimens 
and pus samples from the UK 
Antibiotics discs: Amikacin (30 µg), amoxicillin/clavulanic acid (20 by10), imipenem (10 µg), 
levofloxacin (05 µg) and piperacillin/tazobactam (100 by 10) used from K. pneumoniae spps 
from Indian tissues and pus specimens. All the E-test strips ranged from 0.01 to 256 µg/ml 
used for the K. pneumoniae species from the UK 
 
The antibiotic susceptibility testing was also carried out on Citrobacter 
species and Serratia species cultured from the diabetic foot pus samples 
from the UK but due to the very low numbers, data is not presented in this 
study.
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On a routine basis in the Microbiology laboratory at Raheja Hospital in India 
the Kirby Bauer‟s disc diffusion method was performed using the antibiotics 
discussed in the materials and methods section. The table below (table 
2.16) illustrates the number aerobes, from the pus and tissue specimens 
from Indian diabetic foot patients, tested that showed resistance against the 
19 antibiotics used. 
Table 2.16 In vitro activities of 19 antibiotic discs against aerobes from 
the Indian diabetic foot patient’s pus and tissue specimens  
Antibiotics No of resistant strains  
 MRS 
spp 
(n = 
12) 
MSS 
spp 
(n = 
26) 
Strepto-
coccus  
spp 
(n = 7) 
P. 
aeru- 
ginosa 
(n = 8) 
K. 
pneu- 
moniae 
(n = 
11) 
E. 
coli 
(n = 
8) 
Acineto
-bacter 
(n = 7) 
Ampicillin (10 µg) 8 5 2 4 8 6 3 
Ampicillin/sulbactam
(10 by 10) 
5 1 3 6 6 2 2 
Azithromycin  
(15 µg) 
5 7 2 3 9 1 2 
Carbenicillin  
(100 µg) 
5 7 1 5 4 4 3 
Cefazolin (30 µg) 6 3 2 0 7 4 4 
Cefepime (30 µg) 4 6 2 4 4 3 1 
Cefoperazome  
(75 µg) 
5 2 2 3 5 3 3 
Ceftazidime (30 µg)  7 5 1 4 4 4 3 
Ceftizoxime (30 µg)  8 6 1 4 4 4 3 
Cefuroxime (30 µg) 7 4 1 0 4 4 3 
Chloramphenicol 
(30 µg) 
2 3 1 5 3 2 2 
Co-trimaxazole  
(25 µg) 
7 14 3 6   7 6   5 
Gentamicin (10 µg) 6 3 1 3 4 2 1 
Gatifloxacin (05 µg) 2 1 1 3 2 3 2 
Lomefloxacin  
(10 µg) 
7 18 2 4 5 5 2 
Meropenem (10 µg) 6 1 1 2 1 1 3 
Nitrofurantoin  
(300 µg) 
0 1 2 4 3 2 4 
Penicillin (10 µg) 10 2 2 4 5 2 5 
Ticarcillin/clavulanic 
acid (75 by 10) 
6 2 4 4 6 5 1 
 
From the table 2.16 it is clear that there are some organisms showing high 
resistance to the antibiotics. Those organisms showing more than 50% 
resistant strains are highlighted in bold.  More than 50% of the MRS spp 
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showed resistance to ceftazidime (30 µg), ceftizoxime (30 µg), cefuroxime 
(30 µg), co –trimaxazole (25 µg), lomefloxacin (10 µg) and penicillin (10 µg). 
While more than 50% of the MSS spp showed resistance to co – 
trimaxazole (25 µg) and lomefloxacin (10 µg).  Gram – positive 
Streptococcus spp showed reasonably good sensitivity to all the tested 
antibiotics with very little resistance seen. In the Gram – negative aerobes 
more than 50% of the K. pneumoniae strains showed resistance to 
ampicillin (10 µg), azithromycin (15 µg), cefazolin (30 µg) and co – 
trimaxazole (25 µg), More than 50% of the E. coli strains showed resistance 
to ampicillin (10 µg), co – trimaxazole (25 µg) lomefloxacin (10 µg) and 
ticarcillin/clavulanic acid (75 by 10). Acinetobacter only showed resistance 
to co – trimaxazole (25 µg).    
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2.3.4.3 Antimicrobial susceptibility testing of anaerobes from 
the diabetic foot patients from India and the UK 
As anaerobic culturing was not routine in Raheja hospital the antimicrobial 
testing therefore was also not common hence with the funds available from 
the Society for General Microbiology MIC testing was carried out on the 
anaerobes obtained from India and UK by using agar diffusion method. In 
India the MIC were obtained using E-comb purchased from Hi media 
(Mumbai, India) which is the most popularly used company for 
microbiological testing in the country. While in the UK the most popular and 
convenient MIC testing method using E-test that is used by many hospitals 
was utilised for anaerobic susceptibility testing. The interpretations were 
made using the NCCLS standards for each antibiotic and represented in the 
table 2.17. 
Table 2.17 MIC interpretive chart for antibiotics used for testing 
aerobes and anaerobes from the UK diabetic foot patient’s pus and 
anaerobes from the Indian diabetic foot patient’s pus and tissue 
specimens 
   
NCCLS interpretation for 
the following antibiotics 
Sensitive Intermediate Resistant 
Amikacin ≤16 32 ≥ 64 
Amoxicillin/ Clavulanic acid ≤ 4/2 8/4 ≥16/8 
Ciprofloxacin ≤ 8 16 ≥ 32 
Clindamycin ≤ 1 2 ≥ 4 
Daptomycin ≤ 1 - - 
Erythromycin ≤ 0.5 1-4 ≥ 8 
Imipenem ≤ 4 8 ≥ 16 
Levofloxacin ≤ 2 4 ≥ 8 
Linezolid ≤ 2 4 ≥ 8 
Piperacillin/tazobactam ≤ 32/4 64/4 ≥ 128/4 
All the results are based on results obtained using Brucella agar with supplements and 
using E-test from bioMerieux, France). 
 
The tables 2.18 to 2.23 below are the MIC ranges using E-test (bioMerieux, 
France) and E-comb (HiMedia, Mumbai, India) for pus samples from the UK 
and pus and tissue samples from India respectively. Since most of the MIC 
ranged between intermediate to resistant for the anaerobes tested within the 
Indian diabetic foot cohorts; the data is represented in tables 2.18 to 2.23.  
The tables 2.18 to 2.23 below are the comparison of antibiotics tested on 
the anaerobes cultured from India and UK. This data represents a pilot 
study and can be informative but cannot be considered statistically 
significant due to the low numbers of anaerobes isolated. 
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Among the Gram – positive anaerobes from the Indian DF patient‟s pus and 
tissue specimens in vitro antimicrobial testing was only carried out on 37 
strains while from the UK only 3 strains were tested. 
   
Table 2.18 Comparative in vitro activities of antimicrobial agents 
against Clostridium species from the pus and tissue specimens from 
Indian and pus samples from the UK diabetic foot patients  
 
Organism Country Antibiotics MIC distribution µg/L 
   0.016 – 4 8 – 64 128 – 256 
 
Clostridium 
species 
(n = 28) 
 
 
India 
Amikacin 2 8 18 
Ciprofloxacin 1 2 25 
Clindamycin 1 3 23 
Linezolid 10 6 12 
Levofloxacin 3 3 21 
Piperacillin/ 
Tazobactum 
1 7 20 
  Metronidazole 20 0 0 
      
 
 
Clostridium 
species 
(n = 3) 
 
 
 
UK 
Amikacin 0 1 2 
Amoxicillin/ 
Clavulanic acid 
0 1 2 
Clindamycin 0 0 3 
Daptomycin 1 0 2 
Erythromycin 0 1 2 
Imipenem 3 0 0 
Levofloxacin 3 0 0 
 Linezolid 0 2 1 
  Piperacillin/ 
Tazobactam 
2 1 0 
  Metronidazole 3 0 0 
The Clostridium species in the table 2.18 from the Indian diabetic foot patients specimens 
included the Clostridium acetobutylicam, Clostridium butyricum, Clostridium difficile, 
Clostridium fallax, Clostridium histolyticum, Clostridium innocuum, Clostridium 
paraputrificum, Clostridium perfringens,Clostridium tetani, Clostridium tyrobutyricum and 
Clostridium tertium.  
The Clostridium species from the diabetic foot patient‟s specimens from the UK mainly 
included Clostridium sporogens, Clostridium tertium and Clostridium perfringens.   
 
As seen in the table 2.18 there are very few Clostridium strains from the 
Indian DF patient‟s tissues and pus specimens showing complete sensitivity 
to the tested antibiotics. Of 28 Clostridium species isolated, 10 showed MIC 
in the range of 0.016 – 4 µg/L to linezolid and as per NCCLS the 
breakpoints are ≤ 2 µg/L not all the 10 strains would still be accepted as 
they were still sensitive to Linezolid. Clostridium spps from the UK DF pus 
specimens showed complete sensitivity to imipenem, levofloxacin and 
metronidazole (MIC for all antibiotics less than 2 µg/L). No significant 
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comparison can be made between the Indian and the UK Clostridium 
species as the numbers isolated were not comparable. 
 
Among the Gram – negative species antimicrobial susceptibility testing was 
carried out on the Bacteroides and Veillonella species which were obtained 
from the Indian and the UK DF patient‟s clinical specimens. In total the in 
vitro antimicrobial testing was carried out on 14 Gram – negative anaerobes 
from the Indian DF patient‟s pus and tissue specimens and 2 from the DF 
patient pus samples from the UK. 
 
Table 2.19 Comparative in vitro activities of antimicrobial agents 
against Bacteroides species from the pus and tissue specimens from 
the Indian and pus samples from the UK diabetic foot patients 
 
  
Organism Country Antibiotics MIC distribution µg/L 
   0.016 – 4 8 – 64 128 – 256 
 
Bacteroi-
des 
species 
(n = 8) 
 
 
India 
Amikacin 2 2 4 
Ciprofloxacin 2 2 4 
Clindamycin 1 3 4 
Linezolid 4 1 3 
Levofloxacin 3 0 5 
Piperacillin/ 
Tazobactum 
2 2 4 
  Metronidazole 4 0 4 
      
 
 
Bacteroi-
des 
species 
(n =1) 
 
 
 
UK 
Amikacin 0 0 1 
Amoxicillin/ 
Clavulanic acid 
0 0 1 
Clindamycin 0 0 1 
Erythromycin 0 1 0 
Imipenem 1 0 0 
Levofloxacin 1 0 0 
 Linezolid 1 0 0 
  Piperacillin/ 
Tazobactam 
1 0 0 
  Metronidazole 1 0 0 
The Bacteroides species from the Indian diabetic foot specimens mainly included the 
Bacteroides ureolyticus species while from the UK diabetic foot specimens were 
Bacteroides fragilis.  
 
Bacteroides species isolated from the Indian DF patient‟s clinical specimens 
comprised high numbers of strains that were likely to show resistance when 
compared with the NCCLS breakpoints in table. Similar to the Clostridium 
strains shown in table from the Indian DF samples more than half of the 
Bacteroides spp showed MIC in the range of 0.016 – 4 µg/L however, we 
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cannot state that all the strains were sensitive as the breakpoints for 
linezolid according to NCCLS is ≤ 2 µg/L implying that the strains are either 
sensitive or intermediate. From the UK DF patient‟s pus specimens however 
the Bacteroides species showed sensitivity to imipenem, levofloxacin, 
linezolid, piperacillin/tazobactam and metronidazole (all MIC of less than 2 
µg/L). 
 
Table 2.20 Comparative in vitro activities of antimicrobial agents 
against Veillonella species from the pus and tissue specimens from 
the Indian and pus samples from the UK diabetic foot patients 
 
All the 3 Veillonella species from the Indian DF patient‟s showed resistance 
to all the tested antibiotics but within the UK DF patient‟s samples Veillonella 
showed good sensitivity to levofloxacin, linezolid, piperacillin/tazobactam 
and metronidazole (all with the MIC of less than 2 µg/L). 
 
Organism Country Antibiotics MIC distribution µg/L 
   0.016 – 4 8 – 64 128 - 256 
 
Veillonella
species 
(n = 3) 
 
 
India 
Amikacin 1 1 1 
Ciprofloxacin 0 0 3 
Clindamycin 0 1 2 
Linezolid 0 1 2 
Levofloxacin 0 1 2 
Piperacillin/ 
Tazobactum 
0 1 2 
  Metronidazole 0 2 1 
      
 
 
Veillonella 
species 
(n =1) 
 
 
 
UK 
Amikacin 0 0 1 
Amoxicillin/ 
Clavulanic acid 
1 0 0 
Clindamycin 0 0 1 
Erythromycin 0 0 1 
Imipenem 0 1 0 
Levofloxacin 1 0 0 
 Linezolid 1 0 0 
  Piperacillin/ 
Tazobactam 
1 0 0 
  Metronidazole 1   
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Table 2.21 In vitro activities of antimicrobial agents against 
Peptostreptococcus species from the pus and tissue specimens from 
the Indian diabetic foot patients 
 
Among the Peptostreptococcus species from the Indian DF patient‟s clinical 
specimen‟s piperacillin/tazobactam had shown a MIC of less than 2 µg/L. 
This suggests that the strains were sensitive to the combination antibiotic.  
Organisms Antibiotics MIC distribution µg/L 
  0.016 – 4 8 – 64 128 - 256 
 
Peptostreptococcus 
species 
(n = 3) 
Amikacin 0 2 1 
Ciprofloxacin 0 1 2 
Clindamycin 0 2 1 
Linezolid 1 0 2 
Levofloxacin 0 0 3 
 Piperacillin/ 
Tazobactam 
3 0 0 
 Metronidazole 0 0 3 
The Peptostreptoccocus species tested mainly included Peptostreptococcus 
assacharolyticus, Anaerococcus prevottii and Parvimonas micra.  
 
Table 2.22 In vitro activities of antimicrobial agents against other Gram 
– positive anaerobes from the pus and tissue specimens from the 
Indian diabetic foot patients 
Among the other Gram – positive anaerobes more than half showed a MIC 
range of 0.016 to 4 µg/L for linezolid and levofloxacin, but absolute 
sensitivity is dependent on the breakpoints suggested by NCCLS.  
Organisms Antibiotics MIC µg/L 
  0.016 – 4 8 – 64 128 - 256 
 
Other Gram - positive 
anaerobic species 
(n = 6) 
Amikacin 0 6 0 
Ciprofloxacin 0 4 2 
Clindamycin 1 2 3 
Linezolid 3 1 2 
Levofloxacin 3 0 3 
 Piperacillin/ 
Tazobactam 
1 2 3 
 Metronidazole 1 1 4 
The other Gram – positive anaerobic species tested included the Eubacterium lentum (n = 
3), Actinomyces naeslundii (n = 2) and Propionibacterium acnes.  
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Table 2.23 In vitro activities of antimicrobial agents against other Gram 
– negative anaerobes from the pus and tissue specimens from the 
Indian diabetic foot patients 
 
Among the other tested Gram – negative anaerobes from the DF patients 
from India there were some strains showing resistance.  
Organisms Antibiotics MIC distribution µg/L 
  0.016 – 4 8 – 64 128 - 256 
 
Other Gram – 
negative 
anaerobes 
(n = 3) 
Amikacin 0 1 2 
Ciprofloxacin 1 1 1 
Clindamycin 0 1 2 
Linezolid 0 0 3 
Levofloxacin 0 0 3 
 Piperacillin/ 
Tazobactam 
0 2 1 
 Metrinidazole 0 2 1 
The other Gram – negative anaerobic species tested included the Fusobacterium varium, 
Fusobacterium necrogenes and Capnocytophaga. 
 
The antimicrobial susceptibility testing has indentified the presence of 
sensitive aerobes and multi-drug resistant anaerobes from the Indian DF 
patient‟s pus and tissue specimens and illustrated that there is good 
antibiotic susceptibility of aerobes and anaerobes from the UK DF patient‟s 
pus specimens. This study cannot be used for a strict comparison between 
the Indian and the UK DF patient‟s susceptibility testing due to the unequal 
sample size and low numbers of organisms isolated.   
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2.4 Discussion  
The prevalence of diabetes is increasing in India faster than in any other 
country in the world. There are about 33 million diabetics mainly from the 
urban population (Viswanathan, 2005). Diabetes affects many organs of the 
body but our study was carried out only on the diabetic foot infections of 
affected patients in India. Ischaemic heart diseases and renal failure were 
very common in this cohort. This study was carried out on 89 diabetic foot 
patients of whom 60 had undergone amputation either of toe/toes. Although 
various information was recorded, statistically the numbers were not 
significant hence they cannot be predictive of the role of the risk factors to 
amputations among the Indian DF patients. Some of the most commonly 
seen causes of the formation of an ulcer seen in other studies 
(Viswanathan, 2005) were peripheral vascular disease and neuropathy, 
these were also seen in our study. Ischaemia and trauma are very common 
among the Indian DF patients as also reported by other studies (Kandemir 
et al., 2007; Bansal et al., 2008, Viswanathan, 2002 and Shankar et al., 
2005). These risk factors promote the development of diabetic foot ulcers 
with infections that can spread rapidly and lead to tissue destruction and 
subsequently amputation (Edmonds and Foster, 2004). In one of the studies 
carried out by Vijay, (2000) on 374 patients, 52% had infected foot ulcers. 
Infection thus plays a pivotal role in enhancing diabetic foot towards 
amputation. 
The microbial flora of the normal skin is complex and diverse with a number 
of bacteria residing such as Staphylococcus, Streptococcus, 
Propionibacterium and Corynebacteria. It is also these primary bacteria that 
occur in the healthy skin that are also are cultured from the wound. Since 
the deep tissues are always surrounded by a number of commensal from 
the skin, recognition of the pathogen remains crucial. In the present study 
with 27 pus samples and 73 tissues samples from the Indian DF patient‟s 
there were total 107 aerobes, 71 anaerobes and 14 fungi cultured. From the 
25 pus samples from the DF patient‟s from the UK there were total 35 
aerobes and 5 anaerobes.  
In the Indian DF patient‟s it was found that Staphylococcus species 
predominated in DF ulcers in concordance with other studies carried out in 
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India (Bansal et al., 2008 and Viswanathan et al., 2002). On sub-speciation 
Staphylococcus schleiferi was one of the species of Staphylococcus 
cultured from Indian diabetic foot patient‟s specimens. This organism is 
normally cultured from immunocompromised individuals (Kumar et al., 
2007). Among the Gram – negative aerobes the most commonly 
encountered were the species belonging to the Enterobacteriaceae family 
such as P. aeruginosa, K. pneumoniae and E. coli in agreement with the 
other studies carried out in India (Gadepalli et al., 2006 and Varaiya et al., 
2008). In the UK the common aerobes found included some similar to the 
ones from Indian DF specimens with Serratia, Enterobacter and Citrobacter 
species more commonly seen among the diabetic foot patients from the UK 
(Edmonds and Foster, 2004). Candida tropicalis (51%) was one of the most 
frequently isolated fungi from the DF patient‟s in India, these organisms 
were also found to be dominant in other studies carried out in India 
(Chincholikar and Pal, 2002 and Bansal et al., 2008). Among the Indian DF 
patient‟s clinical specimens tissue and pus there were equal numbers of 
Gram – positive and Gram – negative aerobes cultured in disagreement with 
other studies where Gram – negative aerobes were dominantly cultured 
from the DF patient‟s specimens (Bansal et al., 2008; Shankar et al., 2005). 
 Most of the anaerobes cultured from the specimens from the Indian DF in 
our study were Clostridium species in agreement with the study carried out 
by Viswanathan, (2002). The culturing of high numbers of Clostridium 
species is not very surprising from the DF patient‟s clinical specimens from 
India as barefoot walking due to religious beliefs, the age of the patients, 
personal hygiene, outdoor occupation (e.g.farmers) all can favour the 
multiplication of the Clostridium species in the traumatised foot 
(Viswanathan, 2007; Jayasinghe et al., 2007 and Pradeepa, Deepa and 
Mohan, 2002). Among the Gram – negative species the dominant species 
included the Bacteroides fragilis (n = 18) out of the total 25 Gram – negative 
anaerobes cultured from the tissues and pus specimens from Indian DF 
patients. Bacteroides fragilis was also one of the dominant species found in 
many other studies carried out in India (Chincholikar and Pal, 2002; Shankar 
et al., 2005 and Viswanathan et al., 2002). Bacteroides fragilis has been 
reported to be one of the common Gram – negative anaerobe from DFI (De 
and Gogate, 2001 and Dogan and Baysal, 2010).  
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All of the ulcers were classified according to their Wagners grades and as 
the Wagner‟s grades increased subsequently the number of anaerobes also 
increased. This characteristic was also seen by Bansal and colleagues 
(2008) for aerobes although due to lack of resources they did not carry out 
testing for anaerobes. One of the peculiar characteristics of diabetic foot is 
the polymicrobial nature which was clear from this study in both the Indian 
and the UK DF cohorts as mixed infections were very common. In the UK 
there were comparatively less (n = 6 out of 25) mixed infected pus as 
compared to the Indian DF patient‟s with (n = 37 out of 73) mixed infected 
tissues and (n = 16 out of 27) mixed infected pus. The polymicrobial nature 
of DFI is raised in a number of studies all over the world (Citron et al., 2007, 
Bansal et al., 2008, Viswanthan, 2005, Gadepalli et al., 2006 and Esposito 
et al., 2008). Nevertheless there were differences in the infected flora from 
the Indian DF patient‟s tissues and pus specimens and the DF patient‟s pus 
samples from the UK. It is evident from this study that, the tissue biopsies 
obtained from the Indian diabetic foot patients harboured a greater variety of 
aerobes, anaerobes and fungi than the pus. The main reasons for this would 
have been that the tissues sent for culturing often were obtained from the 
patients with gangrenous wounds or from an amputed toe with necrosis and 
although pus can favour the growth of number of organisms, with strict 
anaerobes exposure to air can cause cell death.  
The in vitro antibiotic susceptibility testing carried out on the aerobes from 
India and the UK showed many aerobes that were sensitive to all the tested 
antibiotics such as amikacin, amoxicillin/clavulanic acid, imipenem, 
levofloxacin, linezolid, metronidazole and piperacillin/tazobactam but with 
high resistance seen among the anaerobes. Arguably it could imply that the 
aerobes when tested in vitro could show sensitivity but when present in a 
mixed culture could interact with other organisms and acquire resistance 
(Zayed et al., 2009). There could also be a possibility that in vivo the 
antibiotics could have killed the aerobes with few resistant strains which 
would have survived and formed a layer in the wound environment thus 
hindering the entry of antibiotics prescribed to kill the anaerobes leading to 
multi-drug resistant anaerobes in vitro. The results of multi-drug resistant 
anaerobes seen in our study carried out at Raheja hospital in Mumbai, India 
were as predicted. One other study carried out in the same hospital in 2001 
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had documented multi-drug resistant organisms suggesting the use of 
antibiotic combination therapy in the management of patients with diabetic 
foot infections (Pathare and Sathe, 2001). Although anaerobes show 
susceptibility to metronidazole one of the studies carried out in the UK 
suggested reduced susceptibility of C. difficile isolates (n = 86) to 
metronidazole (24.4%) dissimilar to our study carried out in India where 
(28.57%) of Clostridium species showed resistance to metronidazole 
(Baines, O‟ Connor and Freeman, 2008). However higher resistance was 
seen among the Clostridium species from the Indian DFI in our study to 
Piperacillin/tazobactam. A study carried out by Esposito and his colleagues 
(2008) suggested that on administering combination antibiotics such as 
Piperacillin/tazobactam 93.4% of patients were either cured or there was 
improvement seen among them. In our study it was evident that amputation 
of the toe/toes among the total 60 out of the 89 DF patients included in the 
study would have occurred due to treatment failure as our results from the 
antimicrobial susceptibility results imply. 
One of the major problems of carrying out antimicrobial susceptibility of 
anaerobes has been the non-compliance of standard procedures employed 
by the hospitals all over the world. A number of surveys carried out in the 
UK suggested that it was unclear to what extent the susceptibility testing of 
anaerobes was undertaken in the UK and what procedures were used for 
testing. Only 5% of laboratories used media specially designed for testing 
anaerobic organisms. Ninety-nine per cent of laboratories used a disc 
testing method and 15% used a combination of disc testing and a gradient 
method (E-test) of determining an MIC. The antibiotics most often tested, 
other than metronidazole, were penicillin, clindamycin, erythromycin and 
amoxicillin/clavulanic acid. Very few of the laboratories tested carbapenems 
(usually imipenem) and piperacillin/tazobactam, respectively (Andrew and 
Wise, 2002 and Smith et al., 2010). In the developing world however there is 
a lack of investment, lack of access (non affordable) to drugs, lack of 
regulatory control, lack of quality standards for test evaluations and all these 
have an active role in the development of antibiotic resistance.  
From the patterns of antimicrobial susceptibility to the tested antibiotics in 
India,  a combination therapy can be used with the advantage of covering 
the gaps in empirical therapy but this could result in misuse and 
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inappropriate reuse of the antibiotics. Antibiotic failure can be due to wrong 
diagnosis, resistant pathogens, suboptimal dosing, an immuno - 
compromised host, delayed therapy, un-drained infection, presence of 
foreign body and medication non-compliance. There were limitations to our 
study mainly that the Indian diabetic foot study was only funded for 3 
months and therefore the number of patients recruited in the study was too 
low and hence no statistical analysis could be carried out. Due to the 
number of patients recruited in the Indian study,  there were low numbers of 
clinical specimens and subsequently of organisms belonging to the same 
genus therefore antibiotic susceptibility testing could not be statistically 
predictive with low numbers of organisms belonging to the same genus. The 
unmatched numbers samples that were microbiologically processed for the 
Indian and the UK DF cohorts did not allow a statistically meaningful 
comparison. However the qualitative information regarding the microbial 
ecology of the ulcer and the general antibiotic susceptibility patterns in India 
and UK were facilitated by our study. It would have been advantageous to 
carry out β-lactamases production testing but due to time constraints and 
resources, this was not carried out. 
From the data obtained from this study on Indian diabetic foot patients, the 
foot problems such as ulceration, infection, gangrene, and amputations 
were common resulting in frequent and long-term admission to hospital. 
This is in agreement with the study carried out by Lavery et al. (2006) who 
concluded that for those patients who developed foot infections the risk of 
hospitalisation with 55.7 times greater than those who did not develop foot 
infections and the risk of amputation were 154.5 times higher. The economic 
and emotional consequences for the family of the patient can be significant 
(Aleem, 2003). One of the studies carried out in the southern parts of India 
found that patients without foot problems spent 9.3% of their total income, 
while patients with foot problems had spent 32.3% of their total income on 
treatment (Shobhana, 2000). 
 
 77 
2.5 Conclusion 
Although this is a pilot study it has highlighted the complexity of leg ulcers 
harbouring wide varieties of aerobes, anaerobes and fungi. The outcome of 
this study has been that it has facilitated routine culturing of anaerobes in 
Raheja hospital, Mumbai – India, where previously culturing of anaerobes 
from clinical specimens was not carried out and therefore none of the 
treatment options available to the patients were based on the nature of the 
organisms. Only broad spectrum antibiotics were only given; this  has now 
been changed after the information provided by this study on the multi-drug 
resistant anaerobes.  
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CHAPTER – 3  
GLYCAN-LECTIN INTERACTIONS 
 
This chapter sets out the potential for glycan-lectin interactions in the 
rapid typing and identification of Staphylococcus species and 
anaerobes. Method development of the ELLA is detailed for whole 
cells, proteinase K treated cells and glycolipids for clinically 
significant organisms. 
 
 
Study aims: 
This study aimed to develop a rapid, easy and cost-effective typing and 
diagnostic method for clinically significant Staphylococci and anaerobes 
using biotinylated lectins in an adapted ELISA methodology (Afrough et al., 
2007).   
3.1 Introduction 
3.1.1 Gram - positive and Gram - negative cell walls 
Bacteria possess cell walls which differ in Gram - positive and Gram - 
negative organisms with a thick and thin peptidoglycan layer respectively. 
The cell wall contains components that are unique to each bacterium with 
the peptidoglycan composed of alternating N-acetylglucosamine acid 
(NAGA) and N-acetylmuramic acid (NAMA) (Dziarski, 1991). This 
peptidoglycan layer protects the bacteria against protease enzymes and 
also from hydrolytic degradation by other organisms. The 
lipopolysaccharides have been shown to be medically important and are 
found in abundance in the Gram - negative outer membrane; the Gram - 
positive cell wall does not express lipopolysaccharide but expresses a 
relatively thick peptidoglycan layer. 
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3.1.2 Lectins as tools in glycoconjugate analysis 
 
Lectins are ubiquitous in nature; they are the carbohydrate-binding proteins 
that each specifically recognise sugar structures and, in mammals mediate 
a variety of biological processes such as cell-cell and host-pathogen 
interactions, serum-glycoprotein turnover and innate immune responses 
(Drickamer, 1994; Powel and Varki, 1995). Lectins were first identified 
because of their property of agglutinating erythrocytes (Matsui et al., 2001). 
In plants, lectins are widely distributed and hence are ingested daily in 
appreciable amounts by both humans and animals (Gallagher, 1984). Most 
lectins exist in the oligomeric form; as a result they bind to their ligands on 
several different cells and so agglutinate them. Various plant lectins that 
have been commercialised, for example Dolichos biflorus (anti-blood group 
A1) (Falk et al., 1991) and Ulex europaeus (anti-blood group H) (Matsui et 
al., 2001)  Mammals also possess lectins termed C-, S-, P- and I- type 
based on the structure of their carbohydrate–recognition domain (CRD) 
(Drickamer,1994; Powell and Varki ,1995),  while in some of the fungi there 
are carbohydrate binding adhesins which act as lectins (Ni. and Tizard, 
1996). The CRD mediates the binding of lectins to the carbohydrates and is 
highly conserved for each lectin type. Bacterial lectins occur on fimbriae/pili, 
filamentous appendages that protrude from the surface of the cells and 
flagella, Lectins are valuable reagents for the clinical diagnostic laboratory 
because of their specificity and commercial availability. Lectins bind to 
defined glycan moieties in polysaccharides (Silfkin and Doyle, 1990).  
3.1.3 Glycan-lectin interactions: scope for diagnostics 
It is important for microbiological laboratories throughout the world to be 
able to identify pathogens efficiently and easily. In developing countries due 
to lack of resources they have relied on traditional culture characteristics. In 
developed countries there are many other ways to identify the pathogens 
such as typing with phage panel (Watson, 2003), the use of techniques such 
as PCR amplification (Kobayashi, 2006), mass spectrometry (Lay, 2001), 
MALDI-MS (Fenselau and Demirev, 2001), biotyping, serotyping, bacteriocin 
typing, protein typing, restriction endonuclease typing, gene probe typing, 
dot-blot (Stoitsova, Ivanova and Dimova, 2004) and ELISA. All require 
expensive reagents and have been employed with the aim of typing 
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clinically significant micro-organisms (Merlino et al., 2003). Although there is 
a range of methods for identifying pathogens it is important to realise the 
practicalities of their use in routine situations in hospitals. Typing is 
significant as it may inform the epidemiological investigations at different 
levels ranging from local to regional to national population data which can 
assist in the control of infection, identify the carriers and establish the 
prevalence of individual strains. Common reasons for microbial typing are to 
identify the common sources of infection, to discriminate between mixed 
strain infections and distinguish relapse or re-infection. Lectins discussed in 
section 3.1.2 have been explored diagnostically for typing clinically 
significant organisms (Munoz et al., 2003; Munoz et al., 1999 and Annuk et 
al., 2001). An enzyme linked assay using biotinylated lectins termed as 
ELLA (enzyme linked lectin sorbent assay) is one of the easiest and cost – 
efficient methods which can be used for typing and identification of clinically 
significant microbes. 
Anaerobes are the most over-looked pathogens due to difficult isolation 
procedures, requiring competent staff and traditionally used laborious 
culturing and expensive biochemical identification. Species within the genus 
are often hard to differentiate because they tend to be largely negative in 
traditional biochemical tests. Classification of anaerobes has long been 
regarded as unsatisfactory and until today is very difficult and constantly 
changing with addition of new species. Following genomic investigations, 
species have been renamed for example Peptostreptoccocus magnus has 
been renamed Finegoldia magna, Peptostreptococcus prevottii to 
Anaerococcus prevottii and Peptostreptococcus micros is now known as 
Parvimonas micra (Song et al., 2007a and 2007b).   
Identification has relied on characterisation of volatile fatty acids using gas 
liquid chromatography which involved lengthy procedures. In laboratories 
where time is the key factor and rapid identification is crucial for doctors to 
prescribe antibiotics it remains a major issue that needs to be addressed 
(Murdoch and Mitchelmore, 1991). Traditional antibiotic resistance patterns, 
once adopted as a method to type some anaerobes up to their species 
level, need to be re-considered especially with the emerging antibiotic 
resistance among anaerobes. In contrast the current molecular methods 
utilised in identification of microbes to their species and genus level can be 
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useful in a research setting but not in clinical laboratories with limited 
resources (Nagy et al., 2006). More significantly, an initial rapid identification 
of the presence of anaerobes can guide the clinicians to prescribe 
antimicrobial therapy or surgical interventions. There have been many other 
rapid and reproducible methods of identification of aerobes described, for 
example the pre-formed enzyme identification kits that generate profile 
numbers that are interpreted using computers available from several 
manufacturers (Bascomb and Manafi, 1998; Huletsky et al., 2005 and 
Horstkotte et al., 2001) and the use of chromogenic media recently 
designed for the rapid identification of MRSA strains (Louie, et al., 2006). 
Although these kits are reliable, rapid and reproducible they are often very 
expensive and limited to the identification of strains from their databases. 
There is an urgency to introduce such methods to identify and discriminate 
pathogens such as methicillin resistant Staphylococcus aureus, methicillin 
sensitive Staphylococcus epidermidis, and methicillin resistant 
Staphylococcus epidermidis as well as in the identification of the clinically 
significant anaerobes. These pathogens have been isolated repeatedly from 
diabetic foot ulcers and there is interaction between them leading to the 
formation of biofilms (Dowd et al., 2008). 
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3.2 Materials and Methods 
3.2.1 Culturing and sub culturing of microbes 
Initial research was carried out on the ATCC (American Type Culture 
Collection), NCTC (National Collection of Type Cultures) and AC strains 
(clinical strains obtained from UCLH) as shown in table 3.1. The strains 
obtained were checked for their purity using commercially available kits. 
Table 3.1: ATCC/NCTC strains and growth requirement 
 
Table 3.1 shows all the organisms used in this work with their growth requirements. All 
media was obtained from Oxoid (Basingstoke, UK). 
 
MRSA, MSSA, MRSE and MSSE were analysed for their resistance or 
sensitivity by molecular methods for the presence or absence of the mec A 
gene and by biochemical tests for coagulase activity at UCLH. 
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3.2.2 Biotinylated lectins 
The biotinylated lectins used in Table 3.2 were selected to cover a wide 
range of sugar specificities. All the lectins were purchased from Vector labs 
UK in the form of Lectin kits I, II and III. These were provided as 1 mg 
powders and dissolved as per instructions in recommended solvents. The 
final concentration used in the assay was 0.6 µg/ml. 
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Table 3.2: Panel of 22 biotinylated lectins, its origin and glycans 
specificity 
 
The sugar specificity of the lectins and their abbreviations has been extracted from 
(Afrough et al., 2007 and Lis and Sharon1998). 
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3.2.3 Buffer solutions used in ELLA analysis  
The buffers used in the ELLA analysis for whole cells, proteinase K treated 
whole cells and glycolipids is Phosphate buffered saline (PBS) with the 
composition of NaCl 5.85 g, Na2HPO4 4.72 g, NaH2PO4 2.64 g dissolved in 
1 litre of distilled water (pH 7.2) and the Tris-HCl buffer with composition of 
12.1 g tris base was dissolved in 100 ml of distilled water and pH was 
adjusted to 8.8 with HCl, Sigma Ltd, UK). For coating the anaerobes on the 
96 well ELISA plate carbonate buffer pH 9.5 was used. The composition of 
carbonate buffer (100mM) was 3.03 g Na2CO3, 6.0 g NaHCO3 in 1 litre of 
distilled water (pH 9.5). All of the chemicals and buffers were obtained from 
Acros Organics (USA). 
3.2.4 Analysis of glycans on whole cell 
Method development was carried out using Staphylococcus aureus strains, 
as the glycan - lectin profile of this organism was already reported (Silfkin 
and Doyle, 1990).Previous research on microbial glycans has focussed on 
agglutination assays (Flemming and Wigender, 2001) and the use of 
confocal microscope or fluorescence microscopy for the detection of glycan-
lectin interactions (Strathmann, Wigender and Flemming, 2002, Leriche, 
Sibille and Carpentier, 2000 and Thomas et al., 1997). This research aimed 
to develop a rapid, easy, reliable, reproducible and cost effective method for 
the rapid identification of the glycan–lectin interactions. An enzyme linked 
lectin assay was developed using biotinylated lectins termed as ELLA. 
Different types of tubes, 96 well Nunc polystyrene plates and tissue culture 
plates were explored for organism immobilisation. With the aim to develop 
an easy method a tube-based approach was investigated using simple 
whole cells. Initial assays were carried out with Staphylococcus aureus.  
Some troubleshooting was required during the method optimisation as 
discussed in section 3.2.4 a, b and c. 
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3.2.4 (a) Method developments for ELLA for glycans analysis 
In the method development of ELLA there were a series of different factors 
that were explored as discussed below: 
 Concentration at which the cells could adhere optimally to the 96 well 
plates. 
 Volume of culture suspension to be used to coat onto 96 well plates 
 Optimum temperature and time for incubation for cells to firmly 
adhere/coat to the plates. 
 Use of appropriate buffer, blocking agents for the assay. 
 Blocking time to avoid non-specific binding. 
 Coating of colonies directly onto 96 well plates in case of anaerobes. 
 Use of formal saline as fixative to avoid cell loss in the case of 
anaerobes. 
 Use of washed cells as well as cells in broth in the case of aerobes 
and anaerobes. 
 Use of freeze dried cells in coating the plates in the case of 
anaerobes. 
 Incubating the above plates aerobically and anaerobically at 37°C 
and at 4°C. 
 Use of higher OD in the case of anaerobes in washed cells.  
 Increasing the time of incubation for coating of anaerobes. 
 Measuring the OD to determine cell loss before blocking and after 
each washing during the assay. 
 Use of washed anaerobic cells and coating with different buffers at 
different pH. 
 Use of washed anaerobic cells and incubating them aerobically at 
37°C. 
 
These troubleshooting and optimisation steps were required for the 
attachment of the organism to the 96 well ELISA plates as well as for the 
exposure of the glycans for accurate recording of the glycan-lectin 
activity. Some of the significant steps in the optimisation and the method 
used throughout the study are described in detail below.  
3.2.4 (b) Optimisation of a tube-based method for glycan analysis 
of whole cells 
 
Immobilisation of microbes was facilitated by using Zirconium (Sigma) a 
heavy metal acting as a non soluble support as suggested by Ibrahim et al., 
(1985). Staphylococcus aureus of known cell density was washed with 
distilled water and zirconium chloride was then added to the tube. 0.05 % 
Tween 20 was used as a detergent to avoid any non specific binding and 
the tube was filled to the brim. This was then left for 2 h at room temperature 
and then 60 µl of 0.6 µg/ml of biotinylated lectins were added and allowed to 
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interact with bacterial glycans for 2 h and then washed with washing buffer 
phosphate buffer saline (PBS - pH 7.2).  Streptavidin alkaline phosphatase 
(100 µl of dilution recommended by the manufacturer) (Vector laboratories) 
was added and incubated for 1h at room temperature. The mixture was then 
washed with PBS (pH 7.2) three times and 100 µl of 1 mg/ml 
paranitrophenol-phosphate substrate added. The reaction was allowed to 
proceed for 30 min at room temperature. The reaction was then quenched 
with 50 µl of 3 M sodium carbonate. Absorbance was measured at 405 nm. 
All these experiments were carried out with fresh working solutions and with 
controls.  
3.2.4 (c) Optimisation of ELLA method for glycan analysis of 
whole cells 
An ELISA based method had been employed by Strathmann et al., (2002) 
for the detection of exopolysaccharides in biofilms using peroxidase labeled 
lectins. In their study they used 96 well microtitre plates for the 
immobilisation of bacterial exopolysaccharides. With modifications to their 
method the current method has been developed as an in-house rapid 
method of detection of glycans utilising biotinylated lectins. A panel of 22 
biotinylated lectins (0.6 µg/ml) have been used in this assay. A number of 
different experiments were carried out for the optimisation and for the 
successful running of the ELLA method. A 96 well polystyrene ELISA plate 
(Nunc Ltd, Germany) was used in this assay. Method development for this 
assay was also carried out using Staphylococcus aureus which is known to 
interact with Con A (Silfkin and Doyle, 1990). 
Sample organisms of known density (absorbance 0.3-0.5 at 600 nm) were 
washed with distilled water and in the case of aerobes PBS (pH 7.2) was 
used as the coating buffer. Wells were coated with 50 µl of sample overnight 
at 37 ºC and washed with PBS and 0.05 % of Tween 20  was used to 
prevent non-specific binding for 2 h. Biotinylated lectins, 60 µl of 0.6 µg/ml 
solution, were added to each well and gently mixed on shaker for 2 h. 
Washing was carried out to remove any unbound lectins using PBS pH 7.2 
and streptavidin alkaline phosphatase (100 µl) was added and incubated at 
room temperature for 1 h. Washing was carried out 3X with PBS buffer pH 
7.2 and 1mg/ml of paranitrophenol-phosphate (100 µl) substrate was added. 
Plates were kept in dark for 30mins at room temperature and then 50 µl of  
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3 M sodium carbonate was added to stop the reaction and absorbance was 
read at 405 nm. Changes were made to the above protocol, for the glycan 
analysis for anaerobes, in which, 2 % gelatin was used as the blocking 
buffer and carbonate buffer (10.6 g/l of 0.1M sodium carbonate (anhydrous), 
8.4 g/l of 0.1 M sodium bicarbonate mixed in 200 ml of distilled water and 
the pH was adjusted to 9.5) instead of using the PBS pH 7.2 buffer for 
coating the anaerobes on the 96 well polystyrene microtitre plate. 
3.2.5 Glycan analysis by proteolytic treatment of whole cells  
Bacterial cultures were grown and the cell densities were adjusted to 0.3-
0.5 at 600 nm with distilled water, these were used for the ELLA with whole 
cells. For the proteolytic treatment the cells were washed once with PBS 
(pH 7.2) and centrifuged at 3000 rpm for 10 min. The pellet was re 
suspended in PBS (pH 7.2) and then heated at 100 ºC for 15 min to remove 
the cell-surface proteins (Annuk et al., 2001). After washing with PBS (pH 
7.2) at 3000 rpm for 10 min, the pellet was treated with 6 µl of Proteinase K 
(Sigma) (10 mg/ml). The suspension was then incubated for 1h at 60 ºC 
and then 5 min at 100 ºC to inactivate the Proteinase K. The suspension 
was then centrifuged at 3000 rpm for 10 min. The pellet was then re-
suspended in distilled water to give and OD 0.3 at 600 nm before analysing 
with biotinylated lectins.  
3.2.6 Analysis of glycans of glycolipids 
With the aim to obtain a defined glycan profile for different aerobes and 
anaerobes, glycolipids and lipopolysaccharide from the Gram - positive and 
Gram -negative organisms were extracted respectively.  
3.2.6(a) Glycolipid extraction 
Lipopolysaccharide (LPS) remains unique to different bacteria and is a 
determinant of their pathogenicity (Boneca et al., 2000). Research on 
lipopolysaccharides is vast, but with the limitations of low yields during 
extraction, they can be difficult to extract (Kay et al., 2006) Thus a 
lipopolysaccharide extraction kit (Intron Bio Molecular solutions) was 
purchased that yielded 30 µg of LPS from a 5 ml culture suspension. The 
company protocol was followed and good yields of glycolipids from Gram – 
positive organisms and LPS from Gram – negative organisms were 
extracted in 1h. 
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LPS extraction methods can be used for the extraction of the peptidoglycan 
layer from the Gram - positive micro-organisms (Dziarski, 1991 and Wang et 
al., 2003, De Jonge, et al., 1992) to further confirm that the material 
obtained was glycolipids; fatty acid composition was determined by mass 
spectrometry for one organism as shown figure 4.3 in the results of chapter 
4.3.4. The carbohydrate and protein content for all the glycolipids and 
lipopolysaccharide were also determined discussed in chapter 4.3.2 in figure 
4.1. 
3.2.6b ELLA method for detection of glycans from 
glycolipids of aerobes and anaerobes 
The extracted glycolipids and lipopolysaccharide were dissolved in 10 mM 
Tris-HCl buffer with pH adjusted to 8.8 with HCl, Sigma Ltd, UK. 50 µl of the 
dissolved glycolipids and lipopolysaccharide were coated onto 96 well 
ELISA plates (Nunc, Germany) and incubated for 4 h at 37 ºC. Further 
assay conditions were adopted from the in-house developed ELLA method 
described in section 3.2.4c. 
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The table 3.3 shown below shows the organisms whose glycan-lectin 
interactions were analysed in this study along with their respective sample 
nature. 
Table 3.3 List of organisms and nature of their Glycan-lectin 
interactions studied in this study 
 
The glycan – lectin interactions were only carried out on the organisms shown in table 3.3. 
ELLA was carried out on whole cells, Proteinase K treated whole cells and the extracted 
glycolipids in case of Gram – positive organisms and LPS in case of Gram – negative 
organisms.
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3.2.7 Inhibition assay 
Inhibition assays were carried out to confirm the specificity of two of the 
biotinylated lectin-glycan interactions. The assay was performed using 
different concentrations of D (+) mannose and D (+) galactose. The sugars 
were preincubated in lectin solutions at final concentration of 0 mM, 10 mM, 
20 mM, 50 mM, 100 mM, 200 mM, 400 mM and 600 mM. These were 
incubated for 2 hours before performing the ELLA assay. The inhibition 
assay was only carried out for the glycolipids of Finegoldia magna that were 
scored greater than (3+) in the original ELLA assay. The lectins used were 
Pisum sativum specific for mannose and Soya bean agglutinin specific for 
galactose. 
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3.3 Results 
3.3.1 Method Optimisation  
To optimise the method for the analysis of glycans on microbial cells, a 
series of different procedures have been explored with the objective to 
develop a rapid, easy and reliable method. Staphylococcus aureus has 
been shown to have glycans containing glucose and reacts with Con A 
lectin (Silfkin and Doyle, 1990). Therefore biotinylated Con A was utilized 
as the lectin of choice with Staphylococcus aureus (NCTC 6571) as the 
microbe for method optimization. There are a number of aspects which 
had to be optimized one of the most important being the immobilization of 
microbes onto an adherent surface, buffer systems, blocking buffer and 
cell density of the organism. 
3.3.1A Glycan analysis by tube method 
Glycan analysis in tubes was performed on simple whole cells of 
Staphylococcus aureus (NCTC 6571) with Con A. A range of tubes such 
as eppendorf tubes, polystyrene tubes, 50 ml polycarbonate tubes were 
used for the assay. Immobilization of organism onto the tubes was difficult 
and hence, zirconium chloride was used which is a non soluble support to 
facilitate immobilisation. For aerobes like Staphylococcus (NCTC 6571) 
aureus (Figure 3.1) the tube method with zirconium chloride gave 
promising and consistent results, but for anaerobes immobilization was not 
facilitated and the cells were not attached. The cells usually washed away 
during the washing step with PBS. So the tube method would not be a 
choice for the rapid identification of glycans of anaerobes. 
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Figure 3.1: Glycan analysis of Staphylococcus aureus (Sa) (NCTC 
6571) whole cells with biotinylated Con A lectin with and without 
zirconium by tube method.  
 
In the absence of zirconium (Figure 3.1), there was no correlation between 
signal and organism concentration, whereas a dose dependent 
relationship was seen in the presence of zirconium. It is concluded from 
this set of experiment that zirconium chloride is the choice for successful 
immobilisation of aerobes. 
3.3.1B Glycan analysis by ELLA method using 96 well 
polystyrene microtitre plates 
 
The tube method was not cost-efficient because, for the identification 
of glycans on the microbial cells, there were a panel of 22 biotinylated 
lectins to be utilised with different glycan specificity. An ELISA based 
solid phase lectin assay was developed using the 96 well polystyrene 
plates. Enzyme linked lectin sorbent assay (ELLA) also worked well for 
the aerobes but for anaerobes, trouble shooting was required mainly 
for the immobilisation of anaerobes onto the ELISA plates. 
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The table 3.4 below represents the optimised buffers to be used and 
the concentration of microbial cells and type of blocking buffer which 
would facilitate the immobilisation of organisms on the 96 well 
polystyrene microtitre plate.  
Table 3.4: ELLA method optimisation for aerobes and anaerobes 
 
 
Immobilisation of aerobes and anaerobes as shown in table 3.4 were facilitated due to 
the buffers with specific pH and blocking the non specific sites on the 96 well 
polystyrene plate facilitated by the specific buffers shown in table 3.4. All the glycan – 
lectin interactions data obtained in this study are based on the buffers, blocking agents, 
pH and cell density shown in table 3.4 
 
 
From these series of optimisation trials it was concluded that PBS (pH 
7.2) was the better buffer to immobilise aerobes for glycan analysis and 
immobilisation onto 96 well ELISA plate while carbonate buffer (pH 9.5) 
remained the buffer of choice for the subsequent immobilisation of 
anaerobes (Table 3.4) in agreement with other studies where carbonate 
buffer had been employed to adhere LPS and live anaerobes on the 
ELISA plates (Bull, Matthews and Rhodes, 1986 and Bantroch, Buhler 
and Lam, 1994). In case of the anaerobes a higher cell density was 
required than aerobes for successful ELLA. 
In all experiments from optimisation of tube method to the fully 
developed ELLA method for aerobes as well as anaerobes, negative 
controls used were (no lectin), (no streptavidin) and (no organism) to rule 
out false-positive results. 
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To further analyse the effectiveness of glycan - lectin interaction at 
different phases of bacterial growth and to confirm the results obtained in 
the previous optimisation trials a growth curve of Staphylococcus aureus  
(NCTC 6571) was constructed and at each phase aliquots were taken and 
an ELLA was performed with biotinylated lectin Con A (figure 3.2).  
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Figure 3.2: Glycans expressed at different phases of bacterial growth 
detected with Con A 
Controls used were no biotinylated lectin, no streptavidin and no organisms and the data 
represented in this figure is the ELLA method of analysis of glycan – lectin interactions of 
Staphylococcus aureus whole cells with Con A lectin at different phases of growth. All work 
was carried out in triplicates and the data represented in this figure is after taking away the 
background.  
 
From this experiment it was confirmed that for aerobes an early exponential 
phase at approximate OD of 0.3-0.5 at 600 nm was the choice for further 
ELLA analysis (Figure 3.2).  
Many aerobes have been shown to have phosphatase activity which would 
interfere with the ELLA detection using phosphatase-streptavidin conjugates 
(Satta et al, 1988). A pilot assay carried out on Staphylococcus aureus 
(NCTC 6571) revealed the presence of phosphatase activity which was 
overcome by denaturation of the enzyme by heating at a series of different 
temperatures and times (figure 3.4). MRSA (NCTC 33591), Escherichia coli, 
MRSE, MSSE, Pseudomonas aeruginosa, Enterococcus faecalis, Proteus 
mirabilis, Streptococcus group B and Streptococcus pyogenes were all 
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checked for the phosphatase activity prior to being tested with biotinylated 
lectins (Data not shown). 
 
Figure 3.3 Denaturation time and temperature: Phosphatase activity of 
Staphylococcus aureus (NCTC 6571). 
The figure 3.3 represents the ELLA analysis of S. aureus with Con A after series of 
temperature treatments and different exposure time to denature the phosphatase activity. 
 
The above figure 3.3 suggests that denaturation of the phosphatase 
activity could be facilitated by heating the sample up to 50ºC for 1h. 
For all aerobes denaturation was performed before further ELLA 
analysis. 
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The scoring system shown below in table 3.5 was followed to record the 
glycan-lectin activity for aerobes and anaerobes. 
Table 3.5: Levels of glycan-lectin binding  
Absorbance @405nm Level of activity score 
0-0.05 +/- 
0.05-0.1 + 
0.1-0.2 ++ 
0.2-0.5 +++ 
0.5 and above ++++ 
Table 3.5 represents the scoring system which would be followed to record the glycan-
lectin activity for all the aerobes and anaerobes listed in table 3.1. These scores represent 
the glycan – lectin activity identified after carrying out ELLA analysis and taken away the 
background from controls such as no lectin, no streptavidin and no organisms.  
3.3.2 Glycan analysis by ELLA of whole cells of aerobes and 
anaerobes: 
During the initial optimisation the glycan lectin interactions of the whole cells 
of a range of aerobes and anaerobes were also carried out to determine 
whether there are any lectins whose binding were unique to particular 
organisms and if those lectins could be explored diagnostically. 
 
The table 3.6A shows the glycan-lectin interactions of whole cells of some 
aerobes growing in diabetic foot ulcers (raw data shown in the appendix VI 
to X). 
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Table 3.6A: Glycan-lectin interactions of whole cells of some aerobes growing in diabetic foot ulcers (raw data shown in the 
appendices XA to XE) 
 
 
Table 3.6A represents the ELLA glycan analysis of whole cells of some of the pre-dominant aerobes in DF ulcers. The scores are based on the scoring system shown 
in table 3.5 and after taking away the background from the controls no lectin, no streptavidin and no organisms. The unique lectins are scored in green colour while 
the higher (2 or >2) glycan-lectin binding affinities are shown in blue.  
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ELLA analysis on whole cells of clinically significant aerobes are 
presented in table 3.6A. The lectins that were unique to S. 
pyogenes whole cells were Jacalin, Soybean agglutinin, Dolicus 
biflorus, and Ricinus communisis I. Among all the other aerobes 
whole cells, P. mirabilis showed distinctive interactions with Lens 
culinaris and Erythrina cristagalli. From the total 22 biotinylated 
lectins E. faecalis showed only Lycopersicon esculentum lectin to 
be uniquely bound. Similarly P. aeruginosa showed only Wheat 
germ agglutinin to be uniquely bound. However there were other 
lectins with higher binding activity which are shown in blue in table 
3.6A. ELLA analysis on whole cells showed many other biotinylated 
lectins which were bound weakly (shown with symbol +/-).  The 
table 3.6B below shows the lectins that bound to aerobes and the 
binding glycans found in diabetic foot ulcers. 
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Table 3.6B: Glycan specificity of whole cells of aerobes in 
diabetic foot ulcers  
 
 
Microbes: E. coli – Eshcherichia coli, P. aeruginosa – Pseudomonas aeruginosa, 
P. mirabilis – Proteus mirabilis, S. pyogenes – Streptococcus pyogenes, E. 
faecalis – Enterococcus faecalis. 
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Table 3.6B shows the presence of α glucose, α and β terminal N-
acetylglucosamine in E. coli as well as α and β-N-
acetylgalactosamine, sialic acid, β1,4-N-acetylglucosamine 
oligomers and the complex structures of mannose. While P. 
mirabilis expresses β galactose, α and β 1,4 - acetylgalactosamine,  
α mannose with core α fucose, α glucose and α fucose. S. 
pyogenes possesses mannose structures including the tri and the 
tetra antennary, N-acetyl glucosamine, α 2, 6 sialic acid along with α 
and β N-acetylgalactosamine. E. faecalis expresses galactose, α-N-
acetylgalactosamine, α mannose, α glucose, terminal α-N 
acetylgalactosamine, GalNAcα1,3 [Fucα1,2]Gal, α-fucose, 
Fucα1,2Gal, β-N-acetylglucosamine, sialic acid and α – 2,6 sialic 
acid-linked to galactose. It should be noted that the specificities of 
these lectins is based largely on work carried out on eukaryotic 
systems and the specificities should therefore be analysed with 
some caution. 
The table 3.7A shows the glycan-lectin interactions of whole cells of 
some anaerobes present in diabetic foot ulcers (raw data shown in 
appendices XIIA, XIIIA, XIVA and XVA). 
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Table 3.7A: Glycan-lectin interactions of whole cells of some anaerobes present in diabetic foot ulcers (raw data shown in 
appendices XIIA, XIIIA, XIVA and XVA). 
 
 
 
Table 3.7A represents the ELLA glycan analysis of whole cells of some of the pre-dominant anaerobes in DF ulcers. The scores are based on the scoring system 
shown in table 3.5 and after taking away the background from the controls no lectin, no streptavidin and no organisms. The unique lectins are scored in green colour 
and the higher (2 or >2) glycan-lectin binding affinities are shown in blue.  
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ELLA analysis on whole cells of clinically significant anaerobes as 
seen in table 3.7A the lectin binding that was unique to P. micra 
whole cells included Phaseolus vulgaris esculentum, Lens culinaris 
and Vicia villosa lectins. Among all the other anaerobes P. bivia 
whole cells showed distinctive interactions with Lycopersicon 
esculentum lectin and Solanum tuberosum lectin. From the total 22 
biotinylated lectins P. acne whole cells bound only Griffonia 
simplicifolia II lectin, while A. prevottii whole cells bound many 
biotinylated lectins weakly shown with symbol (+/-). However there 
were other lectins with higher binding activity which are shown in 
blue in table 3.7A. The table 3.7B below lists the biotinylated lectins 
binding to the above anaerobes found in diabetic foot ulcers. 
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Table 3.7B: Glycan specificity of whole cells of anaerobes in 
diabetic foot ulcers 
 
 
 
Microbes: P.bivia – Prevotella bivia, A. prevotti- Anaerococcus prevottii, P. micra 
– Parvimonas micra, P. acnes – Propionibacterium acnes.  
 
There were differences in the glycan profiles among the anaerobes 
tested (Table 3.7B) for example P. bivia and P. acne express β-
galactose ,Galβ1,3GalNAcα1-Ser/Thr in O-glycans, terminal α-
galactose and β-N-acetylglucosamine (GlcNAc)3, GlcNAc1,4 
oligomers including chitobiose and chitotriose and complex 
structures of mannose.  Parvimonas micra expresses β-galactose, 
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Galβ1,4 GlcNAc, α-mannose in bi and triantennary complex type N 
glycans with core α-fucose, β-N-acetylglucosamine (not sialylated), 
and the complex structures of mannose including the tri and tetra 
antennary. A. prevotti however only showed interaction with Jacalin 
and thus expresses β galactose and terminal α galactose. 
3.3.3 Comparative glycan analysis by ELLA of whole cells 
and Proteinase K treated whole cells of Staphylococci 
species 
 
In order to obtain a homogenous profile of glycan-lectin interactions 
on whole cells Proteinase K was used to treat the whole cells of 
Staphylococci only. This study was part of method development to 
determine the glycan – lectin profile shown after the treatment with 
Proteinase K. The table 3.8A below shows the comparative glycan-
lectin interactions of the whole cells and the Proteinase K treated 
whole cells of Staphylococci species (raw data shown in appendix 
VI A, B to IX A and B).   
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Table 3.8A: Comparative Glycan-lectin interactions of whole cells and Proteinase K treated whole cells of Staphylococci species 
(Raw data shown in appendices VI A, B to IX A and B). 
 
Table 3.8A represents the comparative ELLA glycan analysis of whole cells and Proteinase K treated whole cells of Staphylococcus species The scores are based on 
the scoring system shown in table 3.5 and after taking away the background from the controls no lectin, no streptavidin and no organisms. The unique lectins are 
scored in green colour while the higher (2 or >2) glycan-lectin binding affinities are shown in blue.  
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As seen in table 3.8A the comparative glycan – lectin profiles obtained by 
ELLA analysis demonstrated that some carbohydrate residues were 
exposed and thus were available for binding while other residues were 
destroyed on treatment with Proteinase K and hence there were difference 
in the lectin binding of the whole cells and Proteinase K treated whole cells 
of Staphylococcus species. The lectins that were uniquely binding to 
MSSA whole cells were Jacalin and Griffonia simplicifolia I lectin while 
MRSA whole cells bound Sophora japonica lectin and Lens culinaris lectin. 
Pisum sativum was the only lectin that was uniquely bound by MRSE 
whole cells in comparison to whole cells of all other Staphylococcus 
species as seen in table 3.8A. MSSE on the other hand did not show 
uniquely bind any lectin but showed weak binding to a number of lectins. 
There was other stronger glycan - lectin binding seen which is shown in 
the table 3.8A in blue.  
Proteinase K treatment was only carried out on the Staphylococcus 
species. Among the Proteinase K treated cells there were many weaker 
interactions seen from MSSA, MRSA and MRSE with higher interactions 
seen with MSSE Proteinase K treated cells. Table 3.8B and table 3.8C 
illustrate the glycans expressed by the Staphylococcus species whole 
cells and Proteinase K treated cells respectively. 
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Table 3.8B: Glycan-lectin profiles for the whole cells of 
Staphylococcus species 
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MSSA and MRSA whole cells expressed similar glycans as seen in table 
3.8B. The glycans expressed were α glucose, α mannose with core α 
fucose, α and β terminal N-acetylglucosamine with and without sialic acid 
as well as N-acetylgalactosamine, β1,4-N-acetylglucosamine oligomers, α-
2,6 sialic acid linked to galactose and the complex structures of mannose 
by MSSA and MRSA whole cells. While MRSE whole cells expresses 
terminal α and β N - acetylglucosamine, α galactose, α mannose and α-2,6 
sialic acid. MSSE whole cells express N-acetylglucosamine, α 2, 6 sialic 
acid along with β galactose. The table 3.8C shows the glycans expressed 
by Proteinase K treated Staphylococcus species.  
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Table 3.8C Glycan-lectin profiles for the Proteinase K treated 
Staphylococcus species 
 
 
 
From the table 3.8C, the Proteinase K treated whole cells showed 
comparable interactions to those of the whole cells of Staphylococcus 
species in agreement to the study carried out by Annuk et al., 2001 where 
the proteolytic treatment greatly reduced the auto-agglutination for majority 
of the species apart from L. acidophilus species. All the 4 Proteinase K 
treated Staphylococcus species showed interactions with wheat germ 
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agglutinin, suggesting the presence of GlcNAc/sialic acid. Proteinase K 
treated MRSA showed interactions with Jacalin, Solanum tuberosum, Soy 
bean agglutinin, Succinylated wheat germ agglutinin, Ulex europaeus I 
agglutinin, Datura stramonium and Sambucus nigra lectin expressing β- N 
–acetylglucosamine, β- galactose, α and β N – galactosamine and α 2,6 
sialic acid linked to galactose along with α fucose and fucose linked α 1,2 
galactose. Proteinase K treated cells of MSSA however showed the 
interactions with Dolicus biflorus and Phaseolus vulgaris erythroagglutinin. 
Proteinase K treated MRSE and MSSE showed interactions with Solanum 
tuberosum, Soybean agglutinin and Peanut agglutinin while MRSE alone 
showed interactions with Griffonia simplicifolia II, Succinylated wheat germ 
agglutinin, Phaseolus vulgaris leucoagglutinin and Lycopersicon 
esculentum lectin. Proteinase K treated MSSE cells however showed 
interactions with Solanium tuberosum, Peanut agglutinin, Soy bean 
agglutinin, Dolicus biflorus and Datura stramonium expressing β 1,4 – N 
acetylglucosamine, α and β N –acetylgalactosamine , galactose and Gal β 
1,3 GalNAc.  
3.3.4 Glycans-lectin interactions potential in microbial 
diagnostics 
3.3.4.1 In the rapid typing of Staphylococci species 
 
An in house developed ELLA method was explored on the extracted 
glycolipids of some of the clinically significant aerobes and anaerobes pre 
dominantly found in DFI. 
The ELLA method on the glycolipids of Staphylococcus species showed 
the following glycan-lectin profiles (table 3.9 - raw data shown in 
appendices VIC, VIIC, VIIIC and IX C).  
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Table 3.9: Glycan-lectin profiles of glycolipids of Staphylococcus 
spp. (Raw data shown in appendices VIC, VIIC, VIIIC and IXC). 
 
 
Table 3.9 represents the ELLA glycan analysis of the extracted glycolipids of clinically 
significant Staphylococcus species. The scores are based on the scoring system shown 
in table 3.5 and after taking away the background from the controls no lectin, no 
streptavidin and no organisms. The unique lectins are scored in green colour while the 
higher (2 or >2) glycan-lectin binding affinities are shown in blue. 
Lectins: Jacalin (JAC), Solanum tuberosum (SOL), Soybean agglutinin (SBA), Peanut 
agglutinin (PNA), Dolichos biflorus (DB), Sophora japonica(SJA), Ricinus communis 
agglutinin I (RC), Griffonia simplicifolia lectin II (GSII), Wheat germ agglutinin (WGA), 
Succinylated wheat germ agglutinin (SWGA), Phaseolus vulgaris erythro agglutinin 
(PVE), Lens culinaris agglutinin (LC), Erythrina cristagalli (EC), Pisum Sativum agglutinin 
(PS), Phaseolus vulgaris leucoagglutinin (PVL), Vicia villosa lectin(VV), Lycopersicon 
esculentum(LE), Griffonia simplicifolia lectin I (GS I), Ulex europaeus agglutinin (UEA), 
Datura stramonium (DS), Concanavalin A (CONA), Sambucus nigra (SN). 
Microbes: methicillin resistant Staphylococcus aureus (MRSA), methicillin sensitive 
Staphylococcus aureus (MSSA), methicillin resistant Staphylococcus epidermidis (MRSE) 
and methicillin sensitive Staphylococcus epidermidis (MSSE). 
MRSA, MSSA, MRSE and MSSE were confirmed by the presence of mec A gene by 
molecular typing at UCLH. 
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The lectins that bound specifically to MRSA and MSSA were Lens 
culinaris, Erythrina cristagalli, Vicia villosa, Lycopersicon esculentum, 
Griffonia simplicifolia I as seen in Table 3.9. The lectins shown to be 
specific to MRSE and MSSE were Peanut agglutinin, Phaseolus vulgaris 
erythroagglutinin and Ricinus communis I. MRSA showed activity with 
Erythrina cristagalli and Vicia villosa binding to the glycans α and β N-
acetylgalactosamine, β-N-acetylglucosamine, GalNAcα1, 3 Gal and β-
galactose. While MSSA expressed α-mannose with core α-fucose, α-
glucose and α-N-acetylglucosamine. MRSE showed interactions with 
Peanut agglutinin and Phaseolus vulgaris erythroagglutinin expressing 
glycans β galactose with GalNAcα1, 3 Gal and complex structures of 
mannose. MSSE however showed uniquely interactions only with Ricinus 
communis I expressing β galactose and α and β N-acetylgalactosamine. 
There were other lectins that were also expressed which are shown in 
blue in table 3.9 along with the other weaker expressed lectins shown with 
symbol (+/-). 
3.3.4.2 ELLA in the rapid identification of anaerobes 
ELLA has been employed to identify many aerobes (Munoz et al., 1999 
and Annuk et al., 2004). The assay carried out in this study has 
successfully obtained the glycan - lectin profiles for a number of glycolipids 
from the Gram – positive anaerobes and lipopolysaccharide from the 
Gram - negative anaerobes pre dominantly found in DFI. The following 
table (Table 3.10A and 3.10B) shows the glycan-lectin profiles of the 
extracted lipopolysaccharide and glycolipids of Gram - negative and Gram 
- positive anaerobes respectively (raw data shown in appendices XIC, 
XIIB, XIIIB, XIVB, XVB, XVI A,B and C). 
 114 
3.3.4.2a: Glycan-lectin profiles for Gram - negative anaerobes 
Table 3.10A: Glycan-lectin profiles of glycolipids of Gram - negative 
anaerobes (Raw data shown in Appendices XVIA, B and C). 
 
 
Table 3.10A represents the ELLA glycan analysis of the extracted glycolipids of some of 
the clinically significant Gram – negative anaerobes from the DFI. The scores are based 
on the scoring system shown in table 3.5 and after taking away the background from the 
controls no lectin, no streptavidin and no organisms. The unique lectins are scored in 
green colour while the higher (2 or >2) glycan-lectin binding affinities are shown in blue. 
Lectins: Jacalin (JAC), Solanum tuberosum (SOL), Soybean agglutinin (SBA), Peanut 
agglutinin (PNA), Dolichos biflorus (DB), Sophora japonica(SJA), Ricinus communis 
agglutinin I (RC), Griffonia simplicifolia lectin II (GSII), Wheat germ agglutinin (WGA), 
Succinylated wheat germ agglutinin (SWGA), Phaseolus vulgaris erythro-agglutinin 
(PVE), Lens culinaris agglutinin (LC), Erythrina cristagalli (EC), Pisum Sativum agglutinin 
(PS), Phaseolus vulgaris leucoagglutinin (PVL), Vicia villosa lectin(VV), Lycopersicon 
esculentum(LE), Griffonia simplicifolia lectin I (GS I), Ulex europaeus agglutinin (UEA), 
Datura stramonium (DS), Concanavalin A (CONA), Sambucus nigra (SN). 
Microbes:  Fusobacterium nucleatum (F. nucleatum), Bacteroides fragilis (B. fragilis), 
Prevotella bivia (P. bivia) 
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The results (Table 3.10A) suggest that lectins could be further explored 
diagnostically for the rapid identification of the clinically important Gram - 
negative anaerobes F. nucleatum, B. fragilis and P. bivia. The lectins 
Succinylated wheat germ agglutinin, Pisum sativum, Phaseolus vulgaris 
leucoagglutinin, Griffonia simplicifolia I and Sambucus nigra all showed 
interactions with F. nucleatum but not with B. fragilis and P. bivia. However, 
P. bivia showed binding to Griffonia simplicifolia II, whereas this lectin has 
no or less affinity for B. fragilis and F. nucleatum respectively. Similarly B. 
fragilis showed binding with Vicia villosa lectin that had no affinity for F. 
nucelatum and P. bivia. 
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3.3.4.2b: Glycan-lectin profiles of glycolipids of Gram - positive 
anaerobes 
Table 3.10B: Glycan - lectin profiles of glycolipids of Gram - positive 
anaerobes (Raw data shown in Appendices XIC, XIIB, XIIIB, XIVB, and 
XVB). 
 
 
Table 3.10b represents the ELLA glycan analysis of the extracted glycolipids of some of 
the clinically significant Peptostreptococcus species most commonly cultured from a DF 
ulcer. The scores are based on the scoring system shown in table 3.5 and after taking 
away the background from the controls no lectin, no streptavidin and no organisms. The 
unique lectins are scored in green colour while the higher (2 or >2) glycan-lectin binding 
affinities are shown in blue. 
Lectins: Jacalin (JAC), Solanum tuberosum (SOL), Soybean agglutinin (SBA), Peanut 
agglutinin (PNA), Dolichos biflorus (DB), Sophora japonica (SJA), Ricinus communis 
agglutinin I (RC), Griffonia simplicifolia lectin II (GSII), Wheat germ agglutinin (WGA), 
Succinylated wheat germ agglutinin (SWGA), Phaseolus vulgaris erythro-agglutinin 
(PVE), Lens culinaris agglutinin (LC), Erythrina cristagalli (EC), Pisum Sativum agglutinin 
(PS), Phaseolus vulgaris leucoagglutinin (PVL), Vicia villosa lectin(VV), Lycopersicon 
esculentum (LE), Griffonia simplicifolia lectin I (GS I), Ulex europaeus agglutinin (UEA), 
Datura stramonium (DS), Concanavalin A (CONA), Sambucus nigra (SN). 
Microbes: Peptostreptococcus anaerobius (P. anaerobius), Parvimonas micra (Parvi. 
micra), Finegoldia magna (F.magna), Peptoniphilus asaccharolyticus 
(Pepton.asaccharolyticus) Anaerococcus prevottii (Anaer.prevottii) and Propionibacter 
acnes (P.acnes). 
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The glycan-lectin activity profiles for clinically significant Gram - positive 
anaerobes are shown in Table 3.10B. Some of the lectins are either 
unique in their binding to particular anaerobes or have varied levels of 
binding that could be explored as the basis of a diagnostic tool.  The lectin 
whose binding was unique to F. magna was Soybean agglutinin while all 
the others organisms tested showed no or lesser affinity for this agglutinin. 
Parvi. micra showed no affinity  for the lectins Succinylated wheat germ 
agglutinin, Lens culinaris and Pisum sativum agglutinin while F. magna did 
bind tothem. This could also be used in the diagnostic panel to type Parvi. 
micra and F. magna belonging to the Peptostreptococcus family. A. 
prevottii and Parvi. micra glycolipids shows no affinity to Soybean 
agglutinin, Phaseolus vulgaris leucoagglutinin and Lens culinaris while F. 
magna glycolipids does show stronger affinity. A. prevotti alone also 
shows affinity with Dolicus biflorus agglutinin. Thus Dolicus biflorus, 
Soybean agglutinin, Phaseolus vulgaris leucoagglutinin and Lens culinaris 
could be employed in the diagnostic panel for typing of the clinically 
significant Peptostreptococcus species. P. anaerobius and Peptoniphilus 
asaccharolyticus glycolipids did not show any unique lectin binding. For 
the typing of these species levels of glycan lectin binding could also be 
explored.  P. acne is a Gram - positive anaerobe that belongs to the 
Propionibacterium genus and is a clinically significant skin pathogen. It 
shows unique interactions with the Vicia villosa lectin while all other 
organisms tested showed no affinity to this lectin. Thus Vicia villosa lectin 
could be included in the diagnostic panel to discriminate P. acnes from the 
other species of the Peptostreptococcus family. 
3.3.5 Inhibition assay 
To further confirm that the biotinylated lectins used in the ELLA glycan 
analysis for all the aerobes and anaerobes discussed in this study were 
binding to the glycan on the organisms an inhibition assay was carried out 
only on one anaerobe F. magna glycolipids that were scored greater than 
(3+) in the original ELLA assay. The lectins used were Pisum sativum 
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specific for mannose and Soy bean agglutinin specific for galactose as 
shown in the figure 3.4. 
 
Figure 3.4. Inhibition of lectin binding with monosaccharides 
F. magna glycolipids were coated on to 96 well polystyrene microtitre plate and blocked 
with 2% Gelatin. 0.6 µg/ml of biotinylated lectin Pisum sativum agglutinin and Soybean 
agglutinin were preincubated with their respective monosaccharide mannose and 
galactose respectively were added to the microtitre plate and ELLA analysis was carried 
out discussed in section 3.2.6. 
 
Figure 3.4 shows that with the increasing concentrations of 
monosaccharides mannose and galactose there is a decrease in the 
binding as measured using ELLA suggesting that the lectins were bound 
specifically to the glycans from the glycolipids of Finegoldia magna. No 
inhibition was noted for assay performed on wells with no glycolipids and 
no sugar. 
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3.4 Discussion 
Considering the data obtained by ELLA on whole cells, proteinase K 
treated whole cells and extracted glycolipids of clinically significant 
aerobes and anaerobes predominantly found in DFI, an attempt has been 
made to explore the use of lectin binding as a diagnostic tool. The in 
house developed ELLA method has been used in this study is user 
friendly and economical for the analysis of microbial glycans using 
biotinylated lectins. In the process of development of the ELLA method 
various troubleshooting and optimisation steps were required such as 
denaturation conditions, attachment of the organisms to the 96 well 
NunclonTm plates with problems of adhering anaerobes to the plate and 
loss of cells during washing steps with PBS (discussed in section 3.2.4a) 
and exploration of the use of different buffers with different pHs (Table 
3.3). One of the characteristics shown by aerobes and anaerobes 
interpreted from table 3.3 is that different buffers at different pH facilitated 
the attachment of these organisms on the polystyrene microtitre plate. 
This has been due to the fact that at pH 7.2 phosphate buffered saline was 
best for their attachment of aerobes on the 96 well microtitre plate. For the 
attachment of anaerobes however carbonate buffer at pH 9.5 was 
selected. Sodium carbonate buffer was used as oppose to the calcium 
carbonate buffer as there have been studies suggesting the interference of 
calcium with lectin binding. Different buffers along with their respective pH 
helped to change the charges on the organisms to facilitate secured 
attachment. Although there have been various ELISA assays using bovine 
serum albumin as the blocking buffer in this study however tween 20 and 
gelatin was used to block the non-specific binding for aerobes and 
anaerobes respectively. Bovine serum albumin itself contained sugars so 
the use of it as the blocking buffer would incur false-positive interpretation 
of the glycan-lectin interactions. Many aerobes have been shown to have 
phosphatase activity which would interfere with the ELLA detection using 
phosphatase-streptavidin conjugates (Satta et al., 1988; Porschen and 
Spaulding, 1974). S. aureus showed phosphatase activity that interfered 
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during the assay and gave false-positive results. Therefore a denaturation 
step was carried out by heating at 55ºC for 1 h before performing the 
ELLA (figure 3.3). Similar denaturation steps were required in case of 
other aerobes such as methicillin resistant Staphylococcus aureus, 
Enterobacter species, Escherichia coli and the anaerobes Parvi. micra, 
Peptinophilus asaccharolyticus and B. fragilis.  During the optimisation 
whole cells gave a heterogenous glycan-lectin profiles therefore 
proteinase K treatment was offered to the whole cells with the aim to 
cleave open the peptidoglycan layer to produce a more homogenous 
profile. It is also well noted from figure 3.2 that the glycans where 
expressed in the early exponential phase and that there was decreased 
activities in the other phases. This could be because of varied specificity 
the organism used such that with Staphylococcus aureus with Con A 
biotinylated lectin it could be that in the early exponential phase in the 
growing state there must be Con A bound to glucose and then to 
mannose. While in the mid exponential and other phases there must be 
Con A bound to just glucose then to other sugars and hence the chain did 
not incorporate mannose therefore showing no activity. Therefore to obtain 
a consistent and avoid any false-positive interpretation all the cells were 
picked from the early exponential phase except for glycolipids.  
There are number of biomarkers which have been investigated for the 
rapid identification or typing of micro-organisms. The presence of the 
biomarker sialidase has been utilised for the identification of anaerobes 
such as black-pigmented Bacteroides and Capnocytophaga species by 
performing a simple spot sialidase test (Moncla et al., 1990). MALDI -TOF 
mass spectrometry has been coupled with internet-based proteome 
database search algorithms in an approach for direct micro-organism 
identification. This approach had been applied to characterize intact H. 
pylori a Gram-negative bacterium (Demirev et al., 2001). Similarly there 
are many other molecular methods used such as 16s RNA RT PCR, and 
mass spectrometry. RT-PCR (reverse transcriptase) was employed in the 
differentiation of Staphylococcus aureus from Staphylococcus epidermidis 
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in a case study from a culture negative osteomyelitis (Kobayashi et al., 
2006). An identification technique needs to be simple, rapid, reproducible 
and economical for it to be employed on a regular basis in the routine 
laboratory. Analysis of surface carbohydrates by lectin binding in an ELLA 
format does fulfil the criteria and there have been many studies trying to 
use lectins for diagnostics. Munoz and his colleagues (1999) tried to use 
lectins for the rapid identification of clinically important MRSA, not 
surprisingly he used only cell extracts and simply performed slide 
agglutination test trying to develop a rapid and easy method of 
identification. His study however highlighted that lectin typing can be a 
good first line approach to the epidemiology of MRSA for its rapid 
performance in laboratories but it did not show reproducibility. Our study 
needs to be developed further to analyse many clinical isolates from 
different countries grown on different culture medium as (Munoz et 
al.,1999) also highlights that culture medium used for growth  plays an 
active role in sugar expression. 
Lectin typing has also been employed for many other organisms such as 
Lactobacillus, Candida and also Archebacteria, but all have used simple 
agglutination methods performed on whole cells. Annuk et al., (2001) 
performed lectin typing on proteolytic treated whole cells. However these 
agglutination tests are limited for some organisms and may not facilitate 
agglutination of all clinical isolates (Kuusela et al., 1994). In one of the 
studies carried out by Masarova and his colleagues (2004) an optical 
based biosensor was used as a tool in bacterial identification. Here they 
employed lectins attached on Biacore TM sensor chips and whole cells or 
endotoxins were injected onto the surface. Originally antibodies were 
attached to the Biacore TM for the detection of micro-organisms because of 
the strong and specific interactions but this involved an expensive 
procedure for antibody isolation and purification and as some of these 
monoclonal antibodies were specific to antigens usage was limited. Our 
study has taken further steps towards improving lectin typing by employing 
a simple-user friendly ELLA as the technique, performing lectin typing on 
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whole cells and  Proteinase K treated as well as  glycolipids and 
lipopolysaccharides extracted from the organisms. This study has 
successfully used panel of 22 biotinylated lectins with various glycan 
specificity giving broad overview of glycan-lectin interactions and their 
potential in microbial diagnostics. 
In this study we noted that glycans, due to their conformational and 
structural differences show varied interactions with lectins. The glycan 
specificities of the lectins were derived from the results as shown in Table 
3.2. It was noted that although LC and Con A lectin are specific for α 
mannose and to a  lesser extent α glucose, LC has a preference for  bi 
and  tri anntennary complexes with a core α fucose and α glucose. Con A 
on the other hand recognises unsubstituted α mannose on bi and hexa 
antennary chains. Similarly LE lectin binds to β-N-acetylglucosamine 
especially in oligomers such as (GlcNAc) 3, GlcNAc 1, 4 oligomers, 
chitobiose and chitotriose in contrast to the GII lectin which has specificity 
for terminal α β-N-acetylglucosamine. With these conformational and 
structural preferences, it is clear that lectins can be employed in microbial 
diagnostics where results would be scored as degree of binding and 
hence affinity towards glycans and the uniqueness of the lectins that were 
expressed by aerobes and anaerobes. Some of the lectins bound only to 
specific organisms whereas others were more promiscuous multimeric 
proteins such that they bind monosaccharides of different specificity 
groups in the same combining site while few others possess more than 
one combining site for different monosaccharides in each subunit or can 
recognise oligosaccharides only. Usually the monosaccharides bind to the 
primary combining site of the lectins. The glycan–lectin binding specificity 
is based on the research data available from eukaryotes and therefore the 
results interpretations therefore need to be made with caution. The binding 
patterns and uniqueness can also be explored to distinguish different 
species in their respective genus.  
Previous studies on lectin typing of methicillin resistant Staphylococcus 
aureus have utilised agglutination assays of 77 clinical isolates with 32 
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commercially available lectins have results which differed to our study 
(Kuusela et al., 1994) that  the lectins agglutinating the MRSA isolates 
were Con A, Helix pomatia specific for D-GalNAc (and to a lesser extent 
GlcNAc)and Lens culinaris. They reported auto-agglutination in their study 
and have claimed to have obtained varied glycan-lectin profiles. Among 
the 77 clinical isolates about 30 agglutination patterns were observed. 
Some lectins that were not included in their study proved to be significant 
in our study .They also did not pre-treat the cell suspensions with 
Proteinase K. In our study the whole cells and Proteinase K treated whole 
cells of Staphylococcus species showed different lectins that were 
expressed in coherence with the proposition made by Munoz and 
colleagues (1999) suggesting that proteolytic enzymes can partially 
hydrolyse the proteoglycans, such that some carbohydrate residues can 
be exposed and thus may become available for binding while other 
residues can even become destroyed or modified. With whole cells the 
ELLA results showed many weakly positive interactions with many lectins 
implying that all the glycans on the microbial cells such as peptidoglycan, 
glycolipids, and glycoproteins were expressed thus producing more 
heterogeneous profiles. The results obtained in this study are in 
agreement with other studies (Munoz, Alvarez and Alonso, 1999; 
Masarova, Dey and Danielsson, 2004 and Stoitsova, Ivanova and Dimova, 
2004) carried out that relied on agglutination assays, or the use of 
Biosensor devices, or dot-blot analysis to identify the glycans. In our study 
however a panel of 22 biotinylated lectins, with a broader range of glycan 
specificities were employed.  
Although anaerobes are involved in number of infections they are often 
overlooked and have undergone numerous changes in nomenclature and 
classification with new species being added. API 32A which is the most 
regularly used identification system in the microbiological laboratories do 
not include these new species in the table of identification or the computer 
analysis software (Kitch and Appelbaum, 1989). Some other identification 
systems used in clinical laboratories include the BBL™ crystal anaerobe 
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identification system (Pape, Wadlin and Nachamkin, 2006; Cavallaro, 
Wiggs and Miller, 1997) do not include the new species but most 
importantly these systems are very expensive.  Due to costs, regular 
monitoring of anaerobic cultures in laboratories is limited, affecting the 
prescription of more empirical antibiotics and further leading to antibiotic 
resistance. Typing data should be in a format that is early assimilated into 
a national picture. Different bacterial species often exhibit different 
populations or structures. Some species are characterized by highly 
diverse populations at one extreme and closely similar member at the 
other. The ideal diagnostic tool would be “ASSURED” affordable, 
sensitive, specific, user-friendly (simple to perform, minimal training), 
rapid-robust, equipment – free and deliverable to those who need it. The 
method in this study uses simple ELLA and biotinylated lectins which are 
inexpensive and moreover satisfies most of the characteristics required for 
a good typing and identification method. From the data obtained 
identifying the glycan – lectin interactions for aerobes whole cells for the 
identification of E. coli, P. aeruginosa, S. pyogenes, E. faecalis and P. 
mirabilis whole cells the lectins that could be employed in a diagnostic 
panel (kit) could be WGA, JAC, SBA, DF, RCI, LC, EC and LE (table no 
3.6A). Similarly for the identification of anaerobes whole cells the lectins 
that could be used in a diagnostic panel (kit) would be PVE,LC,VV, LE, ST 
and GII (table 3.7A) which would help identification of P.bivia, A. prevotti, 
Parvi. micra and Prop. acne.  
ELLA results obtained in this study could also be used for typing of 
Staphylococcus species such that a panel of biotinylated lectins could be 
designed using Jac, GI, SJA, LC and PS for whole cells of Staphylococcus 
species and    LC, EC, VV, LE, GI, PNA, PVE and RC I (table 3.9) lectins 
for the typing of glycolipids of Staphylococcus species. Similarly ELLA 
results could use a panel of these biotinylated lectins such as SBA, DB, 
SWGA, LC, PS, SBA, PVE and LC (table 3.10B) with either unique binding 
or no binding for typing of Gram- positive anaerobes of the 
Peptostreptococcus species. VV lectin could be included to identify 
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additionally Propionibacterium acne species among the tested Gram 
positive anaerobes (table 3.10B). Among the Gram negative anaerobes 
the diagnostic panel (kit) could include  SWGA, PS, PVL, GI, SN and GSII 
(table 3.10A) lectins to discriminate the F. nucleatum, B. fragilis and P. 
bivia species. Thus this study although has identified the glycan- lectin 
profiles for number of aerobes, anaerobes exploring different type of 
glycans from the whole cells, treated whole cells and glycolipids to further 
explore its role in microbial diagnostics ELLA analysis needs to be 
repeated on higher numbers of clinical strains to confirm utility  in microbial 
diagnostics and to be statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 126 
3.5 Conclusion 
 
This study has utilised lectins and has developed a cost effective, easy to 
use and practical rapid method for the typing of various clinically 
significant aerobes and anaerobes. Further research is required to 
determine the robustness of this method in the clinical arena. 
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CHAPTER – 4 
CHARACTERISATION OF GLYCOLIPIDS OF FINEGOLDIA 
MAGNA 
 
This chapter discusses the various pathogenic characteristics and 
the mechanisms used by micro-organisms in causing infections. It 
reports the identification of sialic acid and the utilisation of GC-MS in 
the characterisation of the glycans of an anaerobe Finegoldia magna.   
 
 
Study rationale:  
Recognition of the pathogenic qualities of the various anaerobic organisms 
can assist in their prompt identification and in the initiation of appropriate 
therapy. 
4.1 Introduction 
4.1.1 Different modes of pathogenesis 
The ability of an organism to cause disease in a host is referred to as the 
pathogenicity. There are a number of virulence factors that make an 
organism a pathogen and initiate an infection. There are sequences of 
events that occur after a pathogen enters the host from attachment, to 
invasion by overcoming the natural defence barrier. After entry into the 
host, the pathogens multiply and spread until the infection becomes 
persistent and untreatable (Wilson and Devine, 2003).  
Many Gram - negative pathogens have functionally diverse adhesive pili 
which are fibrous organelles on their surface and mediate attachment to 
the host cells (Sauer, et al., 2000). Minor pili like structures have also been 
seen among the Gram – positive organisms which have shown to play a 
major role in host cell colonisation (Proft and Baker, 2008). In other cases, 
adhesion could be directly associated with the microbial surface. Some 
Gram - negative organisms such as Campylobacter coli and 
Campylobacter jejuni have fimbriae, flagella which help them in their first 
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step towards infection facilitating attachment to the host (Doig et al., 
1996). Klebsiella species and some of the mycobacterium species 
(Stokes, et al., 2004) have capsules that are glycan rich and studies have 
shown that they play a role in virulence. In some instances the bacteria 
take advantage of the rigidity of the branched oligosaccharide to improve 
the binding. (Imberty, Mitchell and Wimmerova, 2005) while others have 
proteins which are heavily glycosylated as seen in many of the Gram - 
negative species such as Pseudomonas aeruginosa, Escherichia coli, 
Neisseria and Campylobacter species. 
Virulence factors such as bacterial toxins, exotoxins and endotoxins are 
some of the other ways by which bacteria are capable of imparting toxicity 
to the cells. Most toxins produced are active even in nano molar 
concentrations. Gram - negative organisms have LPS as a component 
and there have been number of studies suggesting the toxicity is due to 
the lipid A moiety of the LPS (Sperandeo, Deho and Polissi, 2009). Some 
of the uropathogenic and enteropathogenic Escherichia coli have 
pathogenicity islands which are large elements that are integrated into the 
chromosome of bacteria which carry the virulence determinants. for 
instance some strains of E. coli have Pai I which encodes for haemolysin, 
Pai II encoding for P fimbriae as well as haemolysin, Pai III is a type II 
secretion system that mediates the infection of proteins directly into the 
cytoplasm of the target host cell. Pai IV encodes for hemolysin adhesion 
associated pili and Pai V encodes for hemolysin and cytotoxic necrotizing 
factor (Hentschel, and Hacker 2001). One of the classic examples of 
bacteria whose virulence is determined by the presence of enterotoxins is 
Clostridium difficle a significant anaerobe known to cause many fatal 
infections (Boquet et al., 2000). 
There are other ways by which  bacteria have evolved by making cell 
surface molecules that mediate bacterial attachment, these cell surface 
carbohydrates and proteins help in protecting  bacteria as  is seen among 
the Gram - positive organism Staphylococcus aureus. It produces a 
collagen binding protein (Deivanayagam et al., 2000) while Streptococcus 
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pyogenes shows the presence of M proteins which are classic virulence 
determinants interacting with the host molecules such as fibrinogen, 
albumin, plasminogen and IgG (Cunningham, 2000). 
4.1.2 Role of glycans in pathogenesis 
Glycans interact with lectins and this is the molecular basis of a number of 
interactions between bacteria and their environment. Thus the binding of 
the surface carbohydrates of one bacterial species by surface adhesins of 
another causes bacterial co-aggregation (Rickard et al., 2003 and 
Kolenbrander et al., 1993), and this plays a role in the formation of 
biofilms.  
Many bacteria are also protected by capsules, which are often 
glycosylated and play a role in attachment to the host as discussed earlier. 
One of the most significant contributions to understanding pathogenesis 
has been made with the advent of lectins as it has now become possible 
to identify the glycan-lectin interactions adopted by various bacteria with 
their host in initiating an infection. There have been many occasions 
where lectins from the bacterial cell wall have been utilised as the first 
mode of attachment to the host glycans. For example the AB5 - type 
proteins of Vibrio cholera, enterotoxic E.coli and Bordella pertussis have 
one toxin and five lectin subunits which enables them to bind to the 
gangliosides of gut or lung walls (Merrit and Hol, 1995). Similarly 
Clostridium species causing botulism have a lectin domain enabling them 
to bind to the ganglioside GM1 on neurons (Lalli et al., 2003). The 
opportunistic human pathogen Pseudomonas aeruginosa produces two 
soluble lectins PA-1L (gene lec A) and PA-IIL (gene lec B) which bind to 
galactose and fucose/mannose containing glycoconjugates of the host. 
These glycans present on the host cells act as specific targets for the 
pathogen binding and are involved in the establishment of infections 
(Lloyd et al., 2007). Conversely there are glycans present on micro-
organisms such as E.coli which use host mannose specific receptors to 
bind to bladder epithelium causing cystitis, and galactobiose specific 
 130 
receptors to invade the upper urinary tract causing pyelonephritis (Imberty 
et al., 2004). 
4.1.3 Role of sialic acid in pathogenesis 
Sialic acid is a collective term for a family of 9-carbon monosaccharide 
which are often found as terminal sugar residues on the glycans of 
glycoproteins and glycolipids. These are found both on eukaryotes as well 
as prokaryotes. Although N-acetylneuraminic acid is one of the most 
abundant of the sialic acids there are other neuraminic acid derivatives 
which occur in a variety of natural sources. The naturally occurring sialic 
acids are from the families of N-acetyl, N-glycolyl, O-phosphate, O-
sulphate, O-methyl and O-lactyl (Schauer, 2000). Sialic is saliva in Greek, 
and neuraminic means brain and amine (Angata and Varki, 2002). 
Studies have shown that sialic acid has played an active role in enabling 
some microbes to colonize, persist and cause disease in mammalian 
species. Sialic acids are present on many pathogens, for example 
Escherichia coli K1, Haemophilus influenzae, Pasteurella multocida, 
Neisseria species, Campylobacter jejuni and Streptococcus agalactiae 
(Severi et al., 2007). Bacteria can also utilize sialic acid as a carbon and 
nitrogen source by scavenging it from the surrounding environment. The 
sialic acid molecule is extensively found in mucus rich environments such 
as the gut and lungs where many pathogens thrive (Severi et al., 2005 and 
Chang et al., 2004). This kind of sialic acid catabolism has been 
demonstrated in five species: Clostridium perfringens, Escherichia coli, P. 
multocida, H. influenzae, and Bacteroides fragilis (Nees, Schauer, Mayer, 
1976 and Brigham et al., 2009). Chang et al., (2004) showed in E. coli that 
the ability to degrade sialic acid was important for the colonization of the 
mouse colon. This finding suggests that the ability to utilize sialic acid as a 
carbon source may be important for bacteria to colonize this niche 
(Almagro-Moreno and Boyd, 2009). Sialic acids help in stabilizing 
glycoconjugates and cell membranes, and also act as chemical 
messengers within the host (Schauer, 2000).  
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There are many other ways by which the presence of sialic acid can prove 
to be harmful to the host. Current studies have shown that several 
bacterial pathogens such as enterohaemorrhagic Escherichia coli, 
Haemophilus influenzae, H. ducreyi, Pasteurella multocida, Neisseria 
gonorrhoeae, N. meningitidis, Campylobacter jejuni, and Streptococcus 
agalactiae can attach sialic acid residues on to their outer surfaces 
(sialylate) masking them from the host immune system. These sialic acids 
can help in evading the host defence by inhibiting the direct activation of 
the alternative pathway of complement (Edwards et al., 1982). This is 
seen in the anaerobe Porphyromonas endodontalis a black pigmented 
obligate anaerobe frequently responsible for causing mixed microbiota of 
infected root canal systems and peripheral abscesses (Collazo et al., 
2003). Interestingly, these pathogens have developed different 
mechanisms for obtaining sialic acid that include de novo biosynthesis of 
sialic acid  in E. coli and N. meningitidis, sialic acid scavenging as seen in 
N. gonorrhoeae, and precursor scavenging  as recognised in H. influenzae 
(Almagro-Moreno and Boyd, 2009). Owing to their negative charge sialic 
acids have been involved in the binding and the transport of positively 
charged molecules as well as in the attraction and repulsion of cells and 
molecules. 
4.1.4 Finegoldia magna, sites of infections and pathogenic 
factors 
Finegoldia magna, belonging to the group Peptostreptococcus spp is one 
of the Gram - positive anaerobes most commonly isolated from diabetic 
foot ulcers. All the Peptostreptococcus species are part of the normal skin 
flora of the mucosal surface in the oropharynx, and in the gastrointestinal 
and genitourinary tracts (Murdoch, 1998; Stephens et al., 2003). In 
association with other pathogens they can become opportunistic 
pathogens. Among all the Gram - positive anaerobes, F. magna mainly 
causes skin infections and is often recovered from osteoarticular surgery 
(Felten, et al., 1998) and is among the most frequently isolated bacterial 
species from chronic leg ulcers (Wall et al., 2002 and Stephens et al., 
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2003). The F. magna recovered from infectious sites is almost always 
found in association with other pathogens. Recently there have been 
many advances in identifying the pathogenic factors of F. magna. It has 
Protein PAB (DeChâteau et al., 1996) suggesting colonisation and ability 
to produce various enzymes. The Protein PAB has been seen to be 
responsible for binding to Human serum albumin to their surface (Lejon et 
al., 2004). The enzymes produced by F.magna which could contribute to 
pathogenesis include hippurate hydrolase, serine dehydratase, threonine 
dehydratase, gelatinase, alkaline phosphatase, esterase C4, catalase and 
collagenase (Krepel et al., 1992). Other factors include encapsulation 
(Brook and Walker, 1985) and increased oxygen tolerance of clinical 
isolates. Most strains also have shown to express subtilisin-like enzymes 
such as Suf A that have proteolytic activity against many antimicrobial 
molecules (Karlsson et al., 2007).  
About 10% of F.magna strains have Protein L which has high affinity for 
immunoglobulin light chains (Bjorck, 1988). A study has also shown that 
Protein L has contributed to colonisation of F.magna. Another protein 
termed as FAF protein (F. magna adhesion factor) has also been involved 
in the aggregation and the colonisation of F.magna strains (Frick et al., 
2008). This study suggested that when the F.magna strains with the FAF 
protein were treated with proteases the cells showed no adherence to any 
other cells. Molecular techniques were also used to confirm the presence 
of FAF gene in some strains of F. magna. The study by Frick and 
colleagues (2008) also highlighted that those strains which did not show 
the FAF protein could use other methods in colonisation. Another study 
has suggested that in the growth medium in vitro many of the F. magna 
isolates inhibited the proliferation of fibroblasts and keratinocytes 
(Stephens et al., 2003). Many strains of F. magna have also been shown 
to express the ABC transporter gene which is associated with the efflux of 
antibiotics out of the cells leading to antibiotic resistance and multi drug 
resistance pumps (Jauhangeer, 2004). All of the above discussed features 
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are utilised by F.magna in colonising, host cell attachment or embracing 
adaptations to avoid host defence and imparting infections. 
4.1.5 Tools in the characterisation of glycolipids 
 
Glycoproteins and glycolipids are also the major classes of 
glycoconjugates found on human epithelial and endothelial tissue 
(Hakomori, 1973 and Ruddiger and Gabius, 2001). These glycoconjugates 
play a wide role in many biological processes and many utilise 
carbohydrate-lectin binding to facilitate cell-cell and small molecule – cell 
recognition (Severi et al., 2007). Therefore it becomes necessary to 
acknowledge all the different types of tools that can be explored to identify 
these important components of cells. Qualitative and quantitative 
measurements of the monosaccharide residues on glycoconjugates can 
easily be made by combinations of approaches including colorometric 
assays, paper or thin chromatography (Carlson, 1968) or using  more 
sophisticated but expensive tools such as gas chromatography-mass 
spectrometry (GC-MS) , high pH anion exchange chromatography 
(HPAEC) (Townsend and Hardy, 1991) and  nuclear magnetic resonance 
(NMR) (Hounsell, 1994)  to help fully characterise the glycolipids and 
glycoproteins. Structural analysis of glycans requires chemical (reduction 
in alkaline or hydrolysis) or enzymatic treatment (endo-exoglycosidases) of 
the glycans. After derivatisation the sample can be analysed by mass 
spectrometry which is a valuable tool to rapidly characterise small 
amounts of materials. It can also be used in determining the chemical 
structures of important peptides and chemical compounds. It relies on the 
principle of ionizing the chemical compounds and generating charged 
molecules or molecule fragments and finally measuring their mass-to-
charge ratios.  
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4.2 Materials and Method 
4.2.1 Micro-organisms, culture conditions and glycolipids 
extraction 
ATCC strain 29328 of Finegoldia magna was provided by the Anaerobic 
Reference Laboratory of London (UCLH). Finegoldia magna ATCC 29328 
was grown under strict anaerobic conditions at 37ºC on 5% defibrinated 
horse blood agar and then cultured in brain heart infusion broth (Oxoid) 
with 0.01% Tween 80.  
The method and materials used for the extraction of glycolipids of 
Finegoldia magna and biotinylated lectins was as outlined in chapter 
3.2.5A and 3.2.2 respectively. 
4.2.2 Proteins and Carbohydrate assay: 
Bradford assays were performed for the detection and the quantification of 
proteins. Bradford reagent was obtained from Sigma and the protocol 
provided by them was followed (Bradford, 1976). Phenol-sulphuric assay 
was the method of choice for the detection and quantification of complex 
carbohydrates (Dubois et al., 1951).  
4.2.3 Warren assay for sialic acid  
Sialic acid analysis was carried by the Warren method (Warren et al., 
1959). Fetuin (0 to 15 µg), known to contain sialic acid, was used as the 
control. Both the controls and Finegoldia magna glycolipids were acid 
hydrolysed with 0.1M sulphuric acid for 2 h at 80 ºC and then the tube was 
cooled for 20 min at room temperature. In brief 20 µl of periodate reagent 
(0.2M sodium periodate in 9M phosphoric acid) was added to 100 µl of 
fetuin and to the hydrolysed glycolipids. This mixture was incubated for 20 
min at room temperature. To this 100 µl of 10% sodium arsenite in 0.05 M 
sulphuric acid with 0.5 M sodium sulphate was added slowly until the 
brownish yellow colour appeared and disappeared entirely. Thiobarbituric 
acid, 250 µl of 0.6 M, in 0.5 M sodium sulphate was added and the 
reactions were kept in boiling water for 20 min and then cooled at RT. The 
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mixture was then added to another eppendorf tube and 750 µl of 
cyclohexane was added and vortex rigorously centrifuged for 7 min at 
2000rpm for phase separation. The upper phase was then measured at 
549nm in a quartz 0.5 ml cuvette.  
4.2.4 Preparation of glycans for high pH anion exchange 
chromatography (HPAEC):  
The calibration standards of a mix of monosaccharides of concentration 
0.5 nmole/10 µl, 1.0 nmole/ 10 µl, 2.0 nmole/10  µl  mix were hydrolysed 
using 400 µl of 2 N trifluoroacetic in 200 mM sodium hydroxide buffer at 
100 ºC for 4 hours. While 400 µl of 2 M acetic acid in 100 mM of sodium 
hydroxide buffer was added to hydrolyse the sialic acid standards (N-
acetyl-neuraminic acid and N-glycol-neuraminic acid) and F.magna 
glycolipids at 80 ºC for 4 hours. After hydrolysis the hydrolysates were 
frozen on dry ice and lyophilised. The lyophilised hydrolysates were 
resuspended in degassed nanopure water and sonicated in cold water for 
7 min. Standards and hydrolysed Finegoldia magna glycolipids (10 µl) 
were injected in the DIONEX machine. 
4.2.5(A) Composition and linkage analysis by Gas 
Chromatography - Mass spectrometry 
Composition analysis: To analyse the composition of glycolipids of 
Finegoldia magna the following chemical derivatisation were carried out 
before injecting the sample.  
Sample preparation:  A sample of 800 µg of glycolipids of F. magna was 
weighed and 20 µg of inositol as an internal standard control was added.  
An aliquot of 200 µl of 2 M trifluoroacetic acid (TFA) was added to the 
sample and incubated for 2 h at 121 ºC. The sample was allowed to cool 
at room temperature and dried with nitrogen. Isopropanol (100 µl) was 
then added and the suspension was dried with nitrogen. This was 
repeated twice. 
Reduction: Freshly prepared solution of 10 µl of 10 mg/ml of sodium 
borodeuteride in 1 M ammonium hydroxide was added to hydrolysed 
sample and incubated at RT for 2 hour. The above solution was 
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neutralised with glacial acetic acid and dried down with nitrogen. 15 µl of 
9:1 methanol: acetic acid was added and dried with nitrogen. Again this 
was repeated twice. To further remove the borates 15 µl of methanol was 
added and dried with nitrogen, the procedure was repeated until a crusty 
white residue was seen on the side of the tube. 
O-acetylation: Acetic anhydride (250 µl) of and 230 µl concentrated TFA 
was added to the above sample and incubated at 50 ºC for 10 minutes. 
After cooling 1 ml of isopropanol was added and the suspension was dried 
in a stream of nitrogen. To neutralise the sample 0.2 M of sodium 
carbonate was added and mixed gently. A 1 ml aliquot of dichloromethane 
was added and centrifuged briefly. The aqueous layer was discarded and 
1 ml of water was added and centrifuged. The organic layer was taken to 
another tube and concentrated prior to injection onto GC-MS (SP2330 
fused silica column, Supelco). 
4.2.5(B) Composition of lipids – by gas chromatography mass 
spectrometry 
A preliminary study was carried out to check the composition of the lipid 
portion of the samples. The dried glycolipid extracts (0.5 mg) were 
suspended in chloroform-methanol-water (65: 25:4, v/v) to remove the non 
lipid material. From the sample (10 µg) of the above lipid fraction was 
hydrolyzed in 0.5 ml 1 M HCl for 4 hrs at 100 ºC in sealed tubes. Following 
evaporation of HCl, samples were reduced and peracetylated according to 
the method discussed earlier in section 4.2.5(A) Internal standard C-17 
heptadecanoic acid was added as a control.  
4.2.6 Linkage analysis by gas chromatography – mass 
spectrometry: 
Permethylation, depolymerisation, reduction and acetylation of glycolipids 
of Finegoldia magna were carried out and the resultant partially 
methylated alditol acetates (PMAAs) analysed by gas chromatography-
mass spectrometry. Initially, aliquots of 0.5 mg/ml of glycolipids in 200 µl 
DMSO were prepared and placed on a magnetic stirrer for 4-8 hours for 
complete dissolution and then freezing of the sample. This reaction and all 
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subsequent reactions were performed in disposable glass tubes with 
Teflon-lined screw cap fittings. 
Permethylation of the samples was carried out by using the Hakomori 
methylation. (Hakomori, 1964) The permethylation of the material was 
carried out by adding methyl iodide (500 -700 µl) with the head space 
purged with nitrogen gas and carefully stirred for 3 hrs. To quench the 
reaction I ml of nano pure water was added and mixed. Methyl iodide was 
then bubbled off completely with low flow of air leaving a clear solution. 
Reverse phase chromatography was performed manually using Sep-Pak 
C18 cartridges. The sample was then extracted with acetonitrile (1 ml). 
Myo-inositol (2-5 µg) was also added to the permethylated sample as an 
internal standard. The permethylated sample was then hydrolyzed using 
2M trifluoroacetic acid to produce partially methylated alditol acetate 
(PMMA) and reduced using 10 mg/ml solution of sodium borodeuteride in 
1 M ammonium hydroxide to produce partially methylated alditols. The 
reduction reaction was neutralized with glacial acetic acid and 20 drops of 
9:1 of methlyalcohol: acetic anhydride. The partially methylated alditols 
were then peracetylated using acetic anhydride and TFA (230 µl) was then 
added and the sample was incubated at 50 ºC for 20 minutes and the 
reaction neutralised with 0.2 M sodium carbonate. The resulting PMAA 
was extracted using dichloromethane and water, and dried down using 
nitrogen gas prior injecting 1 µl onto the GC MS (SP2330 fused silica 
column, Supelco, Bellefonte) with MS operating initial temperature of 80 
ºC and initial time 2.0 min. 
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4.3 Results 
This section discusses the Finegoldia magna glycolipids composition data. 
The main objective is to understand the monosaccharides, presence of 
sialic acid and fatty acid on F. magna glycolipids. In order to achieve this 
objective, the techniques explored were in house developed easy and cost 
efficient ELLA and the expensive yet robust methods such as the GC/MS 
and HPAEC. Simple traditional methods such as Warren‟s assay were 
also used for determining the presence or absence of sialic acid on 
different anaerobes. 
4.3.1: Glycans expressed by Finegoldia magna as 
determined by ELLA method 
ELLA method discussed in section 3.22 was used to determine the 
glycans expressed on F. magna glycolipids. As seen in Appendix XIC 
based on lectin specificity the glycans likely to be expressed by F. magna 
glycolipids include Galβ1-3GalNAc specified by Soybean agglutinin lectin, 
Peanut agglutinin lectin and Ricinus communis agglutinin I lectin, GlcNAc 
as specified by the reaction with succinylated Wheat germ agglutinin lectin 
and structures containing mannose specified by Lens culinaris agglutinin, 
Pisum sativum agglutinin and Phaseolus leucoagglutinin. The reaction 
with Sambucus nigra which is specific for sialic acid attached to the 
terminal galactose was also positive as shown in Appendix XIC. Inhibition 
assay was carried out to confirm the specificity of binding of the 
biotinylated lectins with F.magna glycans shown in chapter 3 in section 
3.3.5 in figure 3.4.  
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4.3.2 Carbohydrate and Protein assay 
The quantification of carbohydrates and proteins of glycolipids of 
Finegoldia magna was determined by reference standard curve generated 
using commercially available Escherichia coli LPS in the range of 0.1-1.4 
mg/ml for proteins and 0 -100 µg/ml for carbohydrates. 
 
Figure 4.1: Bradford and Phenol – sulphuric acid assay for E. coli 
LPS 
The reference standard curve constructed on E. coli LPS as seen in figure 4.1 and the 
equation shown in figure was used to calculate the protein and carbohydrate content of F. 
magna glycolipids 
 
From the absorbance at 595 nm and using the equation from the figure 4.1 
the protein content of F. magna was below the reference range of the 
assay (0 – 1.6 mg/ml) and due to the high amount of carbohydrate the F. 
magna glycolipids was diluted 1 in 100 times and then the carbohydrate 
content was determined using the phenol – sulphuric assay. It was found 
that F.magna glycolipids contained more carbohydrate than the reference 
range of the assay (0 – 120 µg/ml). 
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4.3.3 Composition analysis of glycans of Finegoldia magna 
glycolipids 
Gas chromatography coupled with mass spectrometry was used  to 
analyse the monosaccharide composition of the glycolipids by preparation 
of alditol acetates. Following the derivatisation procedure as described in 
section 4.2.5A, the sample was injected onto the DB -1 column of GC/MS 
for analysis. Samples were derivatised to convert the non – volatile 
metabolites to volatile metabolites prior to injecting on to the column of 
GC/MS analyser.  
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 Initially, a range of monosaccharides were run on the column to 
determine their retention times (Rt). Standard monosaccharides included 
fucose, arabinose, galactose, glucose, mannose, rhamnose and xylose 
and  then the sample was injected to obtain a chromatogram of the F. 
magna glycolipids (Figure 4.2).  The chromatogram of the standards in 
shown in the (Appendix XVII). Inositol was used as an internal standard 
such that Inositol was the last eluted fraction. 
 
 
 
Figure 4.2: Composition analysis of glycans of Finegoldia magna  
Figure 4.2 illustrates the peaks corresponding to the respective monosaccharides on the 
glycolipids of Finegoldia magna obtained after derivatisation by GC-MS analysis. Mass 
spectra of the individual standard monosaccharides were used to compare and identify 
the sample components.   
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GC-MS showed the presence of two peaks representing the alpha and the 
beta forms of monosaccharides. The GC/MS of F. magna glycolipids 
showed the presence of rhamnose, glucosamine, glucose, mannose and 
galactose  with retention times (13.30, 13.4), (18.80), (24.98, 26.02), 
(21.16, 21.49) and (22.76, 24.07) minutes respectively. The 
monosaccharide composition obtained by GC-MS is similar to the glycan 
analysis performed by ELLA with a panel of 22 biotinylated lectins as 
shown in appendix XIC. It is noteworthy that this method cannot be used 
to detect sialic acids. Table 4.1 shows the composition of glycolipids along 
with their retention time and % abundance. 
Table 4.1: Composition of glycolipids of F. magna  
 
Monosaccharides % Abundance GC- Rt (min) 
Glucosamine 4.39% 18.807 
Glucose 15.21% 24.98 and 26.02 
Mannose 15.85% 21.16 and 21.49 
Galactose 39.26% 22.76 and 24.07 
Rhamnose 25.28% 13.30 and 13.4 
GC-Rt is peak retention time of ion on the respective GC column. GC ion abundance is 
used to express % abundance for each monosaccharide as function of total carbohydrate 
in separate experiments. 
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4.3.4 Characterisation of lipids by Gas chromatography – Mass 
spectrometry 
GC/MS was also used to identify the fatty acids making up the lipid part of 
the F. magna glycolipids after the derivatisation step discussed in section. 
10 µgs of the Finegoldia magna lipids were extracted and derivatised to 
obtain alditol acetates and volatilised to obtain a GC/MS chromatogram. 
 
 
Figure 4.3: Fatty acid composition of F. magna lipids  
Figure 4.3 shows the saturated fatty acids seen on the Finegoldia magna glycolipids 
analysed by GC-MS. The retention times and the annotation of the fatty acids expressed 
by F. magna glycolipids are shown in the table. C-17 fatty acid was used as an internal 
standard. 
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Table 4.2: Fatty acids on the glycolipids of F. magna 
The total fatty acid composition of 10 µg of Finegoldia magna glycolipids is 
shown in the table 4.2.  
 
At retention times 16.90, 24.79 and 33.16 the fatty acids expressed by the 
lipids of Finegoldia magna were myristic acid (3.975 nmol), palmitic acid 
(70.122 nmol) and stearic acid (135.749 nmol) respectively. 
Heptadecanoic acid (C-17) was used as an internal standard.  
4.3.5 Linkage analysis by partially methylated alditol acetates of 
Finegoldia magna glycans 
Glycosyl linkage analysis was carried out by the preparation of PMAA 
(Partially Methylated Alditol Acetates) in accordance to Hakomori 
methylation method (Hakomori, 1964). On successful permethylation, 
reduction and acetylation as described in section 4.2.6, the resulting 
partially methylated alditol acetates (PMAA) were injected on to the 
SP2330 (Supelco, Bellefonte) column of the GC/MS (Fig 4.4). 
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Figure 4.4: Linkage analysis of glycans of F.magna   
PMMA derivatives of glycolipids of F. magna showed the linkages seen in figure 4.4. 
These were resolved using Gas Chromatography and identified by EI generated 
fragments patterns by using a library of PMAA sugar standards. 
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Glycans expressed by Finegoldia magna included mannose, glucose and 
galactose shown in figure 4.2 with the linkage data as shown in figure 4.4 
suggesting terminal and 3 - mannose linkages with retention times 11.41 
and 14.03 respectively. A naturally-occurring deoxy sugar rhamnose was 
also seen with 2-rhamnose and 3-rhamnose linkages with retention time 
11.13 and 11.29 minutes respectively. The fragmentation patterns 
produced from each of the peaks were compared to libraries of PMAA 
derivatives present on the CCRC (Complex Carbohydate Research 
Centre, USA) databases specifically prepared for the most common 
monosaccharide linkages. Deuterium was used during the derivatisation to 
enable the distinction between the epimers. Deuterium helped to open the 
cyclic ring which resulted in the alteration of the GC retention time. With 
the methylation step discussed in the section the methylated structures 
would appear on the terminal residues as the reducing end of each 
monosaccharide would be expected to be engaged in a linkage with the 
preceding monosaccharide.  All linkages were identified on the basis of 
relative retention time and fragmentation pattern.  
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4.3.6 Sialic acid determination by HPAEC 
 
Figure 4.5: Sialic acid on the glycolipids of F.magna 
Figure 4.5 illustrates the peak at elution time 5.10 of sialic acid obtained after hydrolysis 
of glycolipids of F. magna. 
 
At elution time of 5.10 minutes as observed in the above figure 4.5 
illustrates that the glycolipids of Finegoldia magna carried N-
acetylneuraminic acid. 400 µg of hydrolysed Finegoldia magna glycolipids 
contained 19.94 nmoles of sialic acid (0.99 nmoles/10 µl /of injected 
sample volume). 
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4.3.7 Detection of sialic acid on glycolipids of anaerobes using 
the Warren assay 
Warren‟s assay was used for the qualitative identification of sialic acid on 
the glycolipids of some of the most predominant anaerobes often isolated 
from the DF patients. Although this method can be used to quantify the 
amount of sialic acid, in this study due to the low amount of sample the 
quantification was not carried out. However the results shown below in 
table 4.3 show the presence or absence of sialic acid on some of the 
significant anaerobes. 
  
Table 4.3: Sialic acid on the glycolipids of anaerobes 
 
 
Table 4.3 shows the presence of absence of sialic acid for glycolipids from a number of 
anaerobes determined by Warren‟s assay. 
 
The anaerobes shown to possess sialic acid by Warren‟s assay included 
F. magna, P. anaerobius, Prevotella bivia, Propionibacterium acnes and F. 
nucleatum.   
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4.4 Discussion 
 
The characterisation of glycolipids of Finegoldia magna using GC/MS 
reveals similar glycan profiles to those obtained by ELLA of Finegoldia 
magna glycolipids shown in Appendix XIC. Finegoldia magna typically has 
a gram-positive cell envelope and monosaccharides decorate the cell 
surface. There have been many previous studies highlighting the 
importance of N-acetylneuraminic acid, N-acetyl glycol neuraminic acid 
and other monosaccharides in the glycopolymers of the glycocalyx of 
bacteria. For example, in Lactobacillus spp these glycopolymers are linked 
to the adhesive properties of the strains (Onyshchenko et al., 1999). There 
have also been many studies highlighting the importance of bacterial 
lectins in adhesion and pathogenesis, but very few describing the glycans 
as virulence factors for anaerobes. 
This study highlights the virulence factors which could play a part in the 
pathogenicity of the anaerobe Finegoldia magna. From the GC/MS carried 
out and the ELLA results, it is clear that glycans expressed by Finegoldia 
magna include glucose, mannose, galactose rhamnose and glucosamine 
with terminal mannose and 3 mannose linkages. In this study a full 
structure of F. magna glycolipids cannot be determined because the 
biotinylated lectins used in the ELLA can help in qualitative identification of 
the glycans and the possible linkages but cannot be confirmative of the 
exact structure of the glycolipids of F. magna. GC/MS can be used to build 
the structures but due to incomplete linkage data obtained during the 
derivatisation a complete structure cannot be assigned except although it 
can be determined from the data that F. magna glycolipids do contain 
terminal mannose, α1, 3 mannose, 2–linked rhamnose and 3-linked 
rhamnose.  
One of the other methods used in this study namely the HPAEC which is a 
robust method utilises a DIONEX columns and is highly sensitive detecting 
as little as 1 pmole. HPAEC analysis on the F. magna glycolipids 
suggested the presence of sialic acid and thus confirmed the results 
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obtained using the ELLA methods with the binding of Sambucus nigra 
lectin which is specific for sialic acid attached to terminal galactose seen in 
Appendix IXC. Rhamnose could also play a role in virulence as there have 
been studies suggesting that rhamnose has been found as a component 
of the outer cell membrane of many clinical isolates. Studies have shown 
the presence of sialic acid on Bacteroides fragilis which is in contrast to 
our study (Severi et al., 2007). However, there can be variations in 
expression of genes amongst the various strains of pathological and non 
pathological origin. This suggests that a number of clinical isolates should 
be tested for an overall comparison and for confirming the presence of 
sialic acids on these pathogens. Our study has demonstrated the 
presence of sialic acid on the ATCC strain of F.magna this knowledge of 
the composition of bacterial surface components may enable a thorough 
understanding of this clinically significant anaerobe which causes many 
skin infections and also interacts with other aerobes and anaerobes. 
A study carried by Moncla et al. (1990) has shown many Gram - negative 
anaerobes differ in their sialidase activity. Sialidase is an enzyme which 
catalyses the hydrolysis of terminal sialic acid residues leaving sialic acid 
free to combine with the capsular polysaccharides or lipopolysaccharides 
(Moran et al.,1991) as seen in Campylobacter jejuni lipopolysaccharides. 
Sialic acid, due to its adhesive properties and its potential to bind to both 
bacterial and host sialic acid binding lectins could help anaerobes isolated 
from diabetic foot wound to adhere to other bacteria or fungi to form 
biofilms, one of the peculiar characteristics of the aetiology of diabetic foot 
ulcers, or to bind directly to the host cells. In diabetic patients the immune 
system is very weak and the presence of sialic acid on the microbes may 
prove to be an additional advantage for the microbes to colonise the 
already weak immuno-compromised diabetics. Sialic acid facilitates cell-
cell adherence or cell-host adherence and the formation of biofilms which 
are often difficult to treat due to their lack of sensitivity to many antibiotics. 
Identifying the virulence factors may enable us to target treatment. 
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4.5 Conclusion 
 
This study highlights the presence of sialic acid on Finegoldia magna and 
the importance of characterising the glycans on the glycolipids of other 
pathogenic anaerobes. The role played by sialic acid in the pathogenesis 
of the organism has yet to be determined. 
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CHAPTER – 5 
GENERAL DISCUSSION  
 
Infection is one of the major factors in the progression of foot ulcers in 
diabetics (Lipsky, 2004a and 2004b and Citron et al., 2007). With a view to 
understand the complete microbiology of DFU,  one part of the research 
focussed on identifying the aetiology of micro-organisms isolated  from the 
DF ulcers of patients from India and the UK, determining antimicrobial 
sensitivity profiles and the establishment of confounding risk factors. This 
work also gathered other risk factors which may have contributed to the 
development of a DFU. From the data collected from the questionnaire 
designed to record the Indian diabetic foot patient‟s medical information it 
was found that the main confounding factors identified were peripheral 
vascular disease, neuropathy, ischaemia, trauma and neuroischaemia. 
These confounding factors were often found to be present in combinations 
of 2 or more signifying the severity of the condition suggestive in many 
studies (Tesfaye, Chaturvedi and Eaton, 2005; Pendsey, 2010 and 
Norgren et al., 2007 ). The statistical significance of each risk factor to the 
risk of DFU could not be determined due to the low numbers with 
individual factors among the Indian diabetic foot patients. All the Indian 
diabetic foot patients had infection due to the presence of aerobes and/or 
anaerobes and/or fungi and many had mixed infections. Among the 
aerobes the most commonly cultured from the ulcers were Gram - positive 
aerobes mainly MRSA, MSSA and Streptococcal species while Gram - 
negative aerobes included those from the Enterobacteriaceae family. 
Among the fungi the most common included the Candida species with 
Candida tropicalis the most frequently isolated fungus among the India DF 
patients. Clostridium species were the most common aetiological agents 
isolated from the DF patients from India and among the Gram - negative 
organisms the Fusobacterium species and B. ureolyticus were most 
commonly seen. Similar microbial aetiology was seen in many other 
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studies carried out in India (Shankar etal., 2005; Varaiya et al., 2008 and 
Gupta et al., 2009). Interestingly there were multi-drug resistant anaerobes 
isolated that had led to treatment failure with the worsening of the ulcer, 
causing some level of amputation either any toes of complete foot.  There 
have been many studies in India suggesting that high glycaemic levels, 
lack of education, compromise in personal hygiene, poverty and 
superstitions to be the factors that may have contributed to the 
development of ulcer and added to the worsening of the ulcers 
(Ramachandran et al., 2004; Pradeepa et al., 2002 and Jayasinghe et al., 
2007). In contrast, the study carried out in the UK where patients received 
treatment at an early stage of the disease revealed less organisms 
resistant to antibiotics as compared to the multi-drug resistant organisms 
from the Indian DFU patients. Linezolid was the only antibiotic to which a 
high number of organisms were susceptible among the Indian patients 
while, based on antibiotic sensitivity testing,  the combination antibiotic 
piperacillin/tazobactam followed by other antibiotics such as amikacin and 
levofloxacin were the antibiotics of choice for the DF patients from the UK. 
The results obtained for the Indian cohort have been used by Raheja 
Hospital in re-evaluating their testing and treatment regimens. 
As outlined in chapter 2, the original aims of this research were to identify 
the glycans expressed by the bacteria and to explore their role in 
pathogenesis. The glycans expressed by bacteria were identified using 
commercially available biotinylated lectins on whole cells, Proteinase K 
treated whole cells and extracted glycolipids. However, it was very difficult 
to attach the bacterium onto the 96 well ELISA plates. Troubleshooting 
was required and an in house ELLA method was developed based on the 
work of Afrough et al., (2007). Glycan – lectin interactions were carried out 
only on those aerobes and anaerobes that had been identified as 
predominantly found in DF. Interpretations of the structure based on lectin 
interaction utilised, in the main data from eukaryotic systems and should 
therefore be viewed with caution. Indeed, given the promiscuity of some of 
the lectins, caution needs to be used in assigning structures based solely 
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on lectin analysis. Experimental characterisation of the glycan-lectin 
interactions for a number of aerobes demonstrated that most of the Gram - 
positive aerobes such as MRSA (NCTC 33591) expressed β-Gal, α and β 
terminal GalNAc, Gal β1-3GalNAc, terminal α/ β GlcNAc, GlcNac, GlcNAc 
with sialic acid, α – 2,6 sialic acid Gal  and α-fucose and  Fucα1,2Gal as 
glycan structures.  MSSA (NCTC 6571) expressed terminal α Gal, α–
GalNac, α–GalNac with 1,2 Fuc ,α- Man, complex Man with core α-fucose,  
α-glucose, terminal GlcNac, β-GlcNAc, GlcNAc1,4 oligomers including 
chitobiose and chitotriose which is in acceptance with the study carried out 
by Silfkin and Doyle(1990), however, they  suggested that there was no 
terminal β-GalNAc or Fucα1,2 Gal. MRSE however expressed complex 
mannose structures, along with Gal β1-3GalNAc, GlcNAc/sialic acid and 
GlcNac while MSSE expressed Gal β1-3GalNAc, terminal α-GalNAc, 
GalNAcα1,3[Fucα1,2]Gal, Gal β1-3GalNAc, GlcNAc/sialic acid, β1-4 
GlcNAc and LacNAc oligomers,  GlcNac  and (Glcβ1,4NAc)n, chitotriose. 
The glycans specific to MSSE include Gal β1-3GalNAc, terminal α-N-
acetylgalactosamine, GalNAcα1,3 [Fucα1,2]Gal, Gal β1-3GalNAc, 
GlcNAc/sialic acid, β1-4 GlcNAc and LacNAc oligomers,  GlcNac  and 
(Glcβ1,4NAc)n, chitotriose. The Gram - negative aerobes expressed α and 
β terminal GalNAc in E. coli as well as GalNAcα1-O-ser, α-fucose, 
Fucα1,2 Gal, β-GlcNAc, sialic acid, β1,4-GlcNAc oligomers and the 
complex structures of mannose. While P. mirabilis expresses α-Gal, α-N-
GalN, Galα1,3 Gal, α and β-GalNac, terminal α-GalNAc complex 
structures of mannose. S. pyogenes shows high mannose structures 
including the tri and the tetra antennary. E. faecalis expresses Gal, α-
GalNAc, terminal α-N GalNAc, GalNAcα1,3 [Fucα1,2]Gal, α-fucose, 
Fucα1,2Gal, β-GlcNAc, sialic acid and α – 2,6 sialic acid linked to Gal. 
Protein glycosylation was not considered to  occur to any extent  among 
the prokaryotes but recently,  there have been studies suggesting that 
glycoproteins are present in bacteria and they have a role to play in cell- 
cell adhesion and pathogenesis (Benz and Schmidt, 2002; Bishop and 
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Gangneux, 2007; Tuomanen, 1996;Zhou and Wu, 2009 and Schmidt, 
Riley and Benz, 2003).  
The identification of the glycans expressed by anaerobic bacteria was 
significant as there is very limited research carried out in this area. In DF 
patients the presence of anaerobes in particular worsens the ulcer 
especially when they are present in a polymicrobial mix along with the 
aerobes. There were differences in the glycans that were expressed by 
the most frequently isolated Gram - positive anaerobes such as F.magna, 
Parvi.micra, Peptoni. asaccharolyticus, P.anaerobius and the Gram - 
negative anaerobes. Although the aims of the research were originally to 
identify the glycans expressed by the bacteria, the ELLA results identified 
unique glycan-lectin binding patterns that could discriminate between 
organisms.  It is clear that there is potential to explore the glycan-lectin 
interactions in the microbial diagnostics. The results showed the potential 
of glycan-lectin binding patterns in the rapid tying of Staphylococcus 
species mainly the methicillin sensitive and methicillin resistant 
Staphylococcus aureus and Staphylococcus epidermidis. In the ELLA the 
biotinylated lectins which were specifically detecting MRSA and MSSA 
were SBA, LC, EC, VV, LE, GI, UEA and Con A with varied levels of 
interaction. The lectins shown to be specific to MRSE and MSSE were Sol, 
SBA, DB, SWGA and PVE with different levels of activity. There were also 
specific binding patterns seen among the Gram - positive and Gram - 
negative anaerobes suggesting ELLA may be useful in the typing of 
anaerobes including the Peptostreptococcus lectin binding patterns, if 
sensitivity and specificity were proven with large numbers of clinical 
isolates, and hence could be used as a typing tool. In the current study, 
the glycan-lectin binding patterns reported were those seen among the 
ATCC, NCTC and AC strains. Clearly the study needs to be expanded to 
analyse statically significant clinical isolates to determine general utility. 
However, the results suggest that glycan analysis could be used in the 
development of a testing/typing kit.  
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Glycan analysis is a specialist area and the work was carried out under 
supervision of experts at the Complex Carbohydrate research Centre 
(CCRC) at the University of Georgia. A complete characterisation of the 
glycolipids of Finegoldia magna was achieved. This Gram - positive strict 
anaerobe is found in many soft tissue infections and is reported to be one 
of the most commonly isolated pathogens from the DF ulcers (Citron et al., 
2007). The glycans detected by the gas chromatography-mass 
spectrometry (GC-MS) were glucose, mannose, galactose and N-
acetylglucosamine and these results correlated with those obtained by the 
ELLA. Linkage analysis by GC-MS suggested the presence of 1, 3 
mannose and terminal mannose along with 2 and 3 linked rhamnose. The 
composition analysis of the lipids of F.magna by GC-MS suggested the 
presence of the C-14 (Myristic acid) C-16 (Palmitic acid) and C -18 
(Stearic acids). 
High pH anion exchange chromatography (HPAEC) suggested the 
presence of sialic acid, the glycan which has often been reported to be 
involved in the pathogenesis in bacteria. Sambucus nigra lectin which is 
specific for α – 2, 6 sialic acid linked to galactose also showed binding to 
the F.magna by the ELLA method confirming the data. These organisms 
probably utilise sialic acid either in attachment to lectins in the host or on 
to other organisms. F.magna is often isolated from biofilms and it is 
possible that glycan- lectin interactions act to stabilise these structures. 
Further work was therefore channelled towards determining whether other 
anaerobes also expressed sialic acid The Warren assay suggested the 
presence of sialic acid on glycolipids isolated from Finegoldia magna, 
Peptostreptococcus anaerobius, Prevotella bivia and Fusobacterium 
nucleatum but not those of Peptoniphilus assachrolyticus, Parvimonas 
micra, Anaerococcus prevottii and Bacteroides fragilis. Interestingly other 
studies have shown the presence of sialic acid on Bacteroides fragilis 
groups in contrast to our study (Severi et al., 2007). This could be due to 
the different strains used or differences in culture and harvesting that 
affected gene expression (Takashashi et al., 2006 and Ruivo et al., 2008). 
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Hence in the work described should be expanded to look at sialic acid 
expression by various strains organisms of pathological and non 
pathological origin grown in standardised conditions.  
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CHAPTER – 6 
 FUTURE WORK 
______________________________________________________ 
The analysis of the glycans expressed by micro-organisms would provide 
a clearer picture of the glycome of bacteria and allow us to determine 
whether glycans have any role in pathogenesis. The increase in antibiotic 
resistant bacterial pathogens makes it vital to find new means of treating 
such bacteria Sharon, (1987) have proposed anti-adhesion therapy, and 
using carbohydrates to block lectin-glycan mediated attachment or 
adhesion of the bacteria to the host tissues at the early stages of infection. 
This strategy can be utilised without fear of toxicity as the method utilises 
saccharides which are non-toxic, cannot induce bacterial resistance and 
are relatively less harmful than chemicals (Ofek, Hasty and Sharon, 2003). 
Some however can stimulate immune response in the host (Tuomanen, 
1996). This approach could be used as a preventive measure rather than 
the treatment measure in those infections that are glycan – lectin 
mediated. There are number of infections that are initiated by adhesion of 
the pathogenic organisms to the cells and the mucosal surfaces of the 
host such as (Sharon and Ofek, 2000). Adhesion is required so that the 
organism remains unaffected by the host clearing mechanisms and natural 
immune defence. If this adhesion is targeted then many infections could 
be treated using a similar strategy. These methods may work best when 
the treatment is topically rather than systemically applied as the blocking 
molecules would have direct access to the bacteria. 
Treatment of diabetic foot infections relies on antibiotics and on surgical 
intervention (Lipsky, 2004a). These methods can lead to long - term 
impairment of normal routine life and increased hospital stay without a 
complete cure. There is a need to explore other ways that the wound can 
be treated effectively, including targeting directly by inhibiting the 
organisms from adhering to the host. By understanding the mechanisms of 
carbohydrate specific adhesion, bacterial infections in vivo could be 
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prevented (Ofek, Hasty and Sharon, 2003 and Battin et al., 2007). The 
presence of the sialic acid on the anaerobe F.magna suggests an 
involvement in pathogenicity (Takahashi et al., 2006; Severi, Hood and 
Thomas, 2007 and Ruivo et al., 2008). If proven, sialic acid analogues in a 
topical cream could be prepared which would block the glycan binding 
sites of the lectins and prevent attachment of F.magna. Indeed, if sialic 
acid – lectin binding is also a key feature of biofilm production through 
binding of sialic acid on one microbe to a sialic acid binding residue on 
another, saccharides could be used to disrupt these structures and hence 
improve access of other antimicrobial agents (Rickard et al., 2003; Battin 
et al., 2007 and Lloyd et al., 2007). Further work to understand how they 
may be utilised needs to be explored. 
The cohort study carried out in India and the UK could be further extended 
to recruit more patients and then identify the risk factors and statistically 
analyse the contribution of individual factors to the risk of DFI. The 
antibiotic susceptibility testing also could be carried out in such as way 
that there are more number of organisms belonging to the same species 
to obtain statistically significant results and is a confirmative conclusion 
based on a high number of organisms belonging to the same species. The 
research design could also be extended by including the microbial flora 
before and after amputations along with the difference in the risk factors. 
Surveillance studies could be carried out to compare the antibiotic 
susceptibility patterns from India and UK with the sample size of 100 
organisms belonging to the same species. However, given the low 
numbers of some organisms isolated, thousands of patients would need to 
be recruited.  
Diabetic foot infections often are polymicrobial with a peculiar 
characteristic of biofilm (Dowd et al., 2008) It would be interesting to 
identify the glycans expressed using the in house developed ELLA method 
with biotinylated lectins on biofilms produced by combination of 2 or more 
organisms (1 facultative aerobe and 1 strict anaerobe) from India and UK. 
Biofilms could be created in the laboratory using a bioreactor (Goeres et 
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al., 2005) or CalgaryTm 96 well polystyrene ELISA plate system with pegs 
(Ceri et al., 1999, Olfson et al., 2002). Confocal microscope can be used 
to visualise the exopolysaccharides layer on the formed biofilms using 
fluorescent lectins (Windernder et al., 2001). „LIVE/DEAD Baclight 
Bacterial Viability Kits‟ would be utilised to determine the presence of 
biofilms (Harrison et al., 2006 and Neu, Swerhone and Lawrence, 2001). 
 
In vitro studies would also allow research into the interactions of 
keratinocyte cell lines and bacterial glycans. On identification of glycans 
from the outer membranes of pathogens from India and UK DF patients, in 
vitro studies using cell culture could then be used to determine whether: 
 
a) Pathogens bind to keratinocyte cell lines in a culture system. 
b) Pre - treatment of cells with sugars (i.e. blocking of host lectins) 
prevent bacteria binding.  
c) Pre - treatment with lectins (i.e. blocking of host sugars) stop 
bacteria binding. 
d) Cells pre-treated with specific glycans bind differently. 
e)  There is a difference in glycan expression in single colony culture, 
biofilms and patient samples and if the interaction is mediated 
through lectin binding and most importantly if there are differences 
in the glycan – lectin expressions seen from India and the UK. 
 
The development of a rapid typing and identification method is now 
feasible with the preliminary information provided by this study. Further 
work could be channelled towards obtaining the glycan-lectin profile on 
clinical strains and to compare them with the already obtained glycan-
lectin profiles of individual organisms. Finally strains vary from different 
geographical locations could be analysed to determine, for example, 
whether those organisms in the Indian cohorts had the same glycan 
profiles as those from the cohort in the UK.  
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A diagnostic kit with a panel of biotinylated lectins can be created which is 
practical as well as economical and affordable in clinical laboratories. The 
reproducibility of the kit can be determined statistically by carrying out the 
tests on a number of strains from different genus. Automation in clinical 
microbiology is still in a very early stage of development compared to the 
level of automation in other disciplines of science. Glycan–lectin 
microarrays can be developed with the aim to introduce automation along 
with user friendly microbial diagnostics. 
In conclusion, therefore this work has increased our understanding of 
anaerobes and their interactions. This study has provided us with 
preliminary information on the glycan-lectin profiles of number of aerobes 
and anaerobes. It has highlighted the potential of glycan-lectin interactions 
in microbial diagnostics. The AST data has identified the multi - drug 
resistant organisms and would alert the clinicians to limit the usage and to 
introduce alternative therapy to target infections. 
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ELLA was also carried out on tests with no lectin and no streptavidin added which 
were negative controls. The data is the mean result of three independent experiments 
VIA) Glycan profile of the whole cells of MSSA by ELLA  
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VIB) Glycan profile of Proteinase K treated whole cells of MSSA by 
ELLA  
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VIC) Glycan profile of glycolipids of MSSA by ELLA 
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VIIA) Glycan profile of the whole cells of MRSA by ELLA 
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VIIB) Glycan profile of Proteinase K treated whole cells of MRSA 
by ELLA  
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VIIC) Glycan profile of glycolipids of MRSA by ELLA 
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VIIIA) Glycan profile of whole cells of MSSE by ELLA 
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VIIIB) Glycan profile of Proteinase K treated cells of MSSE by 
ELLA 
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VIIIC) Glycan profile of glycolipids of MSSE by ELLA 
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IXA) Glycan profile of whole cells of MRSE by ELLA 
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IXB) Glycan profile of Proteinase K treated whole cells of MRSE by 
ELLA 
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IXC) Glycan profile of glycolipids of MRSE by ELLA 
 
 
 
  
Appendix X 
0.00
0.05
0.10
0.15
J
a
c
a
lin
s
o
la
n
u
m
s
o
y
a
b
e
a
n
P
e
a
n
u
t 
a
g
g
lu
tin
in
D
o
lic
h
o
s
 b
ifl
o
ru
s
S
o
p
h
o
ra
 ja
p
o
n
ic
a
R
ic
in
u
s
G
ri
ff
o
n
ia
W
h
e
a
t 
G
e
rm
S
u
c
c
in
y
la
te
s
P
h
a
s
e
o
lu
s
L
e
n
s
 C
u
ln
a
ri
s
 
E
ry
th
ri
n
a
P
is
u
m
 S
a
tiv
u
m
P
h
a
s
e
o
lu
s
V
ic
ia
 V
ill
o
s
a
L
y
c
o
p
e
rs
ia
n
G
ri
ff
o
n
ia
U
le
x
 e
u
ro
p
a
e
u
s
D
a
tu
ra
C
o
n
 A
s
a
m
b
a
c
u
s
 n
ig
ra
biotinylated lectins 0.6 mg/ml
A
b
s
o
rb
a
n
c
e
 @
 4
0
5
 n
m E. coli whole cells
 
XA) Glycan profile of whole cells of Escherichia coli by ELLA 
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XB) Glycan profile of whole cells of Pseudomonas aeruginosa by 
ELLA 
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XC) Glycan profile of whole cells of Proteus mirabilis by ELLA 
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XD) Glycan profile of whole cells of E. faecalis by ELLA 
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XE) Glycan profile of whole cells of Streptococcus pyogenes by 
ELLA 
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XIA) Glycan profile of whole cells of Finegoldia magna by ELLA 
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XIB) Glycan profile of Proteinase K treated whole cells of 
Finegoldia magna by ELLA 
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XIC) Glycan profile of glycolipids of Finegoldia magna by ELLA
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XIIA) Glycan profile of whole cells of Prevotella bivia by ELLA 
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XIIB) Glycan profile of LPS of Prevotella bivia by ELLA 
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XIIIA) Glycan profile of whole cells of Parvimonas micros by ELLA 
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XIIIB) Glycan profile of glycolipids of Parvimonas micros by ELLA 
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XIVA) Glycan profile of whole cells of Propionibacterium acnes by 
ELLA 
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XIVB) Glycan profile of glycolipids of Propionibacterium acnes by 
ELLA 
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XVA) Glycan profile of whole cells of Anaerococcus prevottii by 
ELLA 
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XVB) Glycan profile of glycolipids of Anaerococcus prevottii by 
ELLA 
 
 
 
 
 
 
 
 
  
Appendix XVI 
 
 
 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
J
a
c
a
lin
s
o
la
n
u
m
s
o
y
a
b
e
a
n
P
e
a
n
u
t 
a
g
g
lu
tin
in
D
o
lic
h
o
s
 b
ifl
o
ru
s
S
o
p
h
o
ra
 ja
p
o
n
ic
a
R
ic
in
u
s
G
ri
ff
o
n
ia
II
W
h
e
a
t 
G
e
rm
S
u
c
c
in
y
la
te
s
P
h
a
s
e
o
lu
s
E
ry
th
ro
L
e
n
s
 C
u
ln
a
ri
s
 
E
ry
th
ri
n
a
P
is
u
m
 S
a
tiv
u
m
P
h
a
s
e
o
lu
s
L
e
u
c
o
V
ic
ia
 V
ill
o
s
a
 le
c
tin
L
y
c
o
p
e
rs
ia
n
G
ri
ff
o
n
ia
I
U
le
x
 e
u
ro
p
a
e
u
s
D
a
tu
ra
C
o
n
 A
S
a
m
b
u
c
u
s
 n
ig
ra
biotinylated lectins 0.6 mg/ml
A
b
s
o
rb
a
n
c
e
 @
 4
0
5
n
m
 
F. nucleatum LPS
 
XVIA) Glycan profile of glycolipids of Fusobacterium nucleatum 
by ELLA 
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XVIB) Glycan profile of glycolipids of Peptoniphilus 
asaccharolyticus by ELLA 
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XVIC) Glycan profile of glycolipids of Peptostreptococcus 
anaerobius by ELLA 
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XVID) Glycan profile of glycolipids of Bacteroides fragilis by ELLA 
 
 
 
 
 
 
 
 
 
  
Appendix XVII 
Standard chromatogram of the different monosaccharides by  
GC-MS 
 
Peak (Std) Retention 
time 
Width Area  Start 
time 
End time  
Rhamnose 13.404 0.054 3783129 13.315 13.535 
Rhamnose 13.706 0.059 330543 13.645 13.795 
Xylose 15.669 0.065 2611185 15.532 15.877 
Xylose 16.419 0.066 1336197 16.278 16.557 
Mannose 21.170 0.069 4465559 20.966 21.308 
Mannose 21.498 0.067 622749 21.388 21.594 
Galactose 22.742 0.068 2454944 22.607 22.856 
Galactose 23.018 0.076 195671 22.945 23.122 
GluNAc 25.320 0.071 956160 23.953 24.122 
GluNAc 25.610 0.087 495968 25.091 25.436 
GalNAc 29.662 0.074 511284 29.507 29.758 
GalNAc 31.731 0.070 903089 31.615 31.852 
Inositol 34.731 0.089 3403077 34.601 34.872 
 
The table below in Appendix XVII represents the standard of different 
monosaccharides and internal standard with their retention times, area, 
width, start time and their end time that were run on the column 
SP2330 fused silica, Supelco. The retention times of these standards 
were used to determine the composition of Finegoldia magna glycans.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix XVIII 
List of poster, presentations and potential publications  
 
Posters and presentations  
 
1) Pathogenesis of diabetic foot Infections; The role of glycans – 
poster presented at the conference held by International society 
of chemotherapy and infection in Canada. 
 
2) Antibiotic study of infected flora of diabetic foot ulcers in UK and 
Indian populations – poster presented at the International 
society of chemotherapy and infection in Canada. 
 
3) Role of glycans in the pathogenesis of diabetic foot Infections – 
poster presented at the conference organised by the Institute of 
biomedical science. 
 
4) Role of glycans in the pathogenesis of diabetic foot Infections – 
oral presentation at the conference organised by the Institute of 
biomedical science.  
 
5) Antibiotic resistance and the role of glycans in Diabetic Foot 
infections – oral presentation at the conference organised by the 
Society for General Microbiology. 
 
Potential publications  
 
1) Aerobes, anaerobes and fungi from the diabetic foot patient’s from 
India and the UK 
 
2) Comparison of the antibiotic susceptibility profiles from diabetic foot 
cohorts from India and UK 
3) A comparative view on distribution of aerobes, anaerobes and fungi 
on the pus and tissues specimens from the Indian diabetic foot patients 
4) Glycans of Finegoldia magna: a role in pathogenesis of diabetic foot 
infections? 
 
5) Glycan – Lectin interactions: any scope for diagnostics 
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ELLA was also carried out on tests with no lectin and no streptavidin added which 
were negative controls. The data is the mean result of three independent experiments 
VIA) Glycan profile of the whole cells of MSSA by ELLA  
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VIB) Glycan profile of Proteinase K treated whole cells of MSSA by 
ELLA  
 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
0.60
0.65
0.70
0.75
0.80
0.85
J
a
c
a
lin
s
o
la
n
u
m
s
o
y
a
b
e
a
n
P
e
a
n
u
t 
a
g
g
lu
tin
in
D
o
lic
h
o
s
 b
ifl
o
ru
s
S
o
p
h
o
ra
 ja
p
o
n
ic
a
R
ic
in
u
s
G
ri
ff
o
n
ia
W
h
e
a
t 
G
e
rm
S
u
c
c
in
y
la
te
s
P
h
a
s
e
o
lu
s
E
ry
th
ro
L
e
n
s
 C
u
ln
a
ri
s
 
E
ry
th
ri
n
a
P
is
u
m
 S
a
tiv
u
m
P
h
a
s
e
o
lu
s
L
e
u
c
o
V
ic
ia
 V
ill
o
s
a
 le
c
tin
L
y
c
o
p
e
rs
ia
n
G
ri
ff
o
n
ia
U
le
x
 e
u
ro
p
a
e
u
s
D
a
tu
ra
C
o
n
 A
S
a
m
b
a
c
u
s
 n
ig
ra
biotinylated lectins 0.6 mg/ml
A
b
s
o
rb
a
n
c
e
 @
 4
0
5
 n
m
MSSA glycolipids
 
VIC) Glycan profile of glycolipids of MSSA by ELLA 
 
 
 
  
Appendix VII 
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VIIA) Glycan profile of the whole cells of MRSA by ELLA 
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VIIB) Glycan profile of Proteinase K treated whole cells of MRSA 
by ELLA  
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VIIC) Glycan profile of glycolipids of MRSA by ELLA 
 
 
 
 
  
Appendix VIII 
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VIIIA) Glycan profile of whole cells of MSSE by ELLA 
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VIIIB) Glycan profile of Proteinase K treated cells of MSSE by 
ELLA 
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VIIIC) Glycan profile of glycolipids of MSSE by ELLA 
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0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.45
0.50
0.55
J
a
c
a
lin
s
o
la
n
u
m
s
o
y
a
b
e
a
n
P
e
a
n
u
t 
a
g
g
lu
ti
n
in
D
o
lic
h
o
s
 b
if
lo
ru
s
S
o
p
h
o
ra
 j
a
p
o
n
ic
a
R
ic
in
u
s
G
ri
ff
o
n
ia
II
W
h
e
a
t 
G
e
rm
S
u
c
c
in
y
la
te
d
P
h
a
s
e
o
lu
s
E
ry
th
ro
L
e
n
s
 C
u
ln
a
ri
s
 
E
ry
th
ri
n
a
P
is
u
m
 S
a
ti
v
u
m
P
h
a
s
e
o
lu
s
L
e
u
c
o
V
ic
ia
 V
ill
o
s
a
 l
e
c
ti
n
L
y
c
o
p
e
rs
ia
n
G
ri
ff
o
n
ia
I
U
le
x
 e
u
ro
p
a
e
u
s
D
a
tu
ra
C
o
n
 A
S
a
m
b
u
c
u
s
 n
ig
ra
biotinylated lectins 0.6 mg/ml
A
b
s
o
rb
a
n
c
e
 @
 4
0
5
 n
m MRSE whole cells
 
IXA) Glycan profile of whole cells of MRSE by ELLA 
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IXB) Glycan profile of Proteinase K treated whole cells of MRSE by 
ELLA 
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IXC) Glycan profile of glycolipids of MRSE by ELLA 
 
 
 
  
Appendix X 
0.00
0.05
0.10
0.15
J
a
c
a
lin
s
o
la
n
u
m
s
o
y
a
b
e
a
n
P
e
a
n
u
t 
a
g
g
lu
tin
in
D
o
lic
h
o
s
 b
ifl
o
ru
s
S
o
p
h
o
ra
 ja
p
o
n
ic
a
R
ic
in
u
s
G
ri
ff
o
n
ia
W
h
e
a
t 
G
e
rm
S
u
c
c
in
y
la
te
s
P
h
a
s
e
o
lu
s
L
e
n
s
 C
u
ln
a
ri
s
 
E
ry
th
ri
n
a
P
is
u
m
 S
a
tiv
u
m
P
h
a
s
e
o
lu
s
V
ic
ia
 V
ill
o
s
a
L
y
c
o
p
e
rs
ia
n
G
ri
ff
o
n
ia
U
le
x
 e
u
ro
p
a
e
u
s
D
a
tu
ra
C
o
n
 A
s
a
m
b
a
c
u
s
 n
ig
ra
biotinylated lectins 0.6 mg/ml
A
b
s
o
rb
a
n
c
e
 @
 4
0
5
 n
m E. coli whole cells
 
XA) Glycan profile of whole cells of Escherichia coli by ELLA 
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XB) Glycan profile of whole cells of Pseudomonas aeruginosa by 
ELLA 
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XC) Glycan profile of whole cells of Proteus mirabilis by ELLA 
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XD) Glycan profile of whole cells of E. faecalis by ELLA 
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XE) Glycan profile of whole cells of Streptococcus pyogenes by 
ELLA 
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XIA) Glycan profile of whole cells of Finegoldia magna by ELLA 
 
 
0.00
0.05
0.10
J
a
c
a
li
n
s
o
la
n
u
m
s
o
y
a
b
e
a
n
P
e
a
n
u
t 
a
g
g
lu
ti
n
in
D
o
li
c
h
o
s
 b
if
lo
ru
s
S
o
p
h
o
ra
 j
a
p
o
n
ic
a
R
ic
in
u
s
G
ri
ff
o
n
ia
 I
I
W
h
e
a
t 
G
e
rm
S
u
c
c
in
y
la
te
d
P
h
a
s
e
o
lu
s
E
ry
th
ro
L
e
n
s
 C
u
ln
a
ri
s
 
E
ry
th
ri
n
a
P
is
u
m
 S
a
ti
v
u
m
P
h
a
s
e
o
lu
s
L
e
u
c
o
V
ic
ia
 V
il
lo
s
a
L
y
c
o
p
e
rs
ia
n
G
ri
ff
o
n
ia
 I
U
le
x
 e
u
ro
p
a
e
u
s
D
a
tu
ra
C
o
n
 A
S
a
m
b
u
c
u
s
 n
ig
ra
biotinylated lectins 0.6 mg/ml
A
b
s
o
rb
a
n
c
e
 @
4
0
5
 n
m F. magna Proteinase K
 
XIB) Glycan profile of Proteinase K treated whole cells of 
Finegoldia magna by ELLA 
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XIC) Glycan profile of glycolipids of Finegoldia magna by ELLA
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XIIA) Glycan profile of whole cells of Prevotella bivia by ELLA 
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XIIB) Glycan profile of LPS of Prevotella bivia by ELLA 
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XIIIA) Glycan profile of whole cells of Parvimonas micros by ELLA 
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XIIIB) Glycan profile of glycolipids of Parvimonas micros by ELLA 
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XIVA) Glycan profile of whole cells of Propionibacterium acnes by 
ELLA 
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XIVB) Glycan profile of glycolipids of Propionibacterium acnes by 
ELLA 
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XVA) Glycan profile of whole cells of Anaerococcus prevottii by 
ELLA 
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XVB) Glycan profile of glycolipids of Anaerococcus prevottii by 
ELLA 
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XVIA) Glycan profile of glycolipids of Fusobacterium nucleatum 
by ELLA 
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XVIB) Glycan profile of glycolipids of Peptoniphilus 
asaccharolyticus by ELLA 
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XVIC) Glycan profile of glycolipids of Peptostreptococcus 
anaerobius by ELLA 
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XVID) Glycan profile of glycolipids of Bacteroides fragilis by ELLA 
 
 
 
 
 
 
 
 
 
  
Appendix XVII 
Standard chromatogram of the different monosaccharides by  
GC-MS 
 
Peak (Std) Retention 
time 
Width Area  Start 
time 
End time  
Rhamnose 13.404 0.054 3783129 13.315 13.535 
Rhamnose 13.706 0.059 330543 13.645 13.795 
Xylose 15.669 0.065 2611185 15.532 15.877 
Xylose 16.419 0.066 1336197 16.278 16.557 
Mannose 21.170 0.069 4465559 20.966 21.308 
Mannose 21.498 0.067 622749 21.388 21.594 
Galactose 22.742 0.068 2454944 22.607 22.856 
Galactose 23.018 0.076 195671 22.945 23.122 
GluNAc 25.320 0.071 956160 23.953 24.122 
GluNAc 25.610 0.087 495968 25.091 25.436 
GalNAc 29.662 0.074 511284 29.507 29.758 
GalNAc 31.731 0.070 903089 31.615 31.852 
Inositol 34.731 0.089 3403077 34.601 34.872 
 
The table below in Appendix XVII represents the standard of different 
monosaccharides and internal standard with their retention times, area, 
width, start time and their end time that were run on the column 
SP2330 fused silica, Supelco. The retention times of these standards 
were used to determine the composition of Finegoldia magna glycans.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Appendix XVIII 
List of poster, presentations and potential publications  
 
Posters and presentations  
 
1) Pathogenesis of diabetic foot Infections; The role of glycans – 
poster presented at the conference held by International society 
of chemotherapy and infection in Canada. 
 
2) Antibiotic study of infected flora of diabetic foot ulcers in UK and 
Indian populations – poster presented at the International 
society of chemotherapy and infection in Canada. 
 
3) Role of glycans in the pathogenesis of diabetic foot Infections – 
poster presented at the conference organised by the Institute of 
biomedical science. 
 
4) Role of glycans in the pathogenesis of diabetic foot Infections – 
oral presentation at the conference organised by the Institute of 
biomedical science.  
 
5) Antibiotic resistance and the role of glycans in Diabetic Foot 
infections – oral presentation at the conference organised by the 
Society for General Microbiology. 
 
Potential publications  
 
1) Aerobes, anaerobes and fungi from the diabetic foot patient’s from 
India and the UK 
 
2) Comparison of the antibiotic susceptibility profiles from diabetic foot 
cohorts from India and UK 
3) A comparative view on distribution of aerobes, anaerobes and fungi 
on the pus and tissues specimens from the Indian diabetic foot patients 
4) Glycans of Finegoldia magna: a role in pathogenesis of diabetic foot 
infections? 
 
5) Glycan – Lectin interactions: any scope for diagnostics 
 
 
 
List of Abbreviations 
 
ATCC     American type culture collections 
AD     After death of Jesus 
BC     Before Christ birth 
BUN     Blood urea nitrogen 
CLD     Chronic liver disease 
DFI     Diabetic foot infections 
DMSO    Dimethyl sulphoxide 
ELISA     Enzyme linked immunosorbant assay 
ELLA     Enzyme linked lectin sorbent assay 
Gal      D-Galactose 
GalNAc    2-acetamido-2-deoxy-D-galactopyranose 
GC-MS    Gas Chromatography – Mass spectrometry 
GDM     Gestational Diabetes mellitus 
GlcNAc    2-acetamido-2-deoxy-D-glucopyranose 
H2S     Hydrogen sulphide 
HCl     Hydrochloric acid 
HPAEC    High pH anion exchange chromatography 
IgG     Immunoglobulin G 
LB broth    Luria Bertani broth 
LPS      Lipopolysaccharide 
MALDI     Matrix assisted laser desorption/ionisation 
MODY    Diabetes Maturity Onset Diabetes of the Young  
MS      Mass spectrometry 
NANA     N-acetyl neuraminic acid 
NCCL S    National committee for clinical laboratory standards 
NCTC     National collection of type cultures 
NI     Neuroischemic 
NMR     Nuclear magnetic resonance 
O.D     Optical density 
PCV     Packed cell volume 
PG      Peptidoglycan  
PMAA     Partially methylated alditol acetates 
PN     Peripheral neuropathy 
PNP     Paranitrophenol 
PPA     Phenylalanine deamination test 
PVD     Peripheral vascular disease 
RC     Renal complications 
RT      room temperature 
Sia      Sialic acid 
SPSS     Statistical package for social sciences 
T1DM     Type 1 Diabetes mellitus 
T2DM     Type 2 Diabetes mellitus 
TFA     Trifluoro acetic acid 
TSB     Tryptone soya broth 
TSI      Triple sugar iron test 
UCLH     University college London hospital 
VP     Voges–Proskauer test 
WBC     White blood cells 
 
 
 
 
 
 
 
Microbes Abbreviations 
 
A. baumannii    Acinetobacter baumannii 
C. albicans    Candida albicans 
C. botulinum    Clostridium botulinum 
C. butyricum    Clostridium butyricum 
C. difficile    Clostridium difficle 
C. glabrata    Clostridium glabrata 
C. guilliermondii   Clostridium guilliermondii 
C. histolyticum   Clostridium histolyticum 
C. innocuum    Clostridium innocuum 
C. kefyr    Candida kefyr 
C. krusei     Candida krusei 
C. limosum    Clostridium limosum 
C. paraputrificum   Clostridium paraputrificum 
C. perfringens   Clostridium perfringens 
C. pseudotropicalis   Candida pseudotropicalis 
C. putrificum    Clostridium putrificum 
C .rugosa    Candida rugosa 
C .stellatoid     Candida stellatoid 
C .tertium    Clostridium tertium 
C .tetani    Clostridium tetani 
C .tropicalis    Candida tropicalis 
E.coli      Escherichia coli 
F .necrogenes   Fusobacterium necrogenes 
F .varium    Fusobacterium varium 
F.m     Finegoldia magna 
H. ducreyi    Haemophilus ducreyi 
H. influenzae    Haemophilus influenzae 
K .pneumoniae   Klebsiella pneumoniae 
MRSA     Methicillin resistant Staphylococcus aureus 
MRSE     Methicillin resistant Staphylococcus epidermidis 
MSSE     Methicillin sensitive Staphylococcus epidermidis 
N. gonorrohoeae   Neisseria gonnorrohoeae 
N.meningitides   Neisseria meningitides 
P .mirabilis    Proteus mirabilis 
P .vulgaris    Proteus vulgaris 
P. asaccharolyticus   Peptoniphilus asaccharolyticus 
P. glycinophilus   Peptoniphilus glycinophilus 
P. indolicus    Peptoniphilus indolicus 
P. magnus    Peptoniphilus magnus 
P. niger    Peptoniphilus niger 
P. prevottii    Peptoniphilus prevottii 
P.a     Pseudomonas aeruginosa 
Pst. micros    Peptostreptococcus micros 
Pst. anaerobius   Peptostreptococcus anaerobius 
Pst. asaccharolyticus  Peptostreptococcus asaccharolyticus 
Pst. heliotrinreducens  Peptostreptococcus heliotrinreducens 
Pst. indolicus    Peptostreptococcus indolicus 
Pst. magnus    Peptostreptococcus magnus 
Pst. parvulus    Peptostreptococcus parvulus 
Pst. prevottii    Peptostreptococcus prevottii 
Pst. productus   Peptostreptococcus productus 
Pst. tetradius              Peptostreptococcus tetradius 
S. artitae    Staphylococcus artitae 
S. capitis    Staphylococcus capitis 
S. epidermidis   Staphylococcus epidermidis 
S. intermedius   Staphylococcus intermedius 
S. klossi    Staphylococcus klossi 
S. marcescens   Salmonella marcescens 
S. pisa fermentans   Salmonella pisa fermentans 
S. schleiferi    Staphylococcus schleiferi 
S. typhi    Salmonella typhi 
S.a     Staphylococcus aureus 
Spp     Species 
TB     Tuberculosis
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